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Background The endothelium plays a vital role in the regulation of blood flow and
haemostasis as well as mediating the response to tissue injury and inflammation. Disruption
to these pathways is a critical factor in the development of coronary heart disease (CHD) and
clinical syndromes such as acute myocardial infarction (MI). Endothelial dysfunction may be
demonstrated in patients with CHD and its risk factors such as cigarette smoking with a
decrease in the synthesis and release of endothelial-derived factors including the endogenous
fibrinolytic factor tissue plasminogen activator (t-PA) and nitric oxide (NO) as well as
impaired regulation of vascular tone.
Objectives (1) Although a reduction in endogenous fibrinolytic capacity may be
associated with a greater risk of arterial thrombosis, the relationship between acute t-PA
release and future atherothrombotic events was unknown. (2) Previous work in healthy
subjects had suggested that genetic variation within the t-PA gene may be important in
determining inter-individual differences in t-PA release and the risk of future MI; we
therefore assessed the effect of t-PA genetic polymorphisms on t-PA release in patients with
CHD. (3) Although unable to prove causation, previous studies indicated a relationship
between inflammatory markers, plasma t-PA concentrations and the risk of future
cardiovascular events. However the direct effect of local arterial inflammation in patients
with CHD was unknown. (4) As impaired NO bioavailability may contribute to the
development of atherosclerosis, we postulated that prolonging the effect ofNO with a highly
selective phosphodiesterase type 5 inhibitor (sildenafil citrate) may improve vascular
function.
Outcome Measures In a well characterised cohort of patients with stable CHD:
atherothrombotic events during follow-up (death from a cardiovascular cause, MI, ischaemic
stroke (CVA), hospitalisation for myocardial ischaemia); t-PA genotype; inflammatory
cytokines; acute t-PA release and forearm blood flow (FBF) during intra-brachial infusion of
vaso-agonists.
Results (1) Net t-PA release was 44% lower in the patients who experienced death,
MI, CVA or hospitalisation for myocardial ischaemia (p<0.02) over a median follow-up of
34 months. This novel finding validates the application of the forearm model to studying the
pathophysiological changes observed in CHD and suggests that the acute endogenous
fibrinolytic capacity is important in determining future cardiovascular risk. (2) Despite
confirming previous reports of impaired t-PA release and reduced FBF responses in cigarette
smokers (p<0.05), we found no effect of a number of t-PA genetic polymorphisms on acute
t-PA release. In subjects with established CHD, inter-individual differences in t-PA release
appear to predominantly reflect the presence of environment factors such as cigarette
smoking. (3) Intra-brachial infusion of tumour necrosis factor-a impaired NO-dependent
vasodilatation (p<0.001), increased basal t-PA concentrations and doubled bradykinin-
induced t-PA release (p=0.006). This suggests a pathophysiological mechanism whereby
circulating levels of inflammatory cytokines are directly related to plasma t-PA
concentrations and the risk of future cardiovascular events. Pharmacological interventions
with anti-cytokine therapies may have a therapeutic role in subjects at risk of acute coronary
syndromes. (4) Despite augmenting the effects of basal NO release and a direct NO donor
(p<0.05), a bolus and intravenous infusion of sildenafil did not affect either endothelium-
dependent vasodilatation or acute t-PA release. Sildenafil does not modify acute t-PA release
and phosphodiesterase type 5 inhibitors are unlikely to reverse the generalised vascular
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Atherosclerosis is a chronic inflammatory disorder that places a huge global burden
of morbidity and mortality on the use of health resources. The clinical syndromes
resulting from atherosclerotic conditions such as coronary heart disease are due, in
part, to loss of the normal endothelial control of thrombosis and regulation of blood
flow. The endogenous fibrinolytic system plays a critical role in preventing
unopposed fibrin formation and intravascular thrombosis leading to arterial
occlusion, myocardial ischaemia and infarction. Factors regulating fibrinolysis,
vasomotor tone and inflammation signalling are thus critical to our understanding of




Fibrinolysis describes the hydrolytic cleavage of fibrin by plasmin resulting in the
generation of fibrin degradation products secondary to thrombus dissolution. The
main fibrinolytic components of plasma are plasminogen, a2-antiplasmin, tissue
plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA). The
principal inhibitors of fibrinolysis in the circulation are plasminogen activator
inhibitor type-1 (PAI-1) which rapidly inhibits both t-PA and u-PA, and a.2-
antiplasmin [Sprengers and Kluft 1987] (Figure 1.1). Under physiological conditions,
links between these systems permit localised and timely removal of acutely induced
fibrin deposits to ensure blood fluidity while preventing blood loss [Cesarman-Maus
and Hajjar 2005]. As well as thrombus dissolution, the fibrinolytic system is also
involved in regulating extracellular matrix degradation, cellular migration [Saksela
and Rifkin 1988], angiogenesis and tumour invasion [Dano et al 1985; Bajou et al
1998].
1.1.1 Initiation of Fibrinolysis
1.1.1.1 Plasminogen and Plasmin
Plasmin, a trypsin-like serine protease is generated from the inactive proenzyme,
plasminogen, through the co-ordinated action of a number of enzymes and inhibitors.
Plasminogen is a 791 amino acid molecule principally synthesised within the liver
comprising a pre-activation sequence, a catalytic protease domain and a number of
kringle domains that play a crucial role in the specific recognition of fibrin, cell
surfaces, and a2-antiplasmin [Petersen et al 1990], The conversion of plasminogen
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to plasmin by plasminogen activators causes a conformational change allowing the
mature plasmin molecule to degrade fibrin. In addition to fibrin degradation, plasmin
also activates matrix metalloproteinases (MMPs) that, in turn, degrade the
extracellular matrix [Collen and Lijnen 1991; Birkedal-Hansen 1995].
1.1.1.2 Plasminogen Activators
Plasminogen activators cause thrombus dissolution by initiating fibrinolysis. Two
physiological plasminogen activators have been identified: (1) t-PA and (2) u-PA
which binds to a cellular u-PA receptor (u-PAR). Tissue plasminogen activator is
primarily involved in fibrin degradation within the circulatory system whilst u-PA is
predominantly involved in cell migration and tissue remodelling [Astedt 1979].
1.1.2 Inhibition of Fibrinolysis
The superfamily of serine protease inhibitors (serpins) are a multifunctional group of
peptides which play a central role in regulating fibrinolysis as well as coagulation,
and inflammation [Potempa et al 1994]. All serpins form an irreversible complex
with the active site of the target protease with both protease and inhibitor losing their
activity. In man, the main plasmin inhibitor is a2-antiplasmin though other factors
may play a role. Systemic unbound plasmin is rapidly inhibited by a2-antiplasmin,
whereas fibrin-bound plasmin is relatively protected from inactivation since the a2-
antiplasmin binding site is occupied by fibrin itself [Wiman et al 1979], There are a
number of plasminogen activator inhibitors in man, the most important of which is
PAI-1. These inhibitors prevent excessive plasminogen activation by t-PA and u-PA.
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Figure 1.1 Activation and inhibition of the endogenous fibrinolytic system; adapted from
Kohler and Grant, 2000 [Kohler and Grant 2000],
t-PA - tissue plasminogen activator; PAI-1 - plasminogen activator inhibitor type-1; u-PA - urokinase
plasminogen activator; — Inhibition.
1.2 TISSUE PLASMINOGEN ACTIVATOR
Tissue plasminogen activator is the central enzyme responsible for the regulation of
endogenous fibrinolysis and removal of intravascular thrombus in humans. After
initiation of thrombus formation, the endothelium acutely releases t-PA in response
to a range of factors predominantly related to the coagulation cascade, especially
factor Xa and thrombin [Emeis 1992],
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1.2.1 Protein Structure and Function
Tissue type plasminogen activator consists of 530 amino acids and is composed of
several domains with homologies to other proteins including a finger domain, an
epidermal growth factor domain, two kringle domains and the protease domain
comprising the catalytic triad causing plasminogen activation. Binding of t-PA to
fibrin is most likely mediated via the finger and the second kringle domains [Collen
1999], The human t-PA gene is localised to chromosome 8 with the proximal
promoter sequences containing typical TATA and CAAT boxes as well as
recognition sequences for transcription factors e.g. Spl [Leonardsson and Ny 1997],
1.2.2 Tissue Plasminogen Activity
In the absence of fibrin, t-PA has very weak activity as a plasminogen activator.
However the conversion of plasminogen to plasmin by t-PA is accelerated 1,000-fold
due to conformational changes in the t-PA molecule, in the presence of fibrin and at
the endothelial cell surface [Hoylaerts et al 1982; Ranby 1982; van Zonneveld et al
1986], Fibrin degradation also results in the appearance of new binding sites for
plasminogen on fibrin ensuring efficient localised activation. The efficacy of
plasminogen activation and fibrin degradation is determined by the relative balance
between the acute local release of t-PA and its subsequent inhibition by PAI-1.
Because plasminogen is present at vast molar excess over t-PA in plasma, the onset
and efficacy of fibrinolysis are principally determined by the rapidity and magnitude
of t-PA release [Hrafnkelsdottir et al 2004a].
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1.2.3 Circulating t-PA and t-PA/PAI-1 Complexes
The concentration of t-PA in human plasma is around 3 to 10 ng/mL, though in the
resting state only a relatively small proportion is functionally active principally due
to the rapid formation of complexes with PAI-1 (Figure 1.2) [Meade et al 1993;
Nordenhem and Wiman 1998]. There is a pronounced circadian variation in
fibrinolytic activity with a peak in t-PA antigen concentrations early in the morning
corresponding to low t-PA activity as a consequence of the corresponding 4-fold rise
in PAI-1 concentrations [Andreotti and Kluft 1991]. The proportion of active t-PA
thus varies inversely with plasma PAI-1 concentration, ranging from 2% to 33%
[Chandler et al 1990],
The clearance of t-PA occurs through the removal of active t-PA and t-PA/PAI-1
complexes from the circulation by the liver [Chandler et al 1997], This clearance
process is rapid, with plasma half-lives for active t-PA and t-PA/PAI-1 complexes of
2.4 and 5.0 minutes respectively. In the presence of high PAI-1 activity, total
clearance is slowed due to the longer half-life of the t-PA/PAI-1 complex.
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Figure 1.2 Relationship between t-PA and PAI-1 antigen and activity [Oliver et al 2005],
t-PA - tissue plasminogen activator; PAI-1 - plasminogen activator inhibitor type-1.
PAI-1 Antigen
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1.2.4 Tissue Plasminogen Activator Synthesis and Release
The endothelium is the principal site of t-PA generation where it is released via both
constitutive and regulated pathways [van den Eijnden-Schrauwen et al 1995],
Although present within most endothelial cells, the synthesis and secretion of t-PA is
greatest within those lining precapillary arterioles and postcapillary venules and is
minimal within the major vessels of the aorta [Levin and del Zoppo 1994], There are
regional differences in endothelial t-PA release such that the upper limbs release four
times the amount of the lower limbs [Keber 1988]. Circulating haematopoetic cells
contribute to the production of t-PA within atherosclerotic plaques and may be
important in the degradation of extracellular matrix and plaque instability [Lupu et al
1995; Steins et al 1999],
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The mechanisms regulating synthesis of t-PA are not fully understood though
synthesis is increased by thrombin, prostacyclin and histamine [Hanss and Collen
1987] and reduced by plasmin [Shi et al 1992], Acute stimulated release of
t-PA occurs with rapid translocation of a dynamic intracellular storage pool in
response to blood coagulation and humoral factors [Emeis 1992; van den Eijnden-
Schrauwen et al 1995], The acute capacity of the endothelium to release t-PA is
substantial with continuous release demonstrated over several hours without
significant tachyphylaxis [Wall et al 1997; Newby et al 1998] yielding forearm t-PA
concentrations approaching those following administration of thrombolysis in acute
myocardial infarction (MI) [Oliver et al 2005],
1.2.5 MolecularControl of t-PA Release
In cell culture, constitutive release of t-PA from the endothelium is augmented by
protein kinase C (PKC) activation and in PKC-activated cells, cyclic adenosine
monophosphate (cAMP) agonists augment t-PA secretion [Santell and Levin 1988],
Thrombin and prostacyclin induce a rapid and dose-dependent release of t-PA
through independent G-protein pathways involving Gq/intracellular calcium
concentrations and Gs/cAMP dependent pathways respectively [Tranquille and
Emeis 1991a; van den Eijnden-Schrauwen et al 1997; Hegeman et al 1998; Knop
and Gerke 2002]. In healthy volunteers, basal t-PA release appears to be modified by
genetic variation at the t-PA locus [Jern et al 1999; Ladenvall et al 2001]. Tissue
plasminogen activator genotype might therefore contribute to inter-individual
differences in the endogenous fibrinolytic capacity and the risk of arterial thrombotic
events.
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Endothelial-dependent agonists such as substance P [Newby et al 1997], bradykinin
[Brown et al 1999; Labinjoh et al 2000] and methacholine [Jern et al 1994; Wall et
al 1997] cause a rapid release of t-PA in vivo. This is independent of changes in
blood flow per se since infusion of sodium nitroprusside to increase forearm blood
flow (FBF) by more than 600% does not affect t-PA release [Newby et al 1997; Stein
et al 1998], Although shear stress increases t-PA expression and the intracellular
storage pool, it does not cause appreciable t-PA release in vivo [Sjogren et al 2000].
In addition, norepinephrine releases t-PA while reducing blood flow [Jern et al 1994]
and intra-arterial infusion of tumour necrosis factor-a (TNF-a), induces t-PA release
without changing blood flow [Chia et al 2003b]. Thus blood flow and shear stress
appear to regulate endothelial t-PA synthesis and storage but do not affect its acute
release.
1.3 PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1
1.3.1 Protein Structure and Function
Plasminogen activator inhibitor type-1 is a glycoprotein containing 379 amino acids
and has a plasma concentration of -500 pmol/L. There is a several-fold molar excess
ofPAI-1 over t-PA in plasma [Chandler et al 1990] to which it rapidly binds forming
a stable complex with a ratio of 1:1. Plasminogen activator inhibitor type-1 promotes
the stability and extension of thrombus by preventing t-PA binding to fibrin. The
active form of PAI-1 is unstable with a half-life of about 30 minutes [Kooistra et al
1986]. Inhibition of t-PA by PAI-1 is reduced -90% in the presence of fibrin due to
reduced access to the catalytic domain of fibrin-bound t-PA [Keijer et al 1991], As
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the complex structure of polymerised fibrin decreases access of t-PA to fibrin, the
efficacy of fibrinolysis is greatest in the early phase of fibrin formation on the
surface of atheromatous plaques. In contrast, fully formed and cross-linked fibrin is
resistant to t-PA mediated fibrinolysis [Thorsen 1992],
1.3.2 Synthesis and Release
The majority of PAI-1 synthesis and release occurs in vascular tissue, namely
endothelium and vascular smooth muscle, although the liver and platelets provide
further contributions [Sprengers and Kluft 1987]. Thrombin stimulates PAI-1
synthesis within endothelial cells and expression on the surface of activated platelets.
Platelet-rich thrombi are more susceptible to lysis by t-PA in PAI-1 deficient mice
suggesting platelets may provide a significant local source of PAI-1 [Higgins and
Vehar 1987],
1.3.3 PAI-1 Polymorphisms
The human PAI-1 gene located on chromosome 7 contains nine exons and eight
introns [Strandberg et al 1988], Several polymorphisms have been described
including a common four or five guanine base pair polymorphism in the promoter
region upstream of the transcription start site (4G/5G). Subjects homozygous for the
4G allele have increased gene transcription and increased plasma levels of PAI-1
[Eriksson et al 1995], There appears to be association of the 4G/4G genotype with an
increased risk of coronary disease [Iacoviello et al 1998] though this may reflect
interaction between PAI-1 4G/5G genotype, plasma hypertriglyceridaemia and the
insulin resistance syndrome [Kohler and Grant 2000].
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1.4 ENDOTHELIAL FUNCTION
The endothelium plays a vital role in the regulation of blood flow, coagulation and
fibrinolysis as well as the response to tissue injury and inflammation. This vascular
homeostasis is maintained through the synthesis and release of a number of factors
from the endothelium in response to mechanical, neural and humoral stimuli
(Table 1.1).
1.4.1 RegulationOf Vasomotion
The pioneering work of Furchgott and Zawadski [Furchgott and Zawadzki 1980] led
to the subsequent description of nitric oxide (NO) as the prototypical endothelial-
derived vasodilator. It is now recognised that a number of such factors are
physiologically active within the human circulation (Table 1.1). A number of
endogenous factors including bradykinin and substance P rely on the integrity of the
endothelium to mediate vascular smooth muscle relaxation. An important component
of such endothelium-dependent smooth muscle relaxation consists of calcium-
dependent activation of the constitutive enzyme NO synthase (NOS) and release of
NO [Moncada and Higgs 1993], The relative dependency on NO, endothelium-
derived hyperpolarising factor (EDHF) and prostacyclin-mediated vasodilatation
depends on the specific stimulus as well as the basal resting conditions.
As well as regulating vasodilatation, the endothelium also synthesises and responds
to vasoconstricting factors including endothelin-1 [Webb 1995a] and angiotensin II
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[Kifor and Dzau 1987]. The continual basal release of NO and endothelin plays an
important role in maintaining vascular tone and blood pressure [Vallance et al 1989;
Haynes et al 1996].
Table 1.1 Factors secreted and regulated by the endothelium to maintain vascular
haemostasis
Regulation of vascular tone
Nitric oxide Endothelin-1
Prostaglandins, thromboxane A2 Angiotensin II









Monocyte chemotactic factor-1 (MCP-1)
Adhesion molecule expression (VCAM-1, ICAM-1, selectins)
Interleukins 1, 6, and 18
Tumour necrosis factor-a
1.4.2 Coagulation and Endogenous Fibrinolysis
The endothelium is the source of a number of coagulation and fibrinolytic factors.
Although the intact endothelial monolayer maintains an antithrombotic surface,
arterial injury is associated with the development of a pro-coagulant phenotype. The
regulation of the endogenous fibrinolytic system has been reviewed above and its
role in the pathophysiology of coronary heart disease (CHD) will be discussed
further.
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1.5 ENDOTHELIAL FUNCTION AND ATHEROTHROMBOSIS
Atherosclerosis is associated with a decrease in the synthesis and release of
endothelially-derived factors with an increased risk of local thrombus formation and
reduced blood flow risking vessel occlusion and tissue infarction. Nearly all of the
candidate risk factors for atherosclerosis appear detrimental to endothelial function.
1.5.1 Endothelium DependentVasodilator Responses
To date, most clinical studies have focused on the assessment of endothelium-
dependent vasomotion as a surrogate measure of endothelial function. This can be
undertaken by measuring resistance vessel responses to endothelial stimulants as
well as conduit vessel responses to reactive hyperaemia or pharmacological
stimulation. Invasive and non-invasive methods of assessing endothelial function
have been shown to be highly reproducible with low coefficients of variation
reported for both strain gauge plethysmography and flow-mediated dilatation of the
brachial artery [Tousoulis et al 2005],
The endothelium-dependent regulation of peripheral vascular tone is impaired by
atherosclerosis and its risk factors such as smoking [Celermajer et al 1996; Heitzer et
al 1996; Newby et al 1999; Pretorius et al 2002], hypercholesterolemia [Celermajer
et al 1992; Stroes et al 1995), diabetes mellitus [Calver et al 1992] and a familial
history of atherosclerosis [Clarkson et al 1997], Similarly, impaired vasodilator
responses within the coronary circulation in patients with coronary disease [Ludmer
et al 1986] and its risk factors including smoking [Zeiher et al 1995] suggest
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impaired endothelial responses are a systemic feature of atherosclerosis.
Furthermore, impaired endothelium-dependent vasomotor dilatation in the peripheral
[Heitzer et al 2001; Perticone et al 2001] and coronary [Suwaidi et al 2000; Halcox
et al 2002b] circulations, independently predicts the risk of future adverse
cardiovascular events including subjects without angiographical evidence of
significant coronary disease [Suwaidi et al 2000] (Table 1.2). Whilst providing an
important indicator of endothelial function, the pathophysiological mechanism
linking impaired endothelium-dependent smooth muscle relaxation and subsequent
atherothrombotic events remains unclear.
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Table 1.2 Predictive value of impaired endothelium-dependent vasodilatation and
risk of cardiovascular events adapted from Widlansky et al 2003 [Widlansky et al
2003]
Patient Study Design Vascular Marker of End Findings
Population Bed function Points
157 pts with Retrospective/ Coronary Ach CV Ach responses
mild CAD 28 months response Death, independent
[Suwaidi et al MI, predictor of
2000] CCF or events
PCI
147 pts with Retrospective/ Coronary Ach MI, UA, Vasomotor
CAD 7.7 years response, CVA, response
[Schachinger et FMD CABG, independent
al 2000] PCI, predictor of
PVD events
281 pts with Prospective/ Brachial Ach CV Ach responses
CAD [Heitzer et 4.5 years response Death, independent





225 pts with Prospective/ Brachial Ach CV Ach responses
hypertension 32 months response Death, independent






308 pts Retrospective/ Coronary Ach CV Ach responses
undergoing 46 months response Death, independent
angiography CVA, predictor of
[Halcox et al MI, UA events
2002b]
Ach - acetylcholine; CABG - coronary artery bypass graft surgery; CAD - coronary artery
disease; CCF - congestive cardiac failure; CVA - ischaemic stroke; CV death - death from a
cardiovascular death; FMD - flow-mediated dilation; MI - myocardial infarction; PCI -
percutaneous coronary intervention (angioplasty or stent); PVD - peripheral vascular disease;
TIA - transient ischaemic attack; UA - unstable angina.
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1.5.2 In Vivo Assessment of Acute t-PA Release
In humans, acute release of t-PA can be assessed systemically following venous
occlusion [Gris et al 1991], intravenous infusion ofbradykinin [Brown et al 1997] or
in response to exercise [Chandler et al 1992]. However, these approaches are limited
by potential confounding effects, such as changes in systemic haemodynamics,
activation of the sympathetic nervous system, clearance of t-PA and PAI-1, and
concomitant release of other mediators. Direct assessment of local capacity for acute
t-PA release within individual vascular beds avoids these problems and is likely to
better represent the defence against arterial thrombosis [Oliver et al 2005].
A near instantaneous release of endothelial t-PA is seen during intra-arterial
substance P [Newby et al 1997; Newby et al 1999], bradykinin, [Brown et al 1999;
Witherow et al 2002] and methacholine [Stein et al 1998] infusions with impaired
release of t-PA seen in cigarette smokers [Newby et al 1999; Pretorius et al 2002]
and patients with CHD [Newby et al 2001], Although the forearm circulation is
relatively protected from the development of atheroma, the acute fibrinolytic
responses in the forearm [Newby et al 1999; Labinjoh et al 2001a; Witherow et al
2002] and coronary [Minai et al 2001; Newby et al 2001; Matsumoto et al 2003]
circulations appear similar in subjects with cardiac disease.
1.5.3 Vascular Inflammation
Atherosclerosis is a complex inflammatory process involving numerous cell types
[Ross 1999], Elevated levels of inflammatory markers such as
C-reactive protein (CRP) [Liuzzo et al 1994; Haverkate et al 1997; Ridker et al
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1997b] and interleukin-6 [Ridker et al 2000b] predict the occurrence of adverse
cardiovascular events independent of other conventional risk factors. Acute
inflammation has recently been shown to directly affect endothelial vasomotor
[Hingorani et al 2000b] and fibrinolytic function [Chia et al 2003b] in healthy
volunteers suggesting that inflammatory mediators contribute to vascular
dysfunction. In keeping with this hypothesis, anti-inflammatory therapies may
ameliorate inflammation-induced endothelial dysfunction [Kharbanda et al 2002],
1.6 ENDOGENOUS FIBRINOLYSIS AND CORONARY HEART
DISEASE
1.6.1 Plasma Levels of Fibrinolytic Factors and Risk of Coronary
Disease
In epidemiological studies of patients with ischaemic heart disease [Thompson et al
1995; Juhan-Vague et al 1996; Wiman et al 2000], and in prospective studies in
healthy populations [Ridker et al 1993; van der Bom et al 1997; Lowe et al 1998;
Thogersen et al 1998], higher total plasma t-PA concentrations positively and
independently predict future coronary events. However it would be anticipated that
high t-PA concentrations would protect against subsequent cardiovascular events
rather than the reverse.
There are several plausible mechanisms that may explain the observed relationship
between increased t-PA levels and risk of cardiovascular events. Increased t-PA
antigen levels are associated with increased levels of PAI-1 antigen and circulating
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t-PA/PAI-1 complexes [Carter et al 1998; Wiman et al 2000] thereby reducing
overall free t-PA 'activity' [Jansson et al 1993], Secondly, areas of endothelial
denudation and thrombus deposition are a common finding on the surface of
atheromatous plaques and are usually subclinical [Davies 2000a]. The adverse
prognosis conferred by elevated plasma t-PA antigen concentrations may, therefore,
reflect the extent of occult atheroma and subclinical plaque rupture stimulating t-PA
release. Although effective t-PA release may prevent thrombus propagation,
organisation of the residual thrombus may lead to plaque growth and expansion
increasing the overall burden of atheroma [Mann and Davies 1999], The increase in
systemic circulating t-PA may be linked to enhanced t-PA gene expression observed
within atherosclerotic vessels including aortic aneurysms and atheromatous plaques
[Lupu et al 1995; Schneiderman et al 1995]. Plasminogen activator mRNA
expression is greatest in advanced macrophage and lipid-rich plaques and in areas of
lesion necrosis [Lupu et al 1995; Steins et al 1999] suggesting that higher t-PA levels
might be associated with a greater risk of unstable plaque rupture secondary to
excess fibrinolytic activity.
1.6.2 Acute Tissue Plasminogen Activator Release and Resolution of
Thrombus
Although plaque related microthrombi are a common finding, effective local t-PA
release may result in these remaining subclinical and becoming quiescent. However
deficiencies in t-PA release may cause such microthrombi to propagate, ultimately
leading to arterial occlusion. Once thrombotic occlusion has occurred, the probability
of reperfusion occurring will be determined by the efficacy of endogenous
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fibrinolysis. Indeed, following acute MI and in the absence of reperfusion therapy,
the infarct-related artery undergoes spontaneous reperfusion in around 30% of
patients within the first 12 hours [DeWood et al 1980; Armstrong et al 1989;
Rentrop et al 1989]. If endogenous fibrinolysis is to be effective, then the rapid
mobilisation of t-PA from the endothelium is essential because thrombus dissolution
is much more effective if t-PA is incorporated during, rather than after, thrombus
formation [Fox et al 1985], As the rapidity and extent of acute t-PA release from the
endothelium is the principal determinant of the efficacy of local endogenous
fibrinolysis [Hrafnkelsdottir et al 2004a; Oliver et al 2005], the capacity of the
endothelium to release t-PA might predict the clinical outcome of individual plaque
events and long-term cardiovascular risk.
1.6.3 Acute t-PA Release, Regulation of Vascular Tone and Risk of
Cardiovascular Events
Previous work has demonstrated impaired forearm t-PA release in cigarette smokers
[Newby et al 1999], a group who are at particular risk of coronary thrombosis and
MI [Burke et al 1997], This suggests that endogenous fibrinolysis plays an important
role in the pathogenesis of coronary thrombosis. Reports of preserved endothelium-
dependent vasodilatation in smokers [Pretorius et al 2002] and in patients with
hypertension [Hrafnkelsdottir et al 1998; Hrafnkelsdottir et al 2004b] despite
reduced acute t-PA release suggest that, in some circumstances, reduced t-PA release
may be a more sensitive marker of endothelial dysfunction. However at present, the
relationship between the capacity to release t-PA and the future risk of adverse
cardiovascular events is unknown.
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1.7 GENETIC POLYMORPHISMS AND ATHEROSCLEROSIS
The distribution of atherothrombotic disease amongst individuals and populations
results from the interaction between susceptibility genes and environmental
exposures which combine to produce an overall disease phenotype.
1.7.1 Genetic Factors and Cardiovascular Risk
After correction for traditional risk factors such as hypertension, hyperlipidaemia and
smoking, there remains a significant genetic influence on the risk of developing
symptomatic coronary disease [Marenberg et al 1994; de Lange et al 2001). Indeed,
first-degree relatives of patients with premature coronary disease are themselves at
an increased risk of developing coronary disease at an early age [Shea et al 1984;
Schildkraut et al 1989; Steeds and Channer 1997], The familial risk of CHD could be
due to shared genetic or environmental factors, or more likely a combination of both.
Interestingly, Scandinavian twin registry studies reported an increased concordance
for risk of death from CHD in monozygotic twins compared with dizygotic twins,
suggesting that sharing genes is more important than sharing family environment in
determining mortality from cardiovascular disease [Marenberg et al 1994],
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1.7.2 Single Nucleotide Polymorphisms
Although single mendelian gene defects predisposing to early onset coronary disease
such as familial hypercholesterolaemia do exist, more commonly cardiovascular
disease manifests as a late onset condition without a clear mode of inheritance
[Hingorani 2000a]. There is increasing interest in the paradigm that common genetic
variants with a >1% carrier frequency in the general population might explain the
predisposition to common conditions such as CHD, stroke and hypertension. These
single nucleotide polymorphisms (SNPs) are single base pair positions within
genomic DNA and compromise about 90% of human DNA sequence variation [Li
and Sadler 1991] occurring at a frequency of about 1 per 1,000 base pairs [Collins et
al 1998; Brookes 1999].
1.7.3 Genetic Polymorphisms of the Haemostatic System
As the final common pathway of many cardiovascular diseases involves thrombus
formation there is great interest in how genetic regulation of haemostasis may
contribute to the pathogenesis of vascular events by altering the production or
metabolism of haemostatic factors. Elevated fibrin D-dimer and t-PA antigen
concentrations have been reported in male, healthy relatives of subjects with severe
CHD [Mills et al 2002], with twin studies suggesting genetic factors account for
approximately 60% of the inter-individual variation in t-PA and PAI-1 antigen levels
[de Lange et al 2001]. A number of haemostatic factor and platelet glycoprotein
receptors linked to thrombotic risk are shown (Table 1.3).
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Table 1.3 Polymorphisms in the haemostatic system linked to the risk of arterial
thrombosis adapted from Voetsch and Loscalzo 2004 [Voetsch and Loscalzo 2004]
Fibrinolysis Coagulation Platelet Receptor
t-PA ^4/w-Ins/Del Fibrinogen (3 -455 G/A GPIIIa Leu33Pro
t-PA -7,351 C/T Fibrinogen (3 -854 G/A GPIb a VNTR
PAI-1 4G/5G Fibrinogen a Thr312Ala GPIb a Thrl45Met
TAFI Alal47Thr Factor V Leiden GPIa/IIa ot2 807C/T
t-PA - tissue plasminogen activator; Ins - insertion; Del - deletion; PAI-1 - plasminogen
activator inhibitor type-1; TAFI - thrombin activatable fibrinolysis inhibitor.
1.7.4 Tissue Plasminogen Activator Genetic Polymorphisms
A common intronic polymorphism of the t-PA gene is generated by the insertion of a
311 base pair Alu-repeat sequence [Ludwig et al 1992] with a similar polymorphism
in the angiotensin-converting enzyme (ACE) gene reportedly explaining 50% of the
variability of plasma ACE levels between individuals [Rigat et al 1990], Although
not a consistent finding in all populations [Ridker et al 1997a], there is an
independent association between the insertion (Ins) genotype and the future risk of
MI: a relative risk of 2.24 in comparison with the deletion (Del) genotype [van der
Bom et al 1997],
In young healthy volunteers, basal t-PA release from the forearm circulation
correlates with t-PA Alu genotype with Ins homozygous subjects having greater basal
release than either heterozygotes or Del homozygotes [Jern et al 1999], The nature of
the Ins/Del polymorphism, an insertion of an ,4/w-repeat in an intron, makes a direct
functional effect of the insertion allele on the t-PA protein unlikely but not
impossible [Makalowski et al 1994], Three further polymorphisms at the t-PA locus
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are in significant linkage disequilibrium with the Alu polymorphism and
consequently associated with t-PA release rates: one in the far upstream enhancer
(7,351 C—>T substitution), one in exon 6 (20,099 T—>C), and one in intron 10
(27,445 T—»A) [Ladenvall et al 2000], The -7,351 C/T enhancer SNP resides within
a GC box which is a binding site for the transcription factor Spl with reduced
binding affinity of Spl in the presence of the T allele [Ladenvall et al 2000], As the
T allele is associated with low t-PA release rate, this suggests the -7,351 C/T variant
is important in regulating t-PA levels at the level of transcription [Ladenvall et al
2000; Wolf et al 2005], Recently, -7,351 TT homozygotes have been shown to be at
increased risk of both MI [Ladenvall et al 2002] and lacunar stroke [Jannes et al
2004] compared to CC homozygotes.
Inter-individual differences in t-PA release due to genetic variation at the t-PA locus
may modify the fibrinolytic response to local thrombus formation. Although the
effect of t-PA polymorphisms has been assessed in asymptomatic individuals, the
functional importance of t-PA genotype on acute fibrinolytic capacity in patients
with established CHD and its associated risk factors is unknown.
1.8 ACUTE INFLAMMATION AND ENDOTHELIAL FUNCTION IN
PATIENTS WITH CORONARY DISEASE
1.8.1 Inflammation and Atherosclerosis
Plasma markers of systemic inflammation, such as CRP and TNF-a, are elevated in
patients with cardiovascular disease [Haverkate et al 1997; Ridker et al 2000a] and
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predict the development of cardiovascular disease independent of other risk factors.
Increased levels of CRP in those at greatest risk may reflect a larger total burden of
atheroma, a greater inflammatory activity predisposing to plaque rupture, or a
combination of these mechanisms [Davies 2000a].
Focal arterial inflammation is one of the most prominent characteristics of the
atherosclerotic process [Ross 1999] including the pathogenesis of acute coronary
syndromes [Davies 2000a] with systemic release of thromboxanes and leukotrienes,
and activation of circulating leucocytes [Neumann et al 1997; Aukrust et al 1999],
Indeed, a process of infiltration by mononuclear leucocytes followed by fibrosis and
finally tissue degeneration is common to many other inflammatory disorders apart
from atherosclerosis [Tousoulis et al 2003], In keeping with this observation,
subjects with the auto-immune inflammatory disorder rheumatoid arthritis are at an
increased risk of cardiovascular morbidity and mortality [Mutru et al 1985].
Human recombinant CRP, at concentrations known to predict vascular disease,
contributes to the development of a pro-inflammatory and pro-atherosclerotic
endothelial phenotype characterised by expression of cell adhesion molecules
[Pasceri et al 2000; Pasceri et al 2001], downregulation of endothelial NO synthase
(eNOS) expression [Verma et al 2004] and production of interleukin-6 [Verma et al
2000]. C-reactive protein has recently been shown to protect endothelial cells from
complement mediated injury suggesting the development of atherosclerosis may
depend on a balance of its pro- and anti-atherogenic actions [Verma et al 2004].
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1.8.2 Inflammation and Haemostatic Factors
Although elevated levels of t-PA independently predict the occurrence of
cardiovascular events [Ridker et al 1993; Thompson et al 1995; van der Bom et al
1997; Lowe et al 1998; Thogersen et al 1998], t-PA concentrations may be
implicated in the mechanisms contributing to, or arise as a consequence of,
atherothrombotic events. Previous studies have indicated a direct relationship
between serum CRP and plasma t-PA concentrations [Haverkate et al 1995; Juhan-
Vague et al 1996; Gram et al 2000; Lowe et al 2004], This raises the question of
whether vascular inflammation is causally related to the elevation in plasma t-PA
concentrations or whether CRP and t-PA are independently increased by a common
factor related to the atherosclerotic process itself, such as acute plaque rupture.
1.8.3 Vascular Inflammation and Endothelial Function
In healthy volunteers, experimental inflammation has been shown to impair
endothelium-dependent dilatation in the arterial [Hingorani et al 2000b; Chia et al
2003b] and venous [Bhagat and Vallance 1999] circulations. Pre-treatment with an
anti-inflammatory dose of aspirin inhibits the inflammation-induced rise in
interleukin-1 receptor antagonist levels and impaired endothelium-dependent
vasodilator responses [Kharbanda et al 2002], Together, these observations suggest
that pro-inflammatory cytokines directly affect endothelial function.
In patients with coronary artery disease, elevated serum concentrations of CRP are
associated with impaired forearm endothelial vascular reactivity [Fichtlscherer et al
2000], Furthermore, normalisation of CRP levels over time is associated with a
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significant improvement in endothelium-dependent FBF responses [Fichtlscherer et
al 2000] whereas ongoing chronic inflammation is associated with an impaired
fibrinolytic response to venous occlusion [Speidl et al 2005]. Recently, intra-arterial
infusion of the pro-inflammatory cytokine in healthy volunteers was shown to impair
endothelium-dependent vasodilatation whilst increasing local t-PA release [Chia et al
2003b], This suggests that vascular inflammation has discrete and regulated effects
on endothelial function causing a simultaneous reduction in blood flow whilst
potentiating endogenous fibrinolysis. As the endothelium is the major source of
plasma t-PA, abnormalities of endothelial function may therefore mediate the
potential inflammation-induced elevations in plasma t-PA concentrations and
underlie the link between t-PA levels and future vascular events. However, the effect
of acute arterial inflammation in subjects with pre-existing vascular dysfunction and
coronary disease is unknown.
1.9 NITRIC OXIDE AND ENDOTHELIAL DYSFUNCTION
The normal endothelium, by releasing NO, promotes vasodilation and inhibits
inflammation, thrombosis, and vascular smooth muscle cell proliferation. Although
originally described as a vasodilator [Furchgott and Zawadzki 1980; Ignarro 1989],
these biological actions of NO make it an important component in the defence
against atherosclerosis.
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1.9.1 Endothelial Nitric Oxide Synthesis
A number of vasodilators have since been shown to depend on the integrity of the
vascular endothelium and NO release for their activity, including substance P
[Newby et al 1998] and bradykinin [Cockcroft et al 1994b]. An important
component of such endothelium-dependent responses consists of calcium-dependent
activation of the constitutive enzyme eNOS, which catalyses the conversion of the
amino acid L-arginine to L-citrulline and NO [Moncada and Higgs 1993],
Constitutive NOS can be competitively inhibited by guanidine-substituted analogues
rj
of L-arginine, such as L-N -monomethyl arginine (L-NMMA). Inorganic nitrates,
such as sodium nitroprusside, can activate the same effector pathway by providing an
inorganic source of NO which is not dependent on the functional integrity of the
vascular endothelium.
1.9.2 Nitric Oxide Availability and Atherosclerosis
Reduced nitric oxide availability may be due to (1) decreased endothelial NO
production, (2) increased levels of endogenous NO inhibitors or (3) increased
destruction ofNO by free radicals [Vallance 2003]. Deficiency of biologically active
NO favours leucocyte adhesion to the injured endothelium, platelet aggregation and
smooth muscle migration and proliferation increasing atheroma formation [Cayatte et
al 1994] and the risk of thrombus propagation [Ganz and Vita 2003], In animal
models, gene transfer of eNOS is associated with a reduction in neo-intimal
formation following arterial injury [Varenne et al 2000] whilst in humans
supplementation with L-arginine, the endogenous substrate for NO, restores
37
endothelium-dependent vasodilator responses in hypercholesterolaemic patients
[Drexler et al 1991],
1.9.3 Nitric Oxide andGuanylate Cyclase Activation
Once synthesised, NO diffuses to the underlying vascular smooth muscle where it
activates soluble guanylate cyclase increasing cyclic guanosine monophosphate
(cGMP) concentrations [Ignarro 1989; Moncada and Higgs 1993], The physiological
cell signalling actions ofNO are predominantly due to increased cGMP which occurs
with NO concentrations in the nanomolar range [Vallance 2003], At higher levels
NO has the potential to nitrosylate cysteine residues in proteins [Stamler et al 2001]
as well as affecting a variety of haem-containing and redox sensitive enzymes and
ion channels [Vallance 2003],
1.9.4 Phosphodiesterase Enzymes
Phosphodiesterases (PDEs) were identified as being responsible for the hydrolysis of
cyclic nucleotides over 40 years ago [Sutherland 1972], Phosphodiesterases
hydrolyse cGMP to guanosine monophosphate (GMP) and several isoenzymes exist,
each with a different tissue distribution and specificity for cGMP [Wallis et al 1999;
Mehats et al 2002],
1.9.4.1 Phosphodiesterase Type 5 Inhibition
Phosphodiesterases negatively regulate the action of NO by degrading cGMP to
GMP. Phosphodiesterase isoenzyme type 5 (PDE 5) is the enzyme responsible for
inactivation of cGMP and is found in high concentrations in the corpus cavernosum,
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skeletal muscle, platelets and vascular smooth muscle [Mehats et al 2002]. One
approach to ameliorate some of the deleterious effects of reduced NO release and
bioavailability is to prolong the actions of cGMP through inhibition of PDE 5.
Sildenafil citrate (Viagra® Pfizer Ltd) is a selective PDE 5 inhibitor used in the
treatment of erectile dysfunction. Erectile dysfunction is particularly common in
patients with heart disease, because of the presence of overlapping risk factors,
including older age, diabetes mellitus, hypertension, and hypercholesterolaemia
[Feldman et al 1994]. As sildenafil therapy increases NO levels within the corpus
cavernosum, it might also have favourable effects on NO balance in the presence of
atherosclerotic disease.
1.9.4.2 Phosphodiesterase Inhibition and Endogenous Fibrinolysis
Although substance P-induced t-PA release was inhibited by the NOS inhibitor, L-
NMMA [Newby et al 1998] sodium nitroprusside does not stimulate t-PA release
[Jern et al 1994; Newby et al 1997; Hrafnkelsdottir et al 1998; Brown et al 1999],
Thus, although NO alone does not induce t-PA release, it may play a permissive or
synergistic role in stimulated t-PA release. As NO mediates many of its actions
through cGMP, there is a potential interaction between cGMP and t-PA release. In
animal models, non-selective PDE inhibitors such as pentoxifylline and its
analogues, increase stimulated but not basal plasma t-PA levels [Tranquille and
Emeis 1991b]. Pentoxifylline has also been shown to potentiate the effect of
exogenous thrombolysis in the dissolution of fibrin clots [Ambrus et al 1994],
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There is significant cross-talk between different PDE isoenzymes: phosphodiesterase
isoenzyme type 3 (PDE 3), which normally hydrolyses cAMP and is present within
vascular smooth muscle, is inhibited by increased cGMP concentrations [Maurice et
al 2003], Increased cAMP concentrations levels play a role in thrombin, prostacyclin
and isoproterenol-induced acute t-PA release [Hegeman et al 1998]. Sildenafil might
therefore augment acute t-PA release from endothelial stores via PDE 5-mediated
inhibition of PDE 3 and increased intracellular cAMP concentrations.
1.9.4.3 Phosphodiesterase Type 5 Inhibition and Vascular Tone
Intravenous or oral administration of sildenafil results in a small but consistent
decrease in systemic and pulmonary blood pressure in both normal men [Jackson et
al 1999] and those with stable CHD [Jackson et al 1999; Herrmann et al 2000; Webb
et al 2000]. This presumably reflects augmentation of the vascular effects of basal
NO release mediated through an increase in cGMP. In men with severe coronary
artery disease, sildenafil does not alter coronary blood flow [Herrmann et al 2000]
but augmentation of the coronary hyperaemic response to adenosine in the presence
of sildenafil suggests functional interaction between the cAMP and cGMP pathways
in humans [Herrmann et al 2000].
Oral administration of sildenafil increases vasodilatation during infusion of
acetylcholine in the peripheral circulation of healthy cigarette smokers [Kimura et al
2003] and in the coronary circulation of patients with CHD [Halcox et al 2002a],
Although these results suggest PDE 5 inhibition may improve endothelial-dependent
responses, these studies were not placebo-controlled and do not account for the
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variation in active plasma concentrations seen following a single oral dose of
sildenafil citrate [Boolell et al 1996]. In a more recent randomised double-blinded
placebo-controlled study in young smokers sildenafil therapy did not change flow-
mediated dilatation [Dishy et al 2004].
Despite these initial studies on one aspect of endothelial function in healthy subjects,
the effects of sildenafil on endogenous t-PA release and levels of PAI-1 in subjects
with atherosclerosis are unknown. Therapeutic intervention with PDE 5 inhibitors
could represent a novel approach to restoring endothelial responses by prolonging the
action ofNO and confer secondary preventative benefits in patients with CHD.
1.10 HYPOTHESES
Coronary heart disease and its associated risk factors such as cigarette smoking, are
associated with a pro-inflammatory state and increased risk of vascular occlusion
secondary to thrombus formation. As tissue plasminogen activator is the principal
mediator of endogenous fibrinolysis in humans, acute t-PA release may be a
principal determinant of the future risk of atherothrombotic events. Differences in
t-PA release between individuals may explain the variation in the burden of
cardiovascular events with seemingly similar risk factor profiles. Therapeutic
strategies to augment the endogenous fibrinolytic response may be associated with
favourable outcomes in patients with CHD.
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The following hypotheses will be addressed:
1. Reduced acute release of t-PA will be associated with an increased risk of
future atherothrombotic events in patients with established CHD.
2. That genetic variation within the t-PA locus may influence the acute
fibrinolytic capacity of patients with CHD.
3. Local vascular inflammation will directly affect endothelial control of
vascular tone and fibrinolytic function in patients with CHD.
4. Acute PDE type 5 inhibition will modify t-PA release and vasomotor
function in patients with stable CHD.
1.11 AIMS
The aims of the thesis were:
In patients with stable CHD
• To determine whether acute stimulated t-PA release predicts the future risk of
adverse atherothrombotic events.
• To investigate whether substance P-induced endothelium-dependent
vasodilatation predicts the future risk of adverse atherothrombotic events.
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In patients with CHD
• To determine the frequency of four polymorphisms of the t-PA gene in a
cohort of unrelated Caucasian subjects.
• To investigate whether the (i) Alu-repeat Ins/Del, (ii) C—>T enhancer region
(-7,351 C/T), (iii) T^C exon 6 (20,099 T/C), and (iv) T—>A (27,445 T/A)
intron 10 polymorphisms of the t-PA gene influence vasomotor and
fibrinolytic function.
In patients with CHD
• To establish the relationship between plasma CRP, t-PA and PAI-1 antigen
concentrations.
• To determine whether intra-arterial infusion of the pro-inflammatory cytokine
TNF-a results in local vascular inflammation.
• To establish the effect of acute arterial inflammation on vasomotor and
fibrinolytic function in patients with stable coronary disease established on
secondary preventative medications.
In patients with CHD and age-matched healthy volunteers
• To evaluate the tolerability of an intravenous bolus and infusion of the PDE 5
inhibitor sildenafil citrate.
• To determine whether acute treatment with sildenafil citrate has favourable
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Endothelial function may be assessed in vivo by measuring the response to vaso¬
active substances released by, or those that interact with, the vascular endothelium.
This approach has the advantage that vessels are studied in their physiological
environment under the influence of neuronal, circulating, and local mediators
[Benjamin et al 1995], Local intra-arterial drug infusion permits the direct
assessment of vascular responses without invoking concomitant effects on other
organs.
2.1.1 Assessing Vascular Function
Although measurement of coronary responses may be of greatest clinical relevance,
invasive coronary studies can only really be performed in patients undergoing
angiography. The close correlation between coronary and peripheral endothelium-
dependent responses [Anderson et al 1995] does, however, suggest that endothelial
dysfunction may be a systemic state or that circulating factors have parallel effects in
coronary and peripheral arteries [Vita 2005],
2.1.2 Venous Occlusion Plethysmography
Methods of assessing resistance vessel function in the forearm are based on the
principle of strain gauge venous impedance plethysmography. This technique
examines the change in FBF during intra-arterial (brachial artery) administration of
agonists at subsystemic, locally active doses (Figure 2.1) [Benjamin et al 1995;
Webb 1995b], The technique of venous occlusion plethysmography relies on
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intermittently preventing venous drainage from the arm using upper arm cuffs
inflated to above venous pressure whilst arterial inflow is unaltered: blood can enter
the forearm but cannot escape. This results in a linear increase in forearm volume
over time, which is proportional to arterial blood inflow (Figure 2.2). Under resting
conditions, approximately 70% of total FBF is through skeletal muscle. As the hand
contains a high proportion of arteriovenous shunts with a different pharmacology and
physiology it is excluded from the circulation by the application of inflation cuffs at
suprasystolic pressure during FBF measurement. The technique of bilateral FBF
measurement is highly reproducible within individuals [Walker et al 2001] and is
ideally suited to assessment of interventional strategies with repeated measurements
[Wilkinson and Webb 2001],
Figure 2.1 Intra-brachial artery infusion system along with venous occlusion (upper arm)
and suprasystolic pressure (wrist) cuffs in a left-handed (right arm, non-dominant) volunteer.
A venous cannula for blood sampling is sited in the antecubital vein.
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Figure 2.2 Typical bilateral blood flow recording during forearm plethysmography study.
Non-infused arm
Cuff inflated Cuff deflated
Infused arm during infusion of substance P 8 pmol/min




All studies were undertaken in accordance with the regulations of the Lothian
Research Ethics Committee and with the Declaration of Helsinki of the World
Medical Association. The written informed consent of each subject or patient was
obtained before entry into the study.
2.2.2 Subject Recruitment
2.2.2.1 Subjects with Coronary Heart Disease
Potential subjects were identified from a database of patients undergoing coronary
angiography within the Royal Infirmary of Edinburgh. Study information was posted
to suitable subjects meeting study criteria defined below. The general practitioner
and supervising hospital consultant were informed of all subjects who subsequently
participated in the research study.
2.2.2.2 Inclusion and Exclusion Criteria
We recruited patients aged >18 years with angiographically proven CHD defined as
^50% luminal stenosis of at least one major epicardial coronary vessel or a history of
MI (confirmed by a serial rise in creatine kinase of twice the upper limit of the
normal reference range and the development of pathological Q-waves in at least two
contiguous leads of the electrocardiogram). All patients had stable anginal symptoms
and had not undergone coronary revascularisation within the preceding 3 months.
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Exclusion criteria were significant cardiac failure, renal or hepatic impairment,
systolic blood pressure <100 or >190mmHg, diabetes mellitus, the regular use of
non-steroidal anti-inflammatory medications (excluding aspirin 75 mg/d) or inability
to rest supine during the forearm study.
2.2.2.3 Healthy Volunteer Subjects
A cohort of healthy control men who were age-matched to male subjects with CHD
were also recruited. All control subjects were healthy normotensive euglycaemic
non-smokers without any history of cardiorespiratory or vascular disease and were
not taking any regular medications.
2.2.3 Subject Preparation
Subjects were requested to abstain from alcohol for 24 hours and food, caffeine-
containing drinks and tobacco for at least 4 hours before each study. Cardio-active
medications were withheld on the morning of each CHD subject study visit. All
studies were conducted in a quiet temperature-controlled room maintained at
22-25°C.
2.2.4 Blood Pressure Measurement
Blood pressure was monitored in the non-infused arm at intervals throughout each
study using a semi-automated non-invasive oscillometric sphygmomanometer
(Phillips, Agilent V24). Mean arterial pressure (MAP) was defined as the diastolic
pressure plus a third of the pulse pressure.
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2.3 VENOUS OCCLUSION PLETHYSMOGRAPHY
2.3.1 BrachialArtery Cannulation
The brachial artery of the non-dominant arm was cannulated with a 27-G steel needle
(Cooper's Needle Works Ltd, Birmingham, UK) under 1% lidocaine (Xylocaine;
Astra Pharmaceuticals Ltd, Kings Langley, UK) local anaesthesia. The cannula was
attached to a 16-G epidural catheter (Portex Ltd, Hythe, UK) and patency maintained
by infusion of saline (0.9%: Baxter Healthcare Ltd, Thetford, UK) via an IVAC
P6000 syringe pump (IVAC Ltd, Basingstoke, UK). The total rate of intra-arterial
infusions was maintained constant throughout all studies at 1 mL/min.
2.3.2 Blood FlowMeasurement
Blood flow was measured in the infused and non-infused forearms by venous
occlusion plethysmography using mercury-in-silastic strain gauges that were applied
to the widest part of the forearm [Benjamin et al 1995]. Both arms were placed
above the level of the right atrium and upper arm cuffs were inflated intermittently to
40 mmHg (venous occlusion) pressure for 10 seconds in every 15 seconds to achieve
venous occlusion and obtain plethysmographic recordings. During measurement
periods, the hands were excluded from the circulation by rapid inflation of the wrist
cuffs to a pressure of 220 mmHg (suprasystolic) using E20 Rapid Cuff Inflators
(D.E. Hokanson Inc., Washington, USA). Analogue voltage output from an EC-4
strain gauge plethysmograph (D.E. Hokanson Inc.) was processed by a PowerLab®
analogue-to-digital converter and Chart™ v5.0.1 software (AD Instruments Ltd,
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Oxfordshire, UK) and recorded onto a Dell Latitude® laptop (Dell Computers Ltd,
UK). Calibration was achieved using the internal standard of the plethysmograph.
2.3.3 Plethysmographic Data Analysis
Plethysmographic data were extracted from the Chart™ data files and FBFs were
calculated for individual venous occlusion cuff inflations by use of a template
spreadsheet (Excel 2002; Microsoft Corporation, USA). Recordings from the first
60 seconds after wrist cuff inflation were not used because of the variability in blood
flow that this incurs [Benjamin et al 1995], Usually, the last five flow recordings in
each 3 minute measurement period were calculated and averaged for each arm.
2.3.4 Reproducibility of Plethysmographic Data
Analysis of all data collected during the forearm plethysmography study was
undertaken by a single operator in a blinded fashion as appropriate. Forearm blood
flow responses are reported as absolute blood flow responses
(mL/100 mL tissue/min) in the infused and non-infused arm unless stated otherwise.
Previous work has demonstrated intra-subject variability and coefficient of variation
of 7.8% and 27% for FBF across resting conditions and the dose range of vaso-
agonists used [Roberts et al 1986; Altenkirch et al 1990; Walker et al 2001; Newby
et al 2002].
2.4 VENOUS SAMPLING AND LABORATORY ASSAYS
2.4.1 Forearm Venous Sampling
Following administration of local anaesthetic, venous cannulae (17-G) were inserted
into large subcutaneous veins of the antecubital fossa in both arms as described
previously [Newby et al 1997], Blood was withdrawn simultaneously from each arm
and collected into acidified buffered citrate (Biopool® Stabilyte™, Umea, Sweden; t-
PA), trisodium citrate (Monovette®, Sarstedt, Niimbrecht, Germany; PAI-1 and
prothrombin Fl+2) potassium ethylene diamine tetraacetic acid (Monovette®,
Sarstedt, Niimbrecht, Germany; cotinine; cytokines; full blood count) and serum gel
(Monovette®, Sarstedt, Niimbrecht, Germany; CRP; clinical chemistry) tubes.
2.4.2 Sample Preparation
Citrate and acidified buffered citrate samples were centrifuged at 2,000 g for
30 minutes at 4°C, EDTA samples at lOOOg for 10 minutes at 20°C. Serum samples
were centrifuged at 2,000 g for 20 minutes after being allowed to clot on ice. Platelet
free plasma or serum was decanted and stored at -80°C before assay [Kluft and
Verheijen 1990],
2.4.3 Plasma Fibrinolytic and Haemostatic Assays
Plasma t-PA and PAI-1 antigen concentrations were determined using an enzyme-
linked immunosorbent assay; Coaliza® t-PA [Booth et al 1987] and Coaliza® PAI-1
(Chromogenix AB, Molndal, Sweden) [Declerck et al 1988] respectively. Plasma t-
PA activity was determined by a photometric method, Coatest® t-PA (Chromogenix
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AB) [Gram et al 1987], Intra-assay coefficients of variation are 7.0% and 5.5% for
t-PA and PAI-1 antigen, and 4.0% for t-PA activity, with inter-assay coefficients of
variability of 4.0%, 7.3% and 4.0% respectively [Newby et al 2002], The
sensitivities of the assays are 0.5 ng/mL, 2.5 ng/mL and 0.10 IU/mL respectively
[Newby et al 2002], Prothrombin fragment 1 and 2 (Fl+2; Enzygnost Fl+2; Dade
Behring, Milton Keynes, UK), was determined using an enzyme-linked
immunosorbent assay with intra- and inter- coefficients of variation of 10.4% and
11% respectively [Pelzer et al 1991], All coagulation assays were performed in
duplicate and the mean value taken.
2.4.4 Cytokine and C-Reactive Protein Assays
Plasma TNF-a (Quantikine R&D systems Inc., Minneapolis, USA) and IL-6 (Dako
A/S, Glostrup, Denmark) concentrations were determined using enzyme-linked
immunosorbent assays [Chia et al 2003a; 2003b] Intra-assay, and inter-assay
coefficients of variability were 5.2% and 7.2% and 4.2% and 6.4% for plasma
TNF-a and IL-6 respectively. Serum C-reactive protein concentrations were
determined using with a validated highly sensitive assay (/zs-CRP, Department of
Clinical Biochemistry; Fife NHS Trust, UK) [Roberts et al 2001] using the method
of particle-enhanced immunonephelometry (Behring BN II nephelometer, Dade
Behring Inc.). Intra-assay and inter-assay coefficients of variability for /zs-CRP were
3.7% and 4.2% respectively.
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2.4.5 Haematocrit and Biochemical Assays
Total white cell count and haematocrit and biochemical assays were undertaken on
stored venous samples (Departments of Haematology and Clinical Biochemistry,
Lothian NHS University Hospitals Trust, UK). Plasma cotinine concentrations were
determined using high performance liquid chromatography (ABS Laboratories Ltd;
London, UK) [Feyerabend and Russell 1990], A plasma value of greater than
13.7 ng/mL yields a 100% specificity and 96% sensitivity for smoking and non¬
smoking status with a detection limit of 0.1 ng/mL [Feyerabend and Russell 1990].
2.5 GENOTYPING
2.5.1 DNAExtraction and Polymerase Chain Reaction Assay
All genetic work was undertaken by the Wellcome Trust Clinical Research Facility
(WTCRF) Genetics Core Laboratory (Western General Hospital, Edinburgh, UK).
Genomic DNA was isolated from nucleated cells from frozen whole blood.
Genotyping was performed by allele discrimination analysis using the 5' nuclease
assay [Livak et al 1995], In this assay, the polymorphic target sequence is amplified
by PCR in the presence of two fluorogenic probes specific for each allele. Probes
hybridise to their target during the annealing step and the reporter dye is cleaved by
the 5' nuclease activity of Taq polymerase which gives rise to an increased
fluorescent signal. Any mismatch greatly reduces the efficiency of probe
hybridisation and cleavage allowing the allelic content of a sample to be determined
by comparing the fluorescent contribution of each dye (Figure 2.3).
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Figure 2.3 Allelic discrimination scatterplot for t-PA 27,445 T—>A (intron 10)
polymorphism showing PCR products obtained from AA homozygotes (circled, lower right),
heterozygotes (middle right) and TT homozygotes (top left) (courtesy of Angie Fawkes,
WTCRF Genetics Core).
t-PA - tissue plasminogen activator; PCR - polymerase chain reaction; WTCRF - Wellcome Trust
Clinical Research Facility.


































































2.5.2 Tissue Plasminogen Activator Polymorphisms
For the -7,351 C—>T (upstream enhancer), 20,099 T—>C (exon 6), and 27,445 T—>A
(intron 10) polymorphisms genotyping was performed by allele discrimination
analysis using the 5' nuclease assay. Oligonucleotide primers and fluorescently
labelled probes were obtained from Applied Biosystems (Applied Biosystems, Foster
City, California, USA) on the basis of previously published DNA and primer
sequences [Ladenvall et al 2000; Ladenvall et al 2002], Polymorphic target
sequences were amplified by PCR using two allelic specific probes. Real time
quantitative PCR was performed in an ABI PRISM® 7900HT Sequence Detector
System (Applied Biosystems, California, USA). Thermal cycling conditions were
two initial holds (50° C for 2 minutes and 95° C for 10 minutes) followed by a 40-
cycle two-step program (95° C for 15 seconds and 60° C for 1 minute) utilising a
standardised operating protocol (WTCRF Genetics Core; http://www.wtcrf.ed.ac.uk).
The fluorescent contribution of each dye was determined directly after the
completion of PCR.
For the Alu-intronic polymorphism, the insertion specific sequence was submitted to
the Applied Biosystems Assay-by-design service. Gene expression assays consisted
of unlabelled PCR primers and TaqMan®MGB probes (FAM dye labelled). Forward
and reverse primers were 5'-CGTAACAGGACAGCTCACAGTT-3 and 5'-
CCCTAGGAGAACTTCTCTTTAACTTTGTT-3 respectively. The insertion
specific probe was labelled in its 5' end with FAM and in it 3' end with a NFQ (non
fluorescent quencher): FAM- ACCCTATGAGATTAGAACAC-NFQ. Real time
quantitative PCR was performed with a ABI PRISM® 7900HT Sequence Detector
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using the standardised operating protocol described (WTCRF Genetics Core;
http://www.wtcrf.ed.ac.uk). ^/w-insertion PCR products were normalised to
threshold values against an endogenous control (single copy RNase P gene). Each
sample was run in triplicate with both the gene of interest and the RNase P control.
Genotype for the Alu-intronic polymorphism was calculated from differences in the
threshold cycle between the RNAse P and Alu-Ins sequence.
A confirmatory assay of ^4/w-Ins/Del genotypes utilised PCR amplification of the Ins
fragment with primers designed to flank the region of interest
(PLAT. 1 5' to 3' GTGAAAAGCAAGGTCTACCAG and PLAT.2 5' to
3' GACACCGAGTTCATCTTGAC). PCR was performed on a DNA engine tetrad
from MJ Research (Bio-Rad Laboratories, Inc., California, USA). Thermal cycling
conditions were 94° C for 2 minutes followed by 35-cycles (30 seconds at 94° C for
and 30 seconds at 60° C and 30 seconds at 72° C) with a final extension step of
10 minutes at 72° C. A 10 pL sample of this reaction was analysed on a 2.5%
agarose gel and following electrophoresis DNA was visualised with ethidium
bromide and UV transillumination. Amplification of the products produces a 570-bp
fragment from chromosomes with the Ins allele and a 260-bp fragment from those
without (Del).
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2.6 FREQUENCY OF CARDIOVASCULAR EVENTS DURING
FOLLOW-UP
The frequency of acute thrombotic-related patient events, defined as death from a
cardiovascular cause, MI, ischaemic stroke (CVA), and emergency hospitalisation
for myocardial ischaemia, were determined through the Information and Statistics
Division of the National Health Service in Scotland and the General Register Office
in Scotland. These systems have been successfully applied to evaluate cardiovascular
morbidity and mortality for subjects resident within Scotland [Fox et al 2002].
2.7 DATA ANALYSIS AND STATISTICS
Data were examined, where appropriate, by analysis of variance (ANOVA) with
repeated measures, two-tailed Student's t-test and Chi-squared test using GraphPad
Prism (GraphPad Software, California, USA). Results are expressed as mean and
standard error of mean (SEM) unless otherwise stated. Statistical significance was
assigned at the 5% level.
2.7.1 Calculation ofNet t-PA Release
For the forearm studies, estimated net release of t-PA activity and antigen was
defined as the product of the infused forearm plasma flow (based on the haematocrit,
Hct and the infused FBF) and the concentration difference between the infused
([t-PA]inf) and non-infused arms ([t-PA]Non.jnf).
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Estimated net forearm t-PA release = FBF x {1-Hct} x {[t-PA]inf. [t-PA]Non-inf}
Area under the curves (AUCs) for the dose-response of t-PA release were calculated
using the trapezoid rule [Matthews et al 1990],
2.7.2 Tissue Plasminogen Activator Genotype
Allelic discrimination for the polymorphisms of interest were ascertained by an
individual without information on case status or vascular study data. Allele
frequencies were estimated by gene counting. Chi-square test was used to evaluate
deviations of genotype distributions from the Hardy-Weinberg equilibrium. The
linkage disequilibrium coefficient D' was calculated as previously described [Devlin
and Risch 1995],
2.7.3 CardiovascularEvent Rates
Cumulative event rates were estimated by Kaplan-Meier survival curves, and
probability values were determined with the log-rank test. In those patients who
experienced multiple events, survival analysis was restricted to the first event. For
Kaplan-Meier analyses, subjects were divided into quartiles according to estimated




PREDICTS FUTURE ADVERSE CARDIOVASCULAR EVENTS
IN PATIENTS WITH CORONARY HEART DISEASE
Robinson SD, Ludlam CA, Boon NA, Newby DE.
Endothelial fibrinolytic capacity predicts future adverse
cardiovascular events in patients with coronary heart disease.
(Arterioscler Thromb Vase Biol, in print)
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3.1 SUMMARY
The endothelium-derived fibrinolytic factor t-PA is a major determinant of vessel
patency following coronary plaque rupture and thrombosis. We assessed whether
endothelial fibrinolytic capacity predicts atherothrombotic events in patients with
CHD. Plasma t-PA and PAI-1 concentrations, and net t-PA release were measured
during intra-brachial substance P infusion in 97 patients with angiographically
proven stable CHD. Forearm blood flow was measured during infusion of substance
P and sodium nitroprusside. Cardiovascular events (cardiovascular death, MI, CVA
and emergency hospitalisation for myocardial ischaemia) were determined during a
median follow-up of 34 months. Substance P caused a dose-dependent increase in
plasma t-PA (p<0.001) but not PAI-1 (p=ns) concentrations. Patients experiencing a
cardiovascular event (n=20) during follow-up had similar baseline characteristics to
those free of events (p=ns for all). However, net t-PA release was 91% lower in the
patients who experienced death, MI or CVA, and 44% lower in those who suffered
death, MI, CVA or hospitalisation for myocardial ischaemia (p<0.02). Major adverse
cardiovascular events were most frequent in those with the lowest fibrinolytic
capacity (p=0.04 for trend); the patients with the lowest quartile of t-PA release had
the highest rate of adverse events (p=0.02). Endothelial fibrinolytic capacity, as
measured by stimulated t-PA release, predicts the future risk of adverse
cardiovascular events in patients with CHD. We suggest that endothelial fibrinolytic
capacity is a powerful novel determinant of cardiovascular risk.
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3.2 INTRODUCTION
The endogenous fibrinolytic system protects the circulation from intravascular fibrin
formation and thrombosis. In the presence of developing thrombus, the fibrinolytic
factor t-PA is rapidly released from the vascular endothelium by the coagulation
factors thrombin and factor Xa [Emeis 1992]. Once released, t-PA increases the
enzymatic conversion of plasminogen to plasmin, a process increased a 1,000-fold by
the co-localisation of t-PA and plasminogen in the presence of fibrin [Ranby 1982;
van Zonneveld et al 1986], thereby ensuring plasmin activation, local fibrin
degradation and thrombus dissolution are tightly regulated to sites of fibrin
deposition which characterise arterial injury. The rapidity and extent of acute t-PA
release from the endothelium is therefore a critical factor in determining the efficacy
of local endogenous fibrinolysis [Hrafnkelsdottir et al 2004a; Oliver et al 2005].
Areas of endothelial denudation and thrombus deposition are a common finding on
the surface of atheromatous plaques and are often subclinical [Mann and Davies
1999]. Through t-PA release, endogenous fibrinolysis is usually able to prevent
thrombus propagation, vessel occlusion and tissue infarction, although organisation
of the residual thrombus may lead to plaque growth and expansion [Mann and
Davies 1999]. The resolution of thrombus following atheromatous plaque rupture,
and the resulting clinical sequelae, may therefore be critically dependent on the
efficacy of endogenous fibrinolysis [Rosenberg and Aird 1999]. Accordingly the
capacity of the endothelium to release t-PA may predict the outcome of individual
plaque events and long-term cardiovascular risk.
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Intra-arterial infusion of methacholine [Jem et al 1994], substance P [Newby et al
1997] and bradykinin [Brown et al 1999] cause a rapid and sustained release of t-PA
from the endothelium and acute stimulated t-PA release has been measured within
the forearm [Jern et al 1994; Newby et al 1997] and coronary [Minai et al 2001;
Newby et al 2001] circulations of man. We have previously demonstrated impaired
forearm t-PA release in cigarette smokers [Newby et al 1999], a group who are at
particular risk of coronary thrombosis and MI [Burke et al 1997]. Although this
suggests that endogenous fibrinolysis plays an important role in the pathogenesis of
coronary thrombosis, the relationship between the capacity to release t-PA and the
future risk of adverse cardiovascular events is unknown. The aim of the present study
was, therefore, to determine whether endothelial fibrinolytic capacity predicts the




We recruited patients with CHD defined as >50% luminal stenosis of at least one
major epicardial coronary vessel. All patients had stable anginal symptoms and had
not undergone coronary revascularisation within the preceding 3 months. Exclusion
criteria were significant cardiac failure, renal impairment, systolic blood pressure
<100 or >190 mmHg, diabetes mellitus or the regular use of non-steroidal anti¬
inflammatory medications (excluding aspirin 75 mg/d). All studies were undertaken
with the approval of the local Research Ethics Committee, the written informed
consent of each subject, and in accordance with the Declaration ofHelsinki.
3.3.2 Drugs
Substance P (Clinalfa AG, Switzerland) and sodium nitroprusside (David Bull
Laboratories, UK) were administered following dissolution in 0.9% saline. All
solutions were freshly prepared on the day of study.
3.3.3 Forearm Study Preparation
Subjects abstained from alcohol for 24 hours and from food, tobacco and caffeine-
containing drinks for at least 4 hours before each study visit. Cardio-active
medications were withheld on the morning of study. All studies were carried out in a
quiet temperature-controlled room maintained at 22-25°C. Patients rested recumbent,
strain gauges and cuffs were applied. Venous cannulae were inserted into each arm
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and the brachial artery of the non-dominant arm cannulated. Blood pressure and heart
rate were measured using a semi-automated non-invasive sphygmomanometer.
3.3.4 Study Design
Following a 30 minute saline infusion, intra-arterial substance P at 2, 4 and 8
pmol/min and sodium nitroprusside at 2, 4 and 8 pg/min were administered in a
randomised order with a 15 minute saline washout period between each agent.
Forearm blood flow was measured at baseline and with each dose of vasodilator.
Venous blood sampling for plasma t-PA and PAI-1 antigen concentration estimation
was undertaken before and during each dose of substance P.
3.3.5 Long-Term Follow-Up
Atherothrombotic cardiovascular events, defined as death from cardiovascular
causes, MI, CVA, and emergency hospitalisation for myocardial ischaemia, were
determined through the Information and Statistics Division of the National Health
Service in Scotland and the General Register Office in Scotland. These databases
combine high quality data and consistency, with national coverage and the ability to
link data to allow patient based analysis and follow-up. These systems have been
successfully applied to evaluate cardiovascular morbidity and mortality for subjects
resident within Scotland [Fox et al 2002],
3.3.6 Statistical Analysis
Data of baseline characteristics are expressed as mean ± standard deviation (SD) or
frequency (n, %) and compared using two-tailed Student's t-test and Fisher's exact
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test where appropriate. Responses to substance P and sodium nitroprusside were
examined by ANOVA for repeated measures. To reduce the variability of blood flow
data between groups [Benjamin et al 1995; Webb 1995b], FBF responses to the
vasodilators were calculated as the ratio between the infused and control arms
expressed as a percentage of the ratio measured during the baseline control period as
follows:
% Change in blood flow = 100 x {I/NIt - h/NIb} / h/NIb
where lb and Nib are the infused and non-infused FBFs at baseline (time 0)
respectively, and It and Nit are the infused and non-infused FBFs at a given time
point respectively.
Estimated net release of t-PA was defined as the product of the infused forearm
plasma flow, and the concentration difference between the infused and non-infused
forearms [Newby et al 1997; Newby et al 1999; Oliver et al 2005], Cumulative event
rates were estimated by Kaplan-Meier survival curves, and probability values were
determined with the log-rank test. In those patients who experienced multiple events,
survival analysis was restricted to the first event. For Kaplan-Meier analyses,
subjects were divided into quartiles according to estimated net release of t-PA
antigen. All statistical analysis was completed using GraphPad Prism (GraphPad




Endothelial fibrinolytic capacity was measured in 97 subjects with angiographically
proven CHD who were followed-up for a median of 34 months (range 27 to 45
months). Over the follow-up period, two patients died from cardiovascular disease,
two suffered an MI, two had a CVA and 14 had an emergency hospital admission for
myocardial ischaemia. Patients experiencing cardiovascular events had similar
baseline characteristics and use of secondary preventative medications to those free
from events (p=ns for all; Table 3.1).
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Table 3.1 Baseline subject characteristics




Age, years 59 ±7 62 ±8 59 ±7 0.10
Sex, male/female 79/18 16/3 63/15 1.00
BMI, kg/m2 29 ±4 28 ±4 29 ±4 0.36
Systolic BP, mmHg 132 ± 19 135 ±20 132 ± 19 0.53
Diastolic BP, mmHg 76 ± 12 75 ± 11 76 ± 13 0.88
Pulse, bpm 57 ±9 57 ± 10 57 ±9 0.93
Cigarette smoker, (%) 31 37 29 0.58
Co-morbidity, (%)
Previous MI 41 53 38 0.30
Hypertension 48 47 49 1.00
FHx CHD 33 47 29 0.18
Symptomatic CVD 4 11 3 0.17
Extent of coronary disease, (%)
1 vessel 45 42 46 0.75
2 vessels 27 32 26 0.60
3 vessels 28 26 28 0.92
Medical Therapy, (%)
Aspirin 99 100 99 0.62
Lipid lowering therapy 93 95 93 0.71
ACE inhibitor, ARB 31 32 31 0.94
Urea, mmol/L 5.6 ± 1.3 5.4 ± 1.4 5.6 ± 1.3 0.60
Creatinine, pmol/L 94 ± 13 98 ± 15 92 ± 12 0.11
Glucose, mmol/L 5.7 ±0.9 6.0 ± 1.0 5.6 ±0.8 0.07
Total chol, mmol/L 4.5 ± 1.0 4.6 ± 1.1 4.5 ±0.9 0.62
LDL chol, mmol/L 2.6 ±0.8 2.6 ±1.1 2.5 ±0.6 0.66
t-PA antigen, ng/mL 9.7 ±3.9 9.9 ±5.1 9.7 ±3.5 0.84
PAI-1 antigen, ng/mL 43.7±24.5 33.9±18.6 45.9±25.2 0.07
Values are mean ± SD
'Unpaired t-test or Fishers exact test for subjects with, versus without, events (death from a
cardiovascular cause, MI, CVA, emergency hospitalisation for myocardial ischaemia).
BMI - body mass index; bpm - beats per minute; MI - myocardial infarction; FHx - family
history; CHD - coronary heart disease; CVD - cerebrovascular disease; ACE - angiotensin-
converting enzyme; ARB - angiotensin receptor blocker; chol - cholesterol; t-PA - tissue
plasminogen activator; PAI-1 - plasminogen activator inhibitor type-1.
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Substance P caused a dose-dependent increase in plasma t-PA (p<0.001, ANOVA)
but not PAI-1 (p=ns) concentrations. The concentration differences of t-PA antigen
between the forearms and estimated net release of t-PA both increased dose
dependently (p<0.001 for both, ANOVA) although this increase was reduced in
subjects who subsequently experienced cardiovascular events (p<0.02, ANOVA;
Figure 3.1). Specifically, net release of t-PA during substance P infusion was 91%
lower in those subjects suffering cardiovascular death, MI or stroke (p=0.01,
ANOVA), and 44% lower in those with cardiovascular death, MI, stroke or
emergency hospitalisation for myocardial ischaemia (p=0.02, ANOVA). Major
adverse cardiovascular events were most frequent in those with the lowest
fibrinolytic capacity (p=0.04 for trend); patients with the lowest quartile of t-PA
release had the highest rate of adverse events (p=0.02; Figure 3.2).
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Figure 3.1 Concentration differences between the forearms of plasma t-PA antigen (lower
panels), and estimated net release of t-PA antigen (upper panels), in subjects with (•), and
without (o), death, MI or stroke (left hand panels) or death, MI, stroke or emergency
hospitalisation for myocardial ischaemia (right hand panels).
*p=0.01, tp=0.008 and $p=0.02, ANOVA (•) versus (o); t-PA - tissue plasminogen activator; MI -










































There was no difference in resting FBF between those subjects with and without
atherothrombotic events (2.8 ± 0.2 mL/100 mL tissue/min versus
2.7 ± 0.1 mL/100 mL tissue/min respectively, p=ns). Substance P and sodium
nitroprusside caused dose-dependent increases in infused FBF in all subjects
(p<0.001, ANOVA). There were no differences in either endothelium-dependent or
-independent blood flow responses between subjects in either group (Figure 3.3).
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This is the first study to assess the relationship between endothelial fibrinolytic
capacity and the future risk of atherothrombotic cardiovascular events. The
population that we chose to study was a homogenous cohort of patients with stable
CHD and a typical distribution of conventional cardiovascular risk factors. Even
though this was a relatively low risk population receiving optimal secondary
preventative therapy, endothelial fibrinolytic capacity has emerged as a powerful
novel determinant of future cardiovascular risk.
In a meta-analysis of prospective observational studies [Lowe et al 2004], the risk of
CHD is increased in subjects with plasma t-PA antigen concentrations in the highest
tertile compared to those in the lowest tertile. This may seem counterintuitive but in
part reflects the concomitant rise of plasma PAI-1 concentrations and the associated
reduction in t-PA activity. Moreover, in the basal state, the endogenous fibrinolysis
system is effectively inactive and does not influence in situ thrombus formation.
Neither basal plasma t-PA nor PAI-1 concentrations control the local vascular
fibrinolytic capacity which is determined by the acute release of t-PA from the
endothelium [Hrafnkelsdottir et al 2004a], This underscores the importance of
assessing the pathophysiologically relevant measure of acute stimulated endothelial
t-PA release.
We and others have demonstrated that cigarette smoking [Newby et al 1999; Newby
et al 2001; Pretorius et al 2002], but not hypercholesterolemia [Newby et al 2002],
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is associated with a characteristic and substantial reduction in endothelial t-PA
release. There is also a good correlation and consistency between the endothelial
fibrinolytic capacity of the forearm [Newby et al 1999; Witherow et al 2002] and the
coronary circulation [Minai et al 2001; Newby et al 2001]. The forearm vascular bed
is relatively protected from the development of atheroma and it therefore seems
likely that changes in its fibrinolytic capacity are indicative of a systemic effect and
not simply local plaque burden. These considerations are, therefore, in keeping with
the hypothesis that atherosclerosis is a systemic disorder, and that acute t-PA release
should be considered a distinct marker of endothelial function.
Intravascular thrombus formation is a key feature of clinical atherosclerotic events
associated with eroded or unstable coronary plaques. The importance of endogenous
t-PA release is exemplified by the high rate of spontaneous reperfusion in the infarct-
related artery after acute MI, occurring in up to 30% of patients within the first
12 hours [DeWood et al 1980; Armstrong et al 1989; Rentrop et al 1989], Any
reduction in the acute dynamic fibrinolytic response decreases the capacity to lyse
intraluminal thrombus and the likelihood of restoring vessel patency. In this
prospective observational cohort study, we have further demonstrated that the
capacity to release t-PA appears to be a major determinant of the risk of
cardiovascular events and suggests that endothelial fibrinolytic capacity has a crucial
role in the pathogenesis of atherothrombosis.
Endothelial dysfunction is characterised by the disruption of multiple homeostatic
pathways predisposing to vasoconstriction, platelet activation and thrombosis. To
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date, most clinical studies on endothelial function have focused on endothelium-
dependent vasomotion with decreased responses associated with an increased
incidence of future adverse events [Suwaidi et al 2000; Heitzer et al 2001; Halcox et
al 2002b]. Although a useful surrogate marker, the pathophysiological mechanism
linking impaired endothelium-dependent vascular smooth muscle relaxation and
future atherothrombotic events remains unclear. Moreover, the regulation of vessel
tone may not be the facet of vascular function most closely allied to the future risk of
atherothrombotic events. In this current study, we did not observe a difference in
endothelium-dependent or -independent blood flow responses between subjects with,
and without, subsequent cardiovascular events. This disparity may reflect a lack of
power or the use of differing endothelium-dependent vasodilators. Thus far, studies
assessing the prognostic value of endothelium-dependent vasodilatation have used
acetylcholine. We chose to use substance P because this is a potent stimulant of
endothelial t-PA release, and acetylcholine does not cause demonstrable t-PA release
[Brown et al 1999], Reports of preserved endothelium-dependent vasodilatation in
smokers [Jacobs et al 1993] and in patients with hypertension [Cockcroft et al
1994a] despite reduced acute t-PA release [Hrafnkelsdottir et al 1998; Pretorius et al
2002] suggest that, in some circumstances, reduced t-PA release may be a more
sensitive marker of endothelial dysfunction [Oliver et al 2005], These data also
highlight the complexity of vascular biology and demonstrate that endothelial
dysfunction is not a single clinical entity encompassing a uniform pathophysiological
response to vascular injury.
76
3.5.1 Study Limitations
Plaque growth is induced by episodic subclinical plaque disruption [Mann and
Davies 1999] and if local t-PA release is impaired, the continued presence of
thrombus may favour smooth muscle migration, the production of new connective
tissue and plaque expansion [Davies 2000b]. In keeping with this hypothesis, genetic
murine models of plasminogen deficiency [Carmeliet et al 1994; Xiao et al 1997] as
well as PAI-1 overexpression [Eren et al 2002] have shown that reduced fibrinolytic
potential is associated with enhanced macrovascular fibrin deposition and accelerated
atherogenesis. As we do not have follow-up angiographic data, we do not know if
those subjects with the lowest local t-PA release or recurrent cardiovascular events
exhibited a greater progression of angiographic disease over the study period. We
have previously demonstrated an inverse correlation between acute coronary t-PA
release and local atheromatous plaque burden [Newby et al 2001] and prospective
studies of coronary t-PA release and quantification of disease progression would be
of interest.
In keeping with the risk factor profile and use of secondary preventative therapies in
our study cohort, relatively few events occurred over the study period. Despite this,
similar results were noted for outcomes regardless of whether emergency
hospitalisation for myocardial ischaemia was included. Although the risk factor
profile and severity of coronary artery disease were similar in those patients with or
without events, the study population size was modest and we were therefore unable
to explore potential interactions and independence of endothelial fibrinolytic capacity
with conventional cardiovascular risk factors or the extent of coronary artery disease.
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Confirmation of our findings in larger at risk cohorts with differing cardiovascular
risk profiles is now warranted to explore the importance and more widespread
relevance of endothelial fibrinolytic capacity.
In summary, t-PA release from the endothelium is a distinct marker of endothelial
function. In patients with stable CHD, we have shown that a reduction in acute t-PA
release predicts an increased risk of adverse cardiovascular events. Further studies of
the factors modifying the endogenous fibrinolytic capacity have the potential to




TISSUE PLASMINOGEN ACTIVATOR GENETIC POLYMORPHISMS DO
NOT INFLUENCE TISSUE PLASMINOGEN ACTIVATOR RELEASE
IN PATIENTSWITH CORONARY HEART DISEASE
Robinson SD, Ludlam CA, Boon NA, Newby DE.
Tissue plasminogen activator genetic polymorphisms do not influence
tissue plasminogen activator release in patients with coronary heart disease.
J Thromb Haemost 2006;4(10):2262-2269.
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4.1 SUMMARY
Genetic factors influence plasma concentrations of a number of haemostatic and
fibrinolytic factors including t-PA. Previous work has demonstrated a link between
t-PA release and t-PA polymorphisms in healthy volunteers. We determined if
polymorphisms of the t-PA gene influence acute endogenous t-PA release in patients
with CHD. Forearm blood flow and plasma t-PA concentrations were measured in
response to intra-brachial infusion of substance P and sodium nitroprusside in 96
patients with stable CHD. Genotyping was performed using a Taqman PCR assay
specifically designed to detect the polymorphisms of interest: (i) Alu-repeat Ins/Del
sequence, (ii) C—»T substitution in an upstream enhancer region (-7,351 C/T), (iii)
T—>C in exon 6 (20,099 T/C), and (iv) T—>A (27,445 T/A) in intron 10. Substance P
and sodium nitroprusside caused dose-dependent increases in FBF in all patients
(p<0.001 for all) that were independent of the four genetic polymorphisms.
Similarly, there were no differences in basal plasma t-PA antigen concentrations or
net t-PA release between genotypes. Compared to non-smokers, smokers exhibited
impaired substance P-induced vasodilatation (p<0.001) and t-PA release (p=0.05).
Despite confirming previous findings in cigarette smokers, we have found no effect
of polymorphisms of the t-PA gene on two complementary aspects of endothelial
function. We conclude that genetic variation at the t-PA locus is unlikely to have a
major influence on acute t-PA release in subjects with established CHD.
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4.2 INTRODUCTION
Coronary heart disease and its risk factors, such as cigarette smoking,
hyperlipidaemia and hypertension, are associated with impaired endothelium-
dependent vasorelaxation [Creager et al 1990; Celermajer et al 1993; Panza et al
1993] and t-PA release [Hrafnkelsdottir et al 1998; Newby et al 1999; Pretorius et al
2002]. These aspects of endothelial function are important since plasma fibrinolytic
variables and endothelium-dependent vasodilatation independently predict future
cardiovascular risk [Meade et al 1993; Suwaidi et al 2000],
Genetic factors influence plasma concentrations of a number of haemostatic and
fibrinolytic factors including t-PA, PAI-1 and fibrinogen [de Lange et al 2001]. A
common intronic polymorphism of the t-PA gene is generated by the insertion of a
311 base pair Alu-repeat sequence [Ludwig et al 1992], Although not a consistent
finding in all populations [Ridker et al 1997a], there is an independent association
between the Ins genotype and the future risk of MI: a relative risk of 2.24 in
comparison with the Del homozygotes [van der Bom et al 1997], This Alu-intronic
sequence is now known to be in linkage disequilibrium with three single nucleotide
polymorphisms associated with t-PA release within the upstream enhancer region
(7,351 C—>T), in exon 6 (20,099 T—>C) and within intron 10 (27,445 T—>A)
[Ladenvall et al 2000]. The C—»T substitution within the enhancer region disrupts a
binding site for the Spl transcription factor and appears to be functionally important
[Ladenvall et al 2000; Wolf et al 2005] with TT homozygotes having an increased
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risk of both MI [Ladenvall et al 2002] and lacunar stroke [Jannes et al 2004]
compared to CC homozygotes.
Genetic differences in t-PA release might therefore alter the fibrinolytic balance
predisposing to local thrombus formation and an increased likelihood of adverse
atherothrombotic events. Jem and colleagues previously demonstrated a link between
t-PA release and both the /4/w-Ins/Del and -7,351 C/T enhancer polymorphisms in
healthy volunteers [Jem et al 1999; Ladenvall et al 2000], However the functional
importance of these genetic variants in patients with established CHD is unknown.
We hypothesised that polymorphisms of the t-PA gene may influence endothelial




We recruited patients with CHD confirmed by angiography (defined as >50%
luminal stenosis of at least one major epicardial coronary vessel) or a history of
Q-wave MI. All patients had stable anginal symptoms and had not undergone
coronary revascularisation within the preceding 3 months. Exclusion criteria were
significant cardiac failure, renal impairment, systolic blood pressure <100 or >190
mmHg, impaired fasting glucose (>7 mmol/L) or prior diagnosis of diabetes mellitus.
Self-reported smoking status was confirmed using plasma cotinine levels
[Feyerabend and Russell 1990]. All studies were undertaken with the approval of the
local Research Ethics Committee, the written informed consent of each subject, and
in accordance with the Declaration ofHelsinki.
4.3.2 Drugs
Substance P (Clinalfa AG, Switzerland) and sodium nitroprusside (David Bull
Laboratories, UK) were administered following dissolution in 0.9% saline. All
solutions were freshly prepared on the day of study.
4.3.3 Forearm Study Preparation
Subjects were requested to abstain from alcohol for 24 hours and food, caffeine-
containing drinks and tobacco for at least 4 hours before each study. Cardio-active
medications were withheld on the morning of each study visit. All studies were
conducted in a quiet temperature-controlled room maintained at 22-25°C. Patients
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rested recumbent, strain gauges and cuffs were applied. Venous cannulae were
inserted in each arm and the brachial artery of the non-dominant arm cannulated.
Non-invasive blood pressure and heart rate were measured throughout each study.
4.3.4 Study Design
Following a 30 minute saline infusion to allow equilibration and recording of resting
blood flow, intra-arterial substance P (2, 4 and 8 pmol/min) and sodium nitroprusside
(2, 4 and 8 pg/min) were each administered for 6 minutes in a randomised order with
a 15 minute saline washout period between each agent. Forearm blood flow was
measured at baseline and with each dose of vasodilator; plasma t-PA and PAI-1
antigen concentrations at baseline and with each dose of substance P.
4.3.5 Genotyping
Genomic DNA was isolated from whole blood. For the -7,351 C—>T (upstream
enhancer), 20,099 T—»C (exon 6), and 27,445 T—>A (intron 10) polymorphisms
genotyping was performed by allele discrimination analysis using the 5' nuclease
assay using previously published DNA and primer sequences [Ladenvall et al 2000;
Ladenvall et al 2002], For the ^4/w-intronic polymorphism, the insertion specific
sequence was submitted to the Applied Biosystems Assay-by-design service. An
insertion specific probe was labelled in its 5' end with FAM and in it 3' end with a
NFQ (non fluorescent quencher). Real time quantitative PCR was performed with a
ABI PRISM® 7900HT Sequence Detector and Alu-Ins PCR products normalised to
threshold values against an endogenous control. Each sample was run in triplicate
with both the gene of interest and the RNase P control. Genotype for the A/w-intronic
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polymorphism was calculated from differences in the threshold cycle between the
RNAse P and Alu-Ins sequence.
A confirmatory assay of ^4/w-Ins/Del genotypes utilised PCR amplification of the Ins
fragment with primers designed to flank the region of interest and PCR performed on
a DNA engine tetrad from MJ Research (Bio-Rad Laboratories Inc., USA).
Amplification of the products produces a 570-bp fragment from chromosomes with
the Ins allele and a 260-bp fragment from those without (Del). All genotyping was
performed in triplicate by an individual without information on case status or
vascular study data.
4.3.6 Statistical Analysis
Allele frequencies were estimated by gene counting. Chi-square test was used to
evaluate deviations of genotype distributions from the Hardy-Weinberg equilibrium.
The linkage disequilibrium coefficient D' was calculated as previously described
[Devlin and Risch 1995]. Baseline characteristics of the study population are
presented as frequencies or mean values and SEM. Differences between groups were
compared by Student's t-test, Chi-squared test, and, where appropriate, by ANOVA
with repeated measures. As C-reactive protein values were not normally distributed
they were log transformed prior to analysis. All statistical calculations were
undertaken using GraphPad Prism (GraphPad Software, California, USA). Statistical
significance was assigned at the 5% level.
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4.4 RESULTS
A total of 96 patients were recruited with a cardiovascular risk factor profile in
keeping with their diagnosis of CHD and most were prescribed secondary
preventative medications.
4.4.1 Gene Frequency
The genotype distributions for the .T/w-Ins/Del (II 46%, ID 36% and DD 18%),
-7,351 C/T enhancer (CC 54%, CT 32% and TT 14%), 20,099 T/C exon 6 (TT 42%,
CT 43% and CC 15%) and 27,445 T/A intron 10 (TT 56%, TA 34% and AA 10%)
polymorphisms were in keeping with the Hardy-Weinberg equilibrium. There was
significant linkage disequilibrium between the four polymorphisms (Table 4.1) with
allelic frequencies being similar to published studies of European Caucasian subjects
[Jern et al 1999; Ladenvall et aI 2000). There was complete agreement between the
two PCR methods in the determination of ,4/w-Ins/Del genotype. Three subjects
could be genotyped only for the ^4/w-Ins/Del variant.
Biometric variables were similar between genotypes (Tables 4.2 and 4.3, data on file)
although there were significantly fewer smokers in the -7,351 heterozgote group
(p=0.01, Chi-squared).
86
Table 4.1 Allele frequencies and pairwise linkage disequilibrium (LD) coefficient
between polymorphisms at the tissue plasminogen activator (t-PA) locus; (Chi-
squared, degrees of freedom), p<0.01 for all
Allelic Alu -7,351 20,099 27,445
frequency











4.4.2 Haemodynamics and Forearm Blood Flow
Resting heart rate, blood pressure and non-infused FBF were similar in each group
and these did not change significantly during infusion of either vasodilator
(Tables 4.2, 4.3 and 4.4; data on file).
Substance P and sodium nitroprusside increased the infused FBF in all subjects
(p<0.001, ANOVA). None of the genetic polymorphisms appeared to influence the
endothelium-dependent or -independent blood flow responses (Figure 4.1; data on
file).
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n=44 N=35 n=17 Pf
Age, years 59 ± 1 60 ± 1 59 ±2 0.88
Gender, male/female 33/11 32/3 14/3 0.16
BMI, kg/m2 29 ± 1 28 ± 1 30 ± 1 0.27
Systolic BP, mraHg 136 ±3 128 ±4 132 ±4 0.23
Diastolic BP, mmHg 79 ±2 75 ±2 73 ±2 0.30
Pulse, bpm 57 ± 1 58 ±2 57 ±3 0.96
Current smoker, (%) 30 23 47 0.42
Co-morbidity, (%)
Previous MI 43 46 24 0.28
Hypertension 50 49 47 0.98
FHx CHD 52 37 29 0.74
Prior hyperlipidaemia 93 94 94 1.00
Extent of coronary
disease, (%)*
1 vessel 41 51 41 0.33
2 vessels 27 20 24 0.86
3 vessels 30 17 35 0.43
Medical Therapy, (%)
Aspirin 100 100 94 0.10
Statin therapy 91 97 94 0.52
ACE inhibitor, ARB 27 34 29 1.00
Urea, mmol/L 5.4 ±0.2 5.6 ±0.3 5.7 ±0.4 0.70
Creatinine, pmol/L 93.1±2.5 94.6±2.1 91.3±2.6 0.72
Glucose, mmol/L 5.6 ±0.1 5.7 ±0.2 6.0 ±0.2 0.24
Total chol, mmol/L 4.5 ±0.2 4.4 ±0.2 4.4 ±0.2 0.89
LDL chol, mmol/L 2.6 ±0.1 2.5 ±0.2 2.2 ±0.2 0.28
Triglycerides, mmol/L 1.7 ±0.2 1.7 ±0.2 2.3 ± 0.3 0.09
CRP, mg/L 1.87±0.18 1.92±0.35 1.90±0.41 0.97
Values are mean ± SEM
tP= ANOVA or Chi-squared for difference between genotypes. *Angiographic data unavailable
on 5 subjects.
BMI - body mass index; bpm - beats per minute; MI - myocardial infarction; FHx - family
history; CHD - coronary heart disease; ACE - angiotensin-converting enzyme, ARB -
angiotensin receptor blocker, chol - cholesterol; LDL - low-density lipoprotein; CRP - C-
reactive protein.
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n=50 n=30 n=13 P+
Age, years 59 ± 1 59 ± 1 61 ±3 0.82
Gender, male/female 38/12 27/3 11/2 0.28
BMI, kg/m2 29 ± 1 28 ± 1 29 ± 1 0.47
Systolic BP, mmHg 134 ±3 131 ±4 123 ±6 0.27
Diastolic BP, mmHg 79 ±2 75 ±2 70 ±3 0.07
Pulse, bpm 57 ± 1 57 ±2 54 ±3 0.57
Current smoker, (%) 46 13 38 0.01
Co-morbidity, (%)
Previous MI 44 43 38 0.89
Hypertension 46 40 62 0.43
FHx CHD 32 37 31 0.23
Prior hyperlipidaemia 92 93 92 0.98
Extent of coronary
disease, (%)*
1 vessel 40 50 38 0.64
2 vessels 24 23 23 0.99
3 vessels 30 20 38 0.42
Medical Therapy, (%)
Aspirin 100 97 100 0.35
Statin therapy 88 100 92 0.14
ACE inhibitor, ARB 28 23 54 0.98
Urea, mmol/L 5.2 ±0.2 5.7 ±0.2 6.1 ±0.5 0.09
Creatinine, pmol/L 93.3 ±2.2 92.6 ±2.1 92.3 ±4.0 0.96
Glucose, mmol/L 5.6 ±0.1 5.6 ±0.2 6.0 ±0.3 0.26
Total chol, mmol/L 4.6 ±0.2 4.4 ±0.2 4.2 ±0.3 0.37
LDL chol, mmol/L 2.7 ±0.1 2.6 ±0.1 2.0 ±0.3 0.08
Triglycerides, mmol/L 1.8 ±0.2 1.6 ±0.1 2.4 ±0.3 0.08
CRP, mg/L 2.02±0.29 1.5±0.3 2.3±0.7 0.49
Values are mean ± SEM
tP= ANOVA or Chi-squared for difference between genotypes. *Angiographic data unavailable
on 5 subjects.
BMI - body mass index; bpm - beats per minute; MI - myocardial infarction; FHx - family
history; CHD - coronary heart disease, ACE - angiotensin converting enzyme; ARB -
angiotensin receptor blocker; chol - cholesterol; LDL - low-density lipoprotein; CRP - C-
reactive protein.
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Figure 4.1 Infused (solid line) and non-infused (dashed line) forearm blood flow (FBF)
during intra-brachial substance P (left) and sodium nitroprusside (SNP; right) according to
(a) Alu Ins/Del and (b) -7,351 C/T, genotypes.
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4.4.3 Plasma Fibrinolytic Variables
Baseline plasma t-PA and PAI-1 antigen concentrations were similar for each
genotype (Table 4.4; data on file). Substance P caused a dose-dependent increase in
plasma t-PA antigen within the infused arm in all three groups (p<0.01, ANOVA)
whilst plasma PAI-1 antigen concentrations were unchanged (data on file). There
were no differences in substance P-induced t-PA release between any of the genetic
polymorphisms (Figure 4.2; data on file). Similarly, the area under the curve for net
t-PA release over the 30 minute period of substance P infusion was similar between
genotypes (data on file).
Table 4.4 Effect of .T/w-Ins/Del and -7,351 C/T genotypes on baseline forearm
blood flow, tissue plasminogen activator (t-PA) and plasminogen activator inhibitor




Infused arm 2.7±0.1 2.8±0.2 2.7±0.2 2.6±0.1 2.8±0.2 2.6±0.3
II ID DD CC CT TT




9.1±0.5 10.7±0.8 9.0±0.7 9.4±0.5 9.8±0.8 9.3±1.1




43.3±4.2 43.6±3.7 44.1±6.6 44.5±3.5 44.3±4.8 39.8±7.4
46.0±4.2 44.0±3.6 43.7±6.5 47.7±3.6 42.4±4.6 40.0±7.2
Values are mean ± SEM
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Figure 4.2 Estimated net release of t-PA antigen induced by intra-brachial substance P (2,
4 and 8 pmol/min) according to (a) Alu Ins/Del, and (b) -7,351 C/T, genotypes.













































Smoking status was confirmed by plasma cotinine concentration (median 307.8
versus 0.6 ng/mL in smokers and non-smokers respectively). Subgroup analysis
revealed an interaction between smoking status and vascular function. Consistent
with our previous findings, cigarette smokers had impaired FBF responses (p<0.001,
ANOVA) and net t-PA release (p=0.05, ANOVA; Figure 4.3) compared to non-
smokers. In light of the uneven distribution of smokers across -7,351 genotypes and
the interaction between smoking and t-PA release, we performed a post-hoc analysis
of t-PA release according to smoking status. However we found no difference in the
area under the curve for net t-PA release between CC, CT and TT -7,351 genotypes
in either smokers (111 [48-174]; 167 [94-240]; 193 [5-382]; p=0.41 ANOVA) or
non-smokers (187 [114-260]; 160 [100-220]; 188 [50-325]; p=0.83) respectively
(Mean [95% confidence intervals]).
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Figure 4.3 Infused (solid line) and non-infused (dashed line) forearm blood flow (a), and
net t-PA release (b), in response to intra-brachial substance P in smokers (•) and non-
smokers (o).
*p<0.001, 2-way ANOVA, infused FBF response in smokers versus non-smokers, t p=0.05, 2-way
















This is the first study to assess directly the role of t-PA genetic polymorphisms in
determining acute t-PA release in patients with CHD. Using a validated and
reproducible technique [Oliver et al 2005], we have found no difference in the basal
concentration, or net release of, plasma t-PA antigen between genotypes. These
important findings suggest that, in patients with established coronary atherosclerosis,
variation at the t-PA gene locus does not substantially influence acute endogenous
fibrinolytic capacity.
Tissue plasminogen activator release from endothelial cells is the major arbiter of
local intravascular fibrinolysis [Kooistra et al 1994] and will influence vessel
patency following acute coronary thrombosis [Rosenberg and Aird 1999], Inter-
individual differences in t-PA release may contribute to a pro-thrombotic phenotype
and determine the sequelae of acute MI. Indeed, clustering of individuals with low
rates of t-PA release has been reported in families with a history of thrombosis
[Petaja et al 1991], Moreover, genetic murine models of t-PA deficiency show a
reduced thrombolytic potential and an increased thrombotic tendency [Carmeliet et
al 1994], We therefore wanted to explore the potential genetic influences on t-PA
release in at risk patients with CHD.
The tissue plasminogen activator -7,351 C—>T enhancer site polymorphism has been
associated with an increased risk of first MI [Ladenvall et al 2002] and lacunar
stroke [Jannes et al 2004] although the data on non-lacunar stroke is conflicting
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[Jannes et al 2004; Jood et al 2005]. The strong linkage between the -7,351 C/T
enhancer and the Alu-repeat polymorphisms may explain the association between the
(non-coding) Alu- Ins/Del polymorphism and cardiovascular events [van der Bom et
al 1997; Ladenvall et al 2000]. In healthy volunteers (n=51), both the Alu Ins/Del
and -7,351 C—>T enhancer polymorphisms were associated with significant
differences in basal t-PA release with Ins and C homozgotes having around 2-fold
greater release rates than Del and T homozygotes respectively [Jem et al 1999;
Ladenvall et al 2000], Of the genotypes studied here, the 7,351 C—>T substitution is
thought to result in a functional change occurring within an Spl transcription factor
binding site which is negatively regulated by binding of the thymidine allele
[Ladenvall et al 2000], However despite this difference in basal t-PA release rate,
acute t-PA release was similar between all genotypes. Now, in a larger cohort of
subjects (n=96) with established CHD, we have shown that there is no significant
relationship between basal plasma t-PA concentrations or acute t-PA release, and
these genetic polymorphisms. Furthermore, endothelium-dependent vasodilatation, a
complementary measure of endothelial function, was similarly unaffected by
variation within the t-PA gene locus.
Regulatory control of t-PA release involves distinct pathways from those controlling
vessel calibre and indeed t-PA release can be induced without changes in FBF [Chia
et al 2003b], In view of previous work in healthy volunteers [Jem et al 1999;
Ladenvall et al 2000], we chose to assess whether a number of t-PA genetic
polymorphisms were associated with changes in vascular function in patients with
CHD. If t-PA genotype was important in regulating endogenous t-PA release, certain
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alleles could favour the continued presence of thrombus following atheromatous
plaque rupture. Organisation of residual thrombus is known to stimulate further
plaque growth and expansion [Mann and Davies 1999] disrupting endothelial
integrity which is critical to the regulation of vascular tone and coagulation. Impaired
endothelium-dependent vasodilatation is considered a surrogate of endothelial
dysfunction and has been widely studied as a bio-marker of atherosclerosis. We
therefore hypothesised that t-PA genetic polymorphisms might also be associated
with changes in endothelium-dependent vasodilatation through pathways linking
coagulation, atherogenesis, and endothelial dysfunction. However we found no
evidence to support the contention that t-PA polymorphisms influence endothelial
function in patients with CHD. In contrast, cigarette smoking and CHD are
associated with endothelial dysfunction as demonstrated by impaired endothelium-
dependent vasodilatation [Celermajer et al 1993] and endogenous t-PA release
[Newby et al 1999; Newby et al 2001]. Our study confirms these previous findings
in cigarette smokers in a large cohort of patients with established CHD maintained
on secondary preventative medications. These consistent findings would appear to
reaffirm the validity of our approach and suggest that environmental rather than
genetic factors have a more dominant influence on acute endogenous t-PA release.
There are a number of differences between the current study and previous reports
demonstrating an interaction between acute t-PA release and polymorphisms within
the t-PA gene. Our population was comprised of subjects with established CHD
recruited within the United Kingdom. In contrast, Jern et al [Jern et al 1999;
Ladenvall et al 2000] studied healthy Scandinavian volunteers free of symptomatic
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atherosclerosis. A recent meta-analysis of studies on genetic polymorphisms and
CHD risk demonstrated heterogeneity according to the population studied [Casas et
al 2004], Indeed, the Alu-repeat polymorphism was associated with an increased
incidence of acute MI in Dutch subjects [van der Bom et al 1997] but not in studies
from North America [Ridker et al 1997a] or the United Kingdom [Steeds et al 1998],
Our subjects were all of European Caucasian origin, recruited from within the same
geographical area and had similar risk factor profiles. It seems unlikely that
biological variability or modulation from environmental factors obscured true
differences in t-PA release between genotypes. Although our findings may not be
applicable to other racial groups, Rosenbaum and colleagues [Rosenbaum et al 2002]
failed to demonstrate differences in acute endogenous t-PA release between healthy
black and white Americans.
4.5.1 Study Limitations
Although endothelium-dependent blood flow responses are similar in the forearm
and coronary circulations [Anderson et al 1995], we cannot be sure that these
polymorphisms of the t-PA gene do not influence fibrinolytic responses within the
coronary circulation. Indeed, there are limited data to suggest that, although not
apparent in the forearm circulation, angiotensin-converting enzyme gene Ins/Del
polymorphism can influence acute t-PA release in the coronary circulation [Ohira et
al 2004].
Jem and colleagues previously demonstrated a difference in basal, though not
stimulated, t-PA release according to t-PA genotype [Jem et al 1999; Ladenvall et al
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2000]. Whilst we cannot determine basal t-PA release using the venovenous
technique described, we have found no relationship between t-PA genotype and
stimulated t-PA release. Calculation of net t-PA release provides an accurate
assessment of stimulated t-PA release with good reproducibility [Newby et al 2002],
and basal release contributes only a small proportion of the overall venous plasma
t-PA concentration. In this study we did not find any difference in acute t-PA release
in response to substance P between t-PA genotypes. However, our study protocol
cannot exclude the possibility that these polymorphisms might alter protein
transcription and endothelial storage, or the very early (<6 minutes) release of, t-PA
in response to substance P infusion [Ridderstrale et al 2006],
In our cohort, there was an uneven distribution of smokers between t-PA -7,351 CC,
CT and TT groups. Although we found no difference in net t-PA release between
these three groups when analysed according to smoking status, we accept that the
relationship between cigarette smoking and impaired t-PA release may have
obscured an association between t-PA genotype and fibrinolytic function with the
post-hoc analysis limited by the number of smokers and non-smokers within each
group.
In summary, whilst we have confirmed previous findings showing that cigarette
smokers have impaired endothelial vasomotor and fibrinolytic function, we have
found no major effect of variation within the t-PA gene locus on either plasma t-PA
concentrations or acute t-PA release in subjects with stable CHD.
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CHAPTER 5
VASCULAR AND FIBRINOLYTIC EFFECTS OF INTRA-ARTERIAL
TUMOUR NECROSIS FACTOR-a IN PATIENTS WITH
CORONARY HEART DISEASE
Robinson SD, Dawson P, Ludlam CA, Boon NA, Newby DE.
Vascular and fibrinolytic effects of intra-arterial tumour necrosis
factor-alpha in patients with coronary heart disease.
Clin Sci (Lond) 2006;110 (3):353-60.
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5.1 SUMMARY
Elevated plasma t-PA and serum CRP concentrations are associated with an adverse
cardiovascular risk. We investigated whether acute local inflammation causes
vascular dysfunction, and influences t-PA release in patients with stable CHD. Serum
CRP, plasma t-PA and PAI-1 concentrations were determined in 95 patients with
stable CHD. A representative sub-population of 12 male patients received an intra-
brachial infusion of TNF-a and saline placebo using a randomised double-blind
crossover study design. Forearm blood flow, and plasma fibrinolytic and
inflammatory variables were measured. Serum CRP concentrations correlated with
plasma t-PA concentrations (r=0.37, p<0.001) and t-PA/PAI-1 ratio (r= -0.21,
p<0.05). Intra-arterial TNF-a caused a rise in t-PA concentrations (p<0.001) without
affecting blood flow or PAI-1 concentrations. Tumour necrosis factor-a pre-
treatment impaired acetylcholine and nitroprusside-induced vasodilatation (p<0.001
for both) whilst doubling bradykinin-induced t-PA release (p=0.006). In patients with
stable CHD, plasma fibrinolytic factors correlate with a systemic inflammatory
marker, and local vascular inflammation directly impairs vasomotor function whilst
enhancing endothelial t-PA release. We suggest that the adverse prognosis associated
with elevated plasma t-PA concentrations relates to the underlying causative
association with vascular inflammation and injury.
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5.2 INTRODUCTION
In epidemiological studies of patients with CHD [Thompson et al 1995], and in
prospective studies in healthy populations [Ridker et al 1993], higher plasma
concentrations of the pro-fibrinolytic factor t-PA positively and independently
predict future cardiovascular events. It would be anticipated that high t-PA
concentrations would protect against subsequent cardiovascular events rather than
the reverse. This paradoxical association is, in part, explained by the concomitant
elevation of PAI-1 which complexes with, and inactivates, t-PA. However, the
precise stimulus for this increased t-PA release remains unclear.
Areas of endothelial denudation and thrombus deposition are a common finding on
the surface of atheromatous plaques and are usually subclinical. Through t-PA
release, endogenous fibrinolysis is usually able to prevent thrombus propagation
although organisation of the residual thrombus may lead to plaque growth and
expansion [Mann and Davies 1999]. The adverse prognosis conferred by elevated
plasma t-PA antigen concentrations may therefore reflect the extent of occult
atheroma and subclinical plaque rupture stimulating t-PA release.
Markers of systemic inflammation, such as CRP and TNF-a, are elevated in patients
with cardiovascular disease [Haverkate et al 1997; Ridker et al 2000a], Indeed,
serum CRP concentrations predict the development of cardiovascular disease
independent of other risk factors. Previous studies have indicated a direct
relationship between serum CRP and plasma t-PA concentrations [Haverkate et al
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1995; Lowe et al 2004], This raises the question of whether vascular inflammation is
causally related to the elevation in plasma t-PA concentrations or whether CRP and t-
PA are independently increased by a common factor related to the atherosclerotic
process itself, such as acute plaque rupture.
Abnormalities of endothelial function have been demonstrated in patients with
atherosclerosis [Ludmer et al 1986] and vascular inflammation [Hingorani et al
2000b; Chia et al 2003a; 2003b], In patients with CHD, restoration of endothelium-
dependent vasomotor function occurs when there is normalisation of CRP
concentrations [Fichtlscherer et al 2000] whereas ongoing chronic inflammation is
associated with an impaired fibrinolytic response to venous occlusion [Speidl et al
2005], As the endothelium is the major source of plasma t-PA, abnormalities of
endothelial function may therefore mediate the potential inflammation-induced
elevations in plasma t-PA concentrations.
It therefore remains unclear whether elevated t-PA concentrations are implicated in
the mechanisms contributing to, or arise as a consequence of, atherothrombotic
events. The aims of the present study were, in patients with stable CHD, to confirm
the previous association between plasma CRP and t-PA concentrations, and to
determine the effect of acute local vascular inflammation provoked by direct intra¬




We recruited patients with CHD confirmed by angiography (defined as >50%
luminal stenosis of at least one major epicardial coronary vessel) or a previous
history of Q-wave MI. All patients had stable anginal symptoms and had not
undergone coronary revascularisation within the preceding 3 months. Exclusion
criteria were significant cardiac failure, renal impairment, systolic blood pressure
<100 or >190 mmHg, diabetes mellitus, history or clinical features of recent infective
illness and immunosuppressive or non-steroidal anti-inflammatory medications
(excluding aspirin 75 mg/d). All studies were undertaken with the approval of the
local Research Ethics Committee, the written informed consent of each subject, and
in accordance with the Declaration ofHelsinki.
5.3.2 Drugs
Tumour necrosis factor-a (Knoll Pharmaceuticals, Germany), bradykinin (Clinalfa,
AG, Switzerland), acetylcholine (Novartis UK Ltd, UK), and sodium nitroprusside
(David Bull Laboratories, UK) were administered following dissolution in 0.9%
saline.
5.3.3 Study Design
All subjects abstained from alcohol for 24 hours and from food, tobacco and
caffeine-containing drinks for at least 4 hours before each study visit. A venous
blood sample was taken from all patients for estimation of serum CRP, and plasma
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t-PA and PAI-1 antigen concentrations. Twelve representative male patients were
then recruited into a randomised double-blind placebo-controlled crossover study
comparing the effect of direct intra-brachial infusion of TNF-a and saline placebo on
FBF and endogenous fibrinolytic function.
5.3.4 Forearm Study Protocol
All studies were carried out at 09:00 hours in a quiet temperature-controlled room
maintained at 22-25°C. Patients rested recumbent, strain gauges and cuffs were
applied. Venous cannulae were inserted and the brachial artery of the non-dominant
arm cannulated with a 27-G needle. Blood pressure and heart rate were measured
using a semi-automated non-invasive sphygmomanometer.
Twelve subjects attended on two occasions at least 2 weeks apart and received an
intra-arterial infusion of either TNF-a (80 ng/min) or saline placebo over 60 minutes
followed on each occasion by a further 60 minutes of saline infusion. Thereafter,
intra-arterial bradykinin (100, 300, 1000 pmol/min), acetylcholine (5, 10, 20 pg/min)
and sodium nitroprusside (2, 4, 8 pg/min) were administered at 1 mL/min with a
15 minute saline washout period between each agent. The dose of TNF-a was chosen
to achieve local cytokine concentrations comparable to healthy volunteer studies
[Chia et al 2003b], and those seen in cardiovascular disease [Biasucci et al 1996],
Venous blood samples for t-PA antigen and activity and PAI-1 antigen were obtained
at baseline, after 60 minutes of TNF-a/placebo infusion, following the 60 minute
infusion of saline, before and during each dose of bradykinin and 15 minutes after
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the end of bradykinin infusion. Plasma cytokines, fe-CRP and prothrombin Fl+2
were assessed prior to, and following the TNF-a/placebo and saline infusions, and at
the end of each study.
5.3.5 Statistical Analysis
As basal t-PA concentrations were altered by pre-treatment with TNF-a, net release
of t-PA during bradykinin infusion was calculated by subtracting the mean t-PA
release before, and 15 minutes after cessation of bradykinin infusion [Chia et al
2003b], The area under the curve [Matthews et al 1990] was calculated for the
estimated net release of t-PA in response to bradykinin. Data were examined, where
appropriate, by ANOVA with repeated measures followed by post-hoc t-tests
adjusted with a Bonferroni correction for multiple comparisons. Spearman's
correlation was used to compare CRP and plasma levels of fibrinolytic factors. As
serum CRP concentrations have a skewed distribution, they were logarithmically
transformed. All statistical calculations were undertaken using GraphPad Prism
(GraphPad Software, USA). Results are expressed as mean ± SEM unless otherwise
stated; statistical significance was assigned at the 5% level.
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5.4 RESULTS
Patients had a typical cardiovascular risk factor profile in keeping with their
diagnosis of CHD and most were prescribed secondary preventative medications
(Tables 5.1 and 5.2). The majority of the subjects were male, two-thirds had
previously undergone coronary revascularisation and around one-third were habitual
smokers.
Table 5.1 Baseline characteristics of the 95 subjects with stable coronary heart disease
Age, years 59 ± 7
Body mass index, kg/m2 29 ± 5
Male gender 79 (83)
Previous myocardial infarction 39 (41)
Extent of coronary artery disease*
1 vessel 42 (44)
2 vessels 24 (25)
3 vessels 28 (29)
Previous coronary revascularisation 64 (67)
Co-morbidity
Hypertension 46 (48)
Previous hyperlipidaemia 89 (94)
Family history ofpremature CHD 32 (34)






ACE inhibitor, ARB 30 (32)
Serum urea, mmol/L 5.6 ±1.3
Semm creatinine, pmol/L 93 ± 13
Plasma glucose, mmol/L 5.7 ± 0.9
Total cholesterol, mmol/L 4.5 ± 0.9
LDL cholesterol, mmol/L 2.5 ± 0.7
Triglycerides, mmol/L 1.8 ±0.9
CHD - coronary heart disease; ACE - angiotensin converting enzyme; ARB - angiotensin II receptor
blocker; LDL - low-density lipoprotein. *Angiographic data unavailable on 1 subject. All data are
mean ± SD or n (%).
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Table 5.2 Baseline characteristics of the 12 patients receiving TNF-a and saline
placebo
Age, years 60 ± 2
Body mass index, kg/m2 24 ± 1
Male gender 12(100)
Previous myocardial infarction 5 (42)
Extent of coronary disease*
1 vessel 5 (42)
2 vessels 4 (33)
3 vessels 2(17)
Previous coronary revascularisation 9 (75)
Co-morbidity,
Hypertension 3 (25)
Family history of premature CHD 1 (8)
Previous hyperlipidaemia 12(100)






ACE inhibitor 1 (8)
Serum urea, mmol/L 5.9 ± 0.3
Serum creatinine, pmol/L 93 ± 2
Plasma glucose, mmol/L 5.2 ± 0.1
Total cholesterol, mmol/L, 3.9 ±0.2
LDL cholesterol, mmol/L 2.1 ±0.2
Triglycerides, mmol/L 1.3 ± 0.2
Placebo visit
Heart rate, /min 56 ± 2
Systolic blood pressure, mmHg 145 ± 6
Diastolic blood pressure, mmHg 83 ± 4
Forearm blood flow, mL/100 mL/min
Infused arm 2.1 ± 0.2
Non-infused arm 2.0 ± 0.2
TNF-a visit
Heart rate, /min 56 ± 3
Systolic blood pressure, mmHg 142 ± 4
Diastolic blood pressure, mmHg 81 ± 2
Forearm blood flow, mL/100 mL/min
Infused arm 2.0 ± 0.2
Non-infused arm 2.1 ± 0.2
CHD - coronary heart disease; ACE - angiotensin-converting enzyme; LDL - low-density
lipoprotein; TNF-a - tumour necrosis factor-a. *Angiographic data unavailable on 1 subject.
Values are mean ± SEM or n (%).
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5.4.1 Plasma Fibrinolytic Factors and Correlationwith CRP
In the cohort of 95 patients with stable CHD, serum hs-CRP concentrations
correlated with plasma t-PA antigen concentrations (r=0.37, p<0.001), plasma PAI-1
antigen concentrations (r=0.28, p=0.006), and inversely with the ratio of t-PA/PAI-1
antigen (r= -0.21, p<0.05). As anticipated, plasma t-PA antigen concentrations
correlated with plasma PAI-1 antigen concentrations (r=0.49, p<0.001).
5.4.2 Effect of Acute Inflammation on Vascular and Fibrinolytic
Function
Those subjects who received TNF-a and saline placebo had similar baseline
characteristics to the main cohort; all were receiving statin and aspirin therapy. There
were no differences in resting arterial pressure, heart rate or FBF between the two
study visits (Table 5.2).
There was no change in heart rate or blood pressure during infusion of either TNF-a
or placebo. Flaematocrit, temperature, white cell count and /zs-CRP were similar on
both study visits (p=ns; data on file). The study protocol was well tolerated with no
major adverse effects.
5.4.3 Plasma Cytokine Concentrations
Intra-arterial infusion of TNF-a increased plasma TNF-a concentrations from
1.4 ± 0.2 to 164.5 ± 26.8 pg/mL in the infused arm and from 1.3 ± 0.1 to 33.3 ± 5.6
pg/mL in the non-infused arm (p<0.001; Figure 5.1). One hour after TNF-a infusion,
plasma IL-6 concentrations increased from 4.1 ± 1.9 to 6.4 ± 2.3 pg/mL in the
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infused arm (p<0.001, ANOVA) but were unchanged in the non-infused arm (4.0 ±
1.9 to 3.7 ± 1.3 pg/mL). Placebo infusion had no effect on plasma IL-6
concentrations in the infused arm (3.9 ± 1.7 to 4.3 ± 1.3 pg/mL, p=ns). Serum CRP
concentrations were unchanged following the 60 minute infusion of TNF-a and
saline placebo.
5.4.4. Vasomotor and Fibrinolytic Responses
There was no significant change in resting FBF in the 2 hours after the start of either
TNF-a or placebo infusion. After 60 minutes of TNF-a, plasma t-PA antigen and
activity concentrations in the infused arm had increased from 9.4 ± 1.1 to 11.3 ± 1.2
ng/mL and 0.3 ±0.1 to 2.1 ± 0.6 IU/mL respectively (p<0.001) and these remained
elevated in the 2 hours following discontinuation of the TNF-a infusion (Figure 5.2).
There was no change in plasma PAI-1 antigen concentrations in the infused arm, and
no change in either plasma t-PA or PAI-1 concentrations in the non-infused arm
during the study (p=ns; data on file). Prothrombin Fl+2 concentrations in the infused
arm were unaltered following either saline placebo (0.9 ±0.1 to 0.9 ± 0.1 ng/mL;
p=ns) or TNF-a infusion (0.9 ±0.1 to 1.0 ± 0.1 ng/mL; p=ns).
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Figure 5.1 Plasma TNF-a concentrations in the infused (solid line) and non-infused arm
(dashed line) after 60 minutes of intra-arterial TNF-a (•) and saline placebo (o). p<0.001,
ANOVA, TNF-a dose response in the infused arm; TNF-a (•) versus saline placebo (o) for
infused arm.


















Figure 5.2 Plasma t-PA antigen (bottom), and activity (top), concentrations in the infused
(•) and non-infused arms (o) arms after 60 minutes infusion of intra-arterial TNF-a.
fp<0.001, ANOVA, infused (•) versus non-infused arm (o). *p<0.05 and ***p<0.001, post-hoc t-test
for treatment effect.



























































There was a dose-dependent increase in FBF during bradykinin, acetylcholine and
sodium nitroprusside infusion (p<0.01, ANOVA). Compared to saline placebo, TNF-
a pre-treatment impaired acetylcholine and nitroprusside-induced vasodilatation
(p<0.001 for both) but did not alter the response to bradykinin (Figure 5.3).
Plasma t-PA concentrations increased in a dose-dependent manner during bradykinin
infusion on both study visits (p<0.001). Pre-treatment with TNF-a augmented the
bradykinin-induced rise in plasma t-PA antigen and activity concentrations (p<0.001
for both; Figure 5.4) and significantly increased estimated net release of t-PA antigen
and activity (63.7 ± 14.8 versus 120.6 ± 26.1 ng/100 mL tissue/min and 54.8 ± 14.8
versus 98.8 ±21.0 IU/100 mL tissue/min at peak dose; p<0.05 for both). Over the
30 minute period of bradykinin infusion, TNF-a increased the area under the curve
for net t-PA antigen and activity release by 120% and 188% respectively (p=0.006).
Subgroup analysis showed a significant impairment of endothelium-dependent
vasodilatation as well as bradykinin-induced t-PA response in cigarette smokers.
Qualitatively the effect of intra-arterial TNF-a on the blood flow and fibrinolytic
responses were similar in both smokers and non-smokers.
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5.5 DISCUSSION
We have confirmed the direct association between plasma t-PA and serum CRP
concentrations in patients with stable CHD. For the first time, we have extended this
observation using an acute local vascular inflammatory model and demonstrated that
direct intra-arterial infusion of TNF-a causes a slow onset and sustained increase in
basal t-PA release. This arterial inflammation was also associated with increased
stimulated t-PA release in the presence of impaired vasomotor function. Our findings
are consistent with the suggestion that t-PA is released during vascular inflammation
and endothelial injury and this may, in part, explain the adverse prognosis associated
with increased plasma t-PA concentrations.
The link between markers of inflammation and plasma t-PA concentrations suggests
that vascular inflammation and injury may be responsible for endothelial t-PA
release. However, the association may arise from common aetiological factors and
does not establish a causal relationship. A recent meta-analysis has suggested that
increases in plasma t-PA concentrations largely reflect the presence of concomitant
cardiovascular risk factors [Lowe et al 2004], We therefore sought to induce vascular
inflammation in a representative sample of our study population. Inducing systemic
inflammation will have many biological actions and could be confounded by indirect
or extra-vascular effects. This may explain some of the differences between our
current results and those of previous work in healthy volunteers using s typhi
vaccination [Hingorani et al 2000b; Chia et al 2003a]. We chose to employ an acute
local inflammatory model [Chia et al 2003b] to assess the direct effects of intra-
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arterial TNF-a administration on t-PA release. We were able to induce local vascular
inflammation with a rise in local plasma IL-6 concentrations to levels comparable to
those seen in patients with unstable angina [Biasucci et al 1996], without evidence of
a systemic inflammatory response or change in plasma t-PA or PAI-1 concentrations
in the non-infused arm. This local vascular inflammation caused a slow onset and
sustained increase in plasma t-PA concentrations that continued for at least 2 hours
after cessation of the TNF-a infusion. This establishes that vascular inflammation
directly causes endothelial t-PA release in man.
The mechanism of TNF-a induced t-PA release has not been established.
Inflammatory cytokines, such as TNF-a, may cause t-PA release via induction of
local thrombus formation, activation of specific cellular receptors or through
generation of secondary mediators within the local vasculature. The former seems
unlikely given that we observed no increase in prothrombin Fl+2, a sensitive marker
of in vivo thrombin generation [Paramo et al 2004], Whilst it is likely that plasma t-
PA concentrations are increased by inducing endothelial injury, smooth muscle cells,
macrophages and monocytes also express t-PA mRNA following stimulation by
inflammatory cytokines within atherosclerotic plaques [Lupu et al 1995] and could
theoretically contribute to this fibrinolytic response.
5.5.1 Effects of TNF-a on Vasomotor Function
Impaired vasodilator responses to acetylcholine [Suwaidi et al 2000; Fleitzer et al
2001] and sodium nitroprusside [Fleitzer et al 2001] in patients with cardiovascular
risk factors predict an increased risk of adverse cardiovascular events. Previous
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studies in healthy volunteers have shown acute systemic inflammation is associated
with a transient impairment in vasomotor function [Hingorani et al 2000b]. We have
now shown that, in patients with CHD, acute local vascular inflammation decreases
the vasomotor response to both acetylcholine and nitroprusside. Acetylcholine is
known to stimulate NO production via activation of eNOS and, together with the
impaired nitroprusside response, these findings suggest that local arterial
inflammation can decrease NO bioavailability. Interestingly, impaired vasodilator
responses to both acetylcholine and sodium nitroprusside have been correlated with
plasma TNF-a concentrations in patients with rheumatoid arthritis, a chronic
inflammatory condition which is itself associated with an excess cardiovascular risk
[Yki-Jarvinen et al 2003], Furthermore, intra-arterial infusion of the free radical
scavenger vitamin C restores FBF responses in patients with CHD and elevated
serum levels of CRP [Fichtlscherer et al 2004].
Our results suggest that acute inflammation is associated with impaired NO-
dependent smooth muscle relaxation in response to direct NO donors such as sodium
nitroprusside or endogenously derived NO following stimulation of eNOS. Several
lines of evidence support the contention that cytokines such as TNF-a may impair
NO-dependent signalling. TNF-a decreases eNOS expression [Yoshizumi et al
1993] as well as increasing reactive oxygen species such as superoxide anion that
rapidly inactivate NO and are directly cytotoxic to vascular tissues. TNF-a also
increases plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of
eNOS that inhibits endothelium-dependent vasodilatation [Boger et al 1998], Finally,
inflammatory states may increase inducible nitric oxide synthase (iNOS) expression
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which is associated with receptor uncoupling and endothelial dysfunction [Funakoshi
et al 2002],
Bradykinin-induced vasodilatation was unaltered by pre-treatment with TNF-a.
Previous work has suggested that NO contributes only a small proportion (-15%) to
bradykinin-induced vasodilatation [O'Kane et al 1994; Honing et al 2000] and does
not contribute to the mechanism of bradykinin-induced t-PA release [Brown et al
2000], Moreover, in patients with vascular dysfunction, there may be an increased
contribution of endothelium-derived hyperpolarising factor to smooth muscle
vasorelaxation [Panza et al 1995] particularly if NO is consumed by free radicals
generated by locally active inflammatory cells. These observations are consistent
with our findings of impaired acetylcholine and sodium nitroprusside-induced
vasodilatation but preserved bradykinin responses.
5.5.2 Effects of TNF-a on Acute Endogenous Fibrinolysis
Despite the presence of higher baseline plasma t-PA concentrations in patients with
atherosclerosis [Lowe et al 2004], we have here shown that direct intra-arterial TNF-
a infusion increases bradykinin-induced t-PA release in patients with stable CHD.
Thus, although vasorelaxation was impaired, acute inflammation initiates a sustained
increase in both basal and stimulated t-PA release. The mechanism of this effect is
unknown but may involve direct endothelial injury, upregulation of t-PA synthesis or
alterations in bradykinin receptor expression.
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Under some circumstances, increases in t-PA may protect against the propagation of
intravascular thrombosis and thereby avoid the development of an acute coronary
syndrome. However, elevations in plasma t-PA concentrations may reflect more
widespread endothelial dysfunction and a dominant pro-inflammatory vascular
response that may overwhelm any locally protective pro-fibrinolytic effect. Indeed,
the pro-fibrinolytic actions of vascular inflammation may potentiate degradation of
extracellular matrix and aggravate plaque instability [Steins et al 1999], The clinical
outcome of acute vascular inflammation may, therefore, depend upon the relative
balance between the protective antithrombotic actions and potential plaque
destabilisation associated with increased vascular t-PA release.
In this study, all patients who received TNF-a and placebo infusion were already
receiving secondary preventative therapy including aspirin and lipid-lowering
medications. Although these may have influenced the vascular response to TNF-a, it
was considered unethical to withhold these and, in clinical practice, a large
proportion of patients presenting with acute coronary syndromes and raised
inflammatory markers are already established on such therapies. As our study design
was focused on the question of the link between vascular inflammation and t-PA
release in patients with CHD, we did not include a control population of healthy
subjects. However we have previously shown that intra-arterial TNF-a enhances
endothelium-dependent t-PA release by a similar degree in younger healthy
volunteers [Chia et al 2003b). Although we have again demonstrated that smokers
have impaired endothelial responses including t-PA release [Newby et al 1999],
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intra-arterial TNF-a increased plasma t-PA concentrations to a similar degree in both
smokers and non-smokers with established CHD.
We have found that while TNF-a adversely affects NO-dependent vasodilatation, it
enhances other protective mechanisms, such as the endogenous fibrinolytic capacity.
This reflects the complex and pleiotropic nature of TNF-a which functions as part of
the normal host surveillance mechanisms and response to tissue injury. Although we
only determined the effect of acute vascular inflammation in twelve patients, our
results may explain some of the contradictory findings of previous clinical studies.
For example, in patients with heart failure, TNF-a antagonism causes marked
improvements in endothelium-dependent vasodilatation [Fichtlscherer et al 2001] but
has failed to demonstrate clinical benefit in randomised controlled trials [Mann et al
2004], Thus, the benefits of restoring endothelium-dependent vasomotor function by
TNF-a antagonism may be counterbalanced by inhibiting other potentially beneficial
acute effects such as enhancing endogenous t-PA release.
In summary, we have shown that, in patients with stable CHD, plasma fibrinolytic
factors are correlated with CRP, a sensitive and prognostically relevant marker of
vascular inflammation. We have also demonstrated that acute vascular inflammation
directly impairs vasomotor function whilst enhancing endothelial t-PA release. We
suggest that the adverse prognosis associated with elevated plasma t-PA
concentrations reflects a causative association with vascular inflammation and injury
rather than representing a marker of occult plaque rupture.
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CHAPTER 6
PHOSPHODIESTERASE TYPE 5 INHIBITION DOES NOT REVERSE
ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH
CORONARY HEART DISEASE
Robinson SD, Ludlam CA, Boon NA, Ncwby DE.
Phosphodiesterase type 5 inhibition does not reverse endothelial




Endothelial dysfunction is an independent predictor of cardiovascular events and
may be due to a reduction in NO bioavailability. Phosphodiesterase inhibitors may
augment NO-dependent pathways. We hypothesised that sildenafil citrate, a selective
PDE 5 inhibitor, would improve endothelial vasomotor and fibrinolytic function in
patients with CHD. Sixteen male patients with CHD and eight age-matched healthy
men received intravenous sildenafil or placebo in a randomised double-blind
placebo-controlled crossover study. Bilateral FBF and fibrinolytic parameters were
measured using venous occlusion plethysmography and blood sampling in response
to intra-brachial infusions of acetylcholine, substance P, sodium nitroprusside and
verapamil. Mean arterial blood pressure fell during sildenafil infusion from (mean ±
SEM) 92 ± 1 to 82 ± 1 mmHg in patients and from 94 ± 1 to 82 ± 1 mmHg in
controls (p<0.001 for both). Sildenafil increased endothelium-independent
vasodilatation with sodium nitroprusside (p<0.05) but did not alter the blood flow
response to acetylcholine or verapamil in patients or controls. Substance P caused a
dose-dependent increase in t-PTA antigen concentrations (p<0.01) that was
unaffected by sildenafil in either group. Sildenafil does not improve peripheral
endothelium-dependent vasomotor or fibrinolytic function in patients with CHD.
Phosphodiesterase type 5 inhibitors are unlikely to reverse the generalised vascular
dysfunction seen in patients with CHD.
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6.2 INTRODUCTION
The endothelium plays an important role in the regulation of vascular function
including local blood flow and endogenous fibrinolysis. Coronary heart disease and
its risk factors, such as cigarette smoking, hyperlipidaemia and hypertension
[Creager et al 1990; Celermajer et al 1993; Panza et al 1993] are associated with
impaired endothelium-dependent vasorelaxation and reduced endothelial release of
the endogenous fibrinolytic factor, t-PA [Newby et al 1999; Pretorius et al 2002].
These aspects of endothelial function are important since plasma fibrinolytic
variables and endothelium-dependent vasodilatation independently predict future
cardiovascular risk [Meade et al 1993; Suwaidi et al 2000],
Nitric oxide is a key factor linked to the beneficial protective effects of the
endothelium and a decrease in NO bioavailability favours atherogenesis [Cayatte et
al 1994]. Nitric oxide exerts many of its biological effects through generation of
cGMP following activation of soluble guanylate cyclase. Phosphodiesterase type 5
inactivates cGMP within vascular smooth muscle and thus negatively regulates NO-
mediated cellular actions [Wallis et al 1999], Recently, highly selective PDE 5
inhibitors that prolong the action of cGMP and thereby enhance NO-mediated effects
have become available for clinical use.
It has been suggested that the PDE 5 inhibitor, sildenafil citrate (Viagra®, Pfizer Inc.,
New York), can improve endothelial vasomotor function in the peripheral circulation
of healthy cigarette smokers [Kimura et al 2003] and the coronary circulation of
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patients with CHD [Halcox et al 2002a], Although we have previously demonstrated
a link between NO and acute t-PA release [Newby et al 1998] the potential beneficial
effects of sildenafil on t-PA and its inhibitor, PAI-1, are unknown.
We hypothesised that sildenafil would favourably alter endothelium-dependent
vasomotor function and acute t-PA release in patients with stable CHD. If so, PDE 5
inhibitors might become a useful adjunctive therapy and confer secondary




Sixteen male subjects with stable CHD and eight age-matched healthy control men
participated in the study. The investigation was undertaken with the approval of the
local Research Ethics Committee, the written informed consent of each subject, and
in accordance with the principles outlined in the Declaration ofHelsinki.
6.3.2 Subjectswith CoronaryHeart Disease
A history of CHD was confirmed by angiographic evidence of <50% luminal
stenosis of at least one major epicardial coronary vessel or a history of Q-wave MI.
Nitrate medications were withdrawn for 48 hours prior to each visit and other
medications were withheld on the morning of study. Patient exclusion criteria were
significant cardiac failure, renal impairment, systolic blood pressure <100 or
>190 mmHg and diabetes mellitus.
6.3.3 HealthyControl Subjects
Control subjects were healthy normotensive euglycaemic non-smokers without any
history of cardiorespiratory or vascular disease and were not taking any regular
medications. No subject had received sildenafil or other PDE inhibitor prior to, or
during, participation in this study.
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6.3.4 Drugs
Substance P (Clinalfa AG, Switzerland), acetylcholine (Novartis UK Ltd), sodium
nitroprusside (David Bull Laboratories, UK) and verapamil (Abbott UK Ltd) were
administered following dissolution in 0.9% saline. Sildenafil and matched placebo
(Pfizer Ltd, Sandwich, UK) were administered intravenously as a bolus and
continuous infusion to achieve stable plasma concentrations equivalent to the peak
concentration of a single 100 mg oral dose (pharmacokinetic data, Pfizer UK Ltd).
6.3.5 Forearm Study Protocol
Subjects were requested to abstain from alcohol for 24 hours and food, caffeine-
containing drinks and tobacco for at least 4 hours before each study. All studies were
carried out in a quiet temperature-controlled room maintained at 22-25°C. Subjects
rested recumbent, strain gauges and cuffs were applied. The brachial artery of the
non-dominant arm was cannulated with a 27-G needle, a venous cannula was
inserted into the antecubital vein of each arm and into a dorsal foot vein for the
administration of either intravenous sildenafil or matched placebo. Blood pressure
and heart rate were monitored at intervals throughout the study in the non-infused
arm using a semi-automated non-invasive sphygmomanometer. Mean arterial
pressure was defined as the diastolic pressure plus a third of the pulse pressure.
6.3.6 Study Design
Each subject attended at 09:00 hours on two separate occasions at least 2 weeks apart
and received matched placebo and sildenafil in a randomised double-blind crossover
design.
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Saline was infused intra-arterially for the first 20 minutes to allow recording of
resting FBF, blood pressure and heart rate. After this period, sildenafil or matched
placebo was administered intravenously as a single 26.25 mg bolus over 5 minutes
then as a continuous infusion of 10 mg/hr. Twenty minutes after commencing the
sildenafil or placebo infusion, basal FBF was determined, and thereafter
acetylcholine (5, 10, 20 pg/min), substance P (2, 4, 8 pmol/min), sodium
nitroprusside (2, 4, 8 pg/min) and verapamil (10, 30, 100 pg/min) were infused intra-
arterially for 6 minutes at each dose. Acetylcholine, substance P and sodium
nitroprusside were given in a random order and separated by 20 minute saline
washout periods, but because of its prolonged vasodilator action, verapamil was
infused last. The order of the infusions was maintained constant for each subject
across both visits.
6.3.7 Statistical Analysis
Data were examined, where appropriate, by ANOVA with repeated measures and
two-tailed Student's /-test using GraphPad Prism Software (GraphPad Software,
California, USA). All results are expressed as mean ± SEM. Statistical significance
was assigned at the 5% level. On the basis of a previous study [Newby et al 2002]
the study had an 80% power to detect a 23% change in plasma t-PA concentrations




Most patients with CHD had a prior history ofMI, hypertension and hyperlipidaemia
(Table 6.1).
Reflecting concomitant therapy, mean resting heart rate (55 ± 1 versus 63 ±
2 beats/minute respectively, p<0.001, unpaired /-test) and serum total cholesterol
concentration (4.2 ± 0.2 versus 5.5 ± 0.2 mmol/L, p<0.001) were lower in patients
with CHD than controls. There were no differences in baseline MAP, resting heart
rate, baseline FBF or haematocrit between the two study visits. Infusions were well
tolerated and there were no serious adverse events. For technical reasons, 1 control
subject was unable to complete both visits.
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Table 6.1 Baseline characteristics
Patients Controls
Age, years 57±2 54±2
Body mass index, kg/m2 27±1 27±1
Co-morbidity, n
Myocardial Infarction 10 0
Hypertension 12 0
Diabetes mellitus 0 0
Previous hyperlipidaemia 15 0
Smoker / Non-smoker 1 / 15 0/8
Medical Therapy, n
Aspirin 16 0
P-Adrenergic blockade 13 0
Calcium antagonist 3 0
Long acting nitrate/nicorandil 2 0
ACE inhibitor, AT II antagonist 5 0
Lipid-lowering therapy 16 0
Serum urea, mmol/L 5.5±0.3 5.1±0.4
Serum creatinine, pmol/L 92±3 95±4
Glucose, mmol/L 5.6±0.2 5.5±0.3
Total cholesterol, mmol/L 4.2±0.2 5.5±0.2*
HDL cholesterol, mmol/L l.OdhO.O 1.1±0.1
Triglycerides, mmol/L 1.7±0.2 1.2±0.2
Placebo visit
Heart rate /min 55±1 61±3*
Mean arterial pressure, mmHg 95±2 95±4
Forearm blood flow, mL/100 mL/min
Infused arm 2.5±0.2 2.2±0.2
Non-infused arm 2.3±0.2 2.1±0.4
Sildenafil visit
Heart rate/min 55±1 65±3*
Mean arterial pressure, mmHg 95±2 91±3
Forearm blood flow, mL/100 mL/min
Infused arm 2.5±0.2 2.6±0.3
Non-infused arm 2.5±0.2 2.4±0.3
All values are mean ± SEM. *p<0.001, unpaired Mest, patients versus controls.




Over the course of the study, the average MAP was lower during sildenafil than
placebo infusion in patients with CHD (82 ± 1 versus 92 ± 1 mmHg, p<0.001,
unpaired Mest sildenafil versus placebo; Figure 6.1) and control subjects (82 ± 1
versus 94 ± 1 mmHg, p<0.001, unpaired /-test). It returned to baseline after
discontinuation of infusion (data not shown). There was a transient rise in heart rate
following the sildenafil bolus in both groups (Figure 6.1 and data on file).
6.4.2 Placebo Visit
Acetylcholine caused dose-dependent increases in FBF in both groups although this
rise was significantly less in patients with CHD than controls (p=0.005, ANOVA;
Figure 6.2). There were no differences in FBF responses between the two groups
during sodium nitroprusside and verapamil infusions (Figure 6.2). There were no
significant changes in the non-infused FBF.
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Figure 6.1 Heart rate (a) and MAP (b) during sildenafil (closed circles, solid line) or
placebo (open circles, dashed line) infusion (shaded box) in patients with coronary heart
disease.
*p<0.001, ANOVA, sildenafil versus matched placebo; Control subject data on file (p<0.001,
ANOVA, MAP sildenafil versus matched placebo).
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6.4.3 Sildenafil Therapy and Vascular Function
Compared with placebo, administration of sildenafil caused no significant change in
the infused FBF response during intra-arterial infusion of acetylcholine (at
20 gg/min, mean difference 0.1 ml./l00 mL/min; 95% confidence intervals -0.2 to
+0.4), substance P (at 8 pmol/min, mean difference 0.5 mL/100 mL/min; 95%
confidence intervals 0.0 to +0.9) or verapamil (at 8 pmol/min, mean difference 0.3
mL/100 mL/min; 95% confidence intervals -0.1 to +0.7). However, sildenafil
augmented the vasodilatation to sodium nitroprusside in both patients with CHD
(p<0.05, ANOVA; Figure 6.3) and control subjects (p<0.001, ANOVA; Figure 6.4).
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6.4.4 Plasma Fibrinolytic Variables
Baseline plasma t-PA antigen concentrations were unchanged by sildenafil in either
group (Table 6.2, Figure 6.5). Substance P caused a dose-dependent increase in
plasma t-PA concentrations in both patients and controls (p<0.01 for both, ANOVA;
Table 6.2). There was no difference in substance P-induced increase in plasma t-PA
concentrations during the sildenafil or placebo infusion (Table 6.2; at 8 pmol/min,
mean difference -0.1 ng/mL; 95% confidence intervals -1.3 to +1.1) and there was no
significant change in plasma PAI-1 concentrations throughout either study.
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Table 6.2 Plasma tissue plasminogen activator (t-PA) and plasminogen activator
inhibitor type 1 (PAI-1) concentrations at baseline and during sildenafil and matched
placebo infusion in patients with coronary heart disease
*p<0.01, ANOVA for t-PA response; Control subject data on file (p<0.01, ANOVA for t-PA
response).
Sildenafil/Placebo 0 Bolus Continuous infusion (lOmg/hr)
Substance P dose, pmol/min 2 4 8
Placebo
Plasma t-PA Antigen, ng/mL
Infused arm 9.0±0.7 8.7±0.6 9.3±0.6 9.8±0.7 10.5±0.8*
Non-infused arm 9.0±0.6 9.1±0.6 9.1±0.6 8.9±0.6 9.1±0.6
Plasma PAI-1 Antigen, ng/mL
Infused arm 46.8±6.9 43.1±6.0 - - 34.4±5.4
Non-infused arm 45.2±7.1 45.5±7.6 - - 36.4±6.3
Sildenafil
Plasma t-PA Antigen, ng/mL
Infused arm 9.0±0.6 8.7±0.6 9.1±0.6 9.4±0.6 10.5±0.7*
Non-infused arm 9.1±0.6 8.8±0.6 9.0±0.6 8.9±0.6 9.0±0.6
Plasma PAI-1 Antigen, ng/mL
Infused arm 44.0±5.6 39.6±4.6 - - 36.0±3.8
Non-infused arm 47.9±5.6 43.2±4.9 - - 38.6±4.2
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6.5 DISCUSSION
We have shown that sildenafil, a selective PDE 5 inhibitor, does not modify
endothelium-dependent vasodilatation or acute t-PA release in men with stable CHD.
However, sildenafil did augment the vasodilator effect of the exogenous NO donor,
sodium nitroprusside. Thus, whilst our study confirms the well-described interaction
of sildenafil with NO donors [Ishikura et al 2000; Kimura et al 2003) we have found
no evidence to support the contention that PDE 5 inhibitors improve endothelium-
dependent vasomotor or fibrinolytic function in patients with CHD.
Compared to matched controls, patients with CHD exhibited impairment of the
endothelium-dependent responses to acetylcholine whilst having preserved
vasodilator responses to the endothelium-independent agonists, sodium nitroprusside
and verapamil. This prognostically significant impairment [Suwaidi et al 2000;
Heitzer et al 2001] was evident in patients who were already receiving standard anti¬
anginal, anti-platelet and lipid-lowering therapies.
Sildenafil had no effect on flow-mediated dilatation of the brachial artery in patients
with CHD [Halcox et al 2002a] and there are conflicting reports on the vasomotor
responses of the coronary vessels to sildenafil. Herrmann and colleagues [Herrmann
et al 2000] found no change in coronary artery diameter, blood flow or coronary
vascular resistance whilst Halcox and colleagues [Halcox et al 2002a] reported
enhanced coronary artery vasodilatation to acetylcholine. Unlike previous studies, we
have, for the first time, used a more robust double-blind randomised placebo-
controlled crossover study design and have shown that PDE 5 inhibition does not
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alter either endothelium-dependent vasomotor or fibrinolytic function in patients
with CHD or age-matched controls. Moreover, we used a bolus and continuous
intravenous sildenafil infusion to minimise variations in plasma concentrations
during the administration of each of the intra-arterial vasodilators. This is an
important study consideration given the short half-life of sildenafil in humans.
We observed a decrease in MAP in both patients and controls during administration
of sildenafil that presumably reflected an augmentation of the vascular effects of
basal vascular NO release and is mediated through an increase in cGMP. Our
findings are consistent with the published haemodynamic data in both healthy
volunteers [Herrmann et al 2000] and patients with CHD [Jackson et al 1999;
Herrmann et al 2000; Webb et al 2000] and confirm that we achieved a physiological
effect with sildenafil infusion. The consistent vasodilatory response to the NO
independent agonist, verapamil, makes it unlikely that administration of the PDE 5
inhibitor impaired vascular smooth muscle function or obscured potentially
beneficial effects on endothelial function. Moreover, both acetylcholine and
substance P produced similar, consistent and reproducible responses on both study
days. This suggests that prolonging cGMP actions in patients with established
atherosclerosis will not reverse endothelial dysfunction. As would be predicted from
its mechanism of action, sildenafil augmented the responses to sodium nitroprusside,
an exogenous NO donor, in both controls and CHD patients.
There are a number of potential reasons for the differences observed in the effect of
sildenafil on the acetylcholine and sodium nitroprusside responses. The modest
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decrease in acetylcholine-induced vasodilatation [Vallance et al 1989; Kamper et al
2002] seen following NOS inhibition suggests that non-NO-dependent pathways
such as EDHF may predominate particularly in the presence of endothelial
dysfunction [Bauersachs et al 1996; Katz and Krum 2001], Indeed, differences in the
relative contribution of endothelium-derived NO across vascular beds may explain
some of the previously conflicting data on the vascular responses to sildenafil [Katz
et al 2000; Halcox et al 2002a; Dishy et al 2004], As well as endothelial dysfunction,
atherosclerosis is associated with high levels of free radicals such as superoxide
anion that rapidly react with NO to generate peroxynitrite, a powerful oxidant species
that induces significant cellular damage and directly inhibits soluble guanylate
cyclase [Vallance and Chan 2001]. Elegant studies in animals with specific
knockouts of NO-dependent pathways [Ruetten et al 1999] also suggest that tissue
specific downregulation of NO/cGMP, including cGMP-dependent protein kinase,
may be an early feature of endothelial dysfunction in atherosclerotic conditions
[Munzel et al 2003], Phosphodiesterase type 5 inhibition would not be anticipated to
influence changes in oxidative stress or directly affect cGMP independent NO
molecular targets that contribute to endothelial dysfunction and atherogenesis.
Therefore, the contrasting effects of sildenafil on acetylcholine and sodium
nitroprusside-induced vasodilatation are likely to reflect a major dependence upon
non-NO-mediated pathways, increased oxidative stress and decreased NO
bioavailability associated with CHD.
Although the precise mechanism underlying acute t-PA release remains uncertain,
several reports have previously suggested involvement of NO and cyclic nucleotides
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regulated by PDEs. In animals, pentoxifylline and its analogues, non-selective PDE
inhibitors, increased acute t-PA release [Tranquille and Emeis 1991b] and
potentiated the effects of thrombolytic therapy [Ambrus et al 1994], We and others
have reported acute endothelial t-PA release during intra-arterial substance P [Newby
et al 1997; Newby et al 1999], bradykinin [Brown et al 1999] and methacholine
[Stein et al 1998] infusions as well as an inverse relationship between acute t-PA
release and atherosclerotic plaque burden within the coronary circulation [Newby et
al 2001]. In the present study, we have again demonstrated a rise in both plasma t-
PA antigen concentrations and net t-PA release with local intra-arterial substance P
infusion. However, infusion of sildenafil did not change basal plasma t-PA
concentrations or substance P-induced t-PA release. It would, therefore, appear that
enhancement of cGMP does not directly augment endothelial t-PA release in man.
Although we failed to show such a change in acute t-PA release using substance P, it
remains possible that sildenafil could improve the response to other agonists such as
bradykinin which causes B2 receptor mediated prostacyclin and NO generation
[Cockcroft et al 1994b]. However, the dominant mechanism of t-PA release with
bradykinin appears to be NO and prostacyclin independent, and involves coupling of
the B2 receptor to the calcium-dependent Gq/phospholipase C-beta pathway [Brown
et al 2000], Some of the conflicting results on the effect of NOS inhibitors on t-PA
release may suggest that there is physiological redundancy within the NO-dependent
pathways that contribute to the regulation of acute t-PA release in man.
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6.5.1 Study Limitations
In light of the haemodynamic changes seen in our study, intra-brachial infusion of
sildenafil using subsystemic locally active doses would be one approach to assess the
direct vascular actions of PDE 5 inhibition. However sildenafil is metabolised by the
liver to an active metabolite that accounts for nearly half of its PDE inhibitory
activity. Local intra-arterial infusion would not assess the action of this important
metabolite. The effect of chronic PDE 5 inhibitor therapy is unclear and further
studies involving females and subjects with diabetes mellitus would be of interest as
these groups may show differences within NO-dependent pathways [Forte et al 1998;
Brodsky et al 2001],
In summary, despite being highly effective in the management of erectile
dysfunction, sildenafil does not modify endothelium-dependent vasomotor or
fibrinolytic function in patients with CHD. Phosphodiesterase inhibitors have already
shown promise as novel therapies in conditions such as chronic heart failure [Katz et
al 2000] and pulmonary hypertension [Michelakis et al 2003] and these areas clearly
warrant further research. However on the basis of our results, we believe that PDE 5




CONCLUSIONS AND FUTURE DIRECTIONS
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7.1 SUMMARY OF THESIS FINDINGS
The endothelium plays a vital role in the regulation of blood flow, coagulation and
fibrinolysis as well as mediating the response to tissue injury and inflammation.
Disruption to these pathways is a critical factor in the development of atherosclerosis
and coronary heart disease including clinical syndromes such as acute myocardial
infarction. We have described a number of inter-related studies on factors affecting
vascular function in a well characterised cohort ofpatients with stable CHD.
Our group had previously shown that cigarette smokers exhibited impaired
fibrinolytic and vasomotor responses within both the forearm [Newby et al 1999]
and coronary [Newby et al 2001] circulations. As smokers are at particular risk of
coronary thrombosis, we hypothesised that endothelial fibrinolytic capacity would
predict the future risk of atherothrombotic events in patients with CHD. We have for
the first time shown that acute stimulated t-PA release from the forearm circulation is
a powerful predictor of the risk of future atherothrombotic events. This validates the
application of the forearm model to studying the pathophysiological changes
observed in CHD and suggests that the acute endogenous fibrinolytic capacity is a
novel bio-marker of future cardiovascular risk. Previous studies in healthy volunteers
suggested that genetic variation within the t-PA locus affected basal t-PA release.
However, we found no effect of a number of t-PA genetic polymorphisms on acute
t-PA release in patients with established coronary disease. Inter-individual
differences in t-PA release in subjects with CHD may therefore predominantly reflect
the presence of environment factors such as cigarette smoking or the presence of as
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yet unidentified genetic factors. Given the association between circulating levels of
inflammatory markers and the risk of CHD, we determined the effect of an intra¬
arterial infusion of a pro-inflammatory cytokine on vascular function. We found that
local intra-arterial inflammation impaired NO-dependent vasodilatation whilst
augmenting endogenous t-PA release. This suggests a pathophysiological mechanism
whereby circulating levels of inflammatory cytokines are directly related to plasma
t-PA concentrations in subjects at risk of future cardiovascular events. Although
impaired NO bioavailability appears to play a role in the expression of a pro-
thrombotic endothelial phenotype, infusion of a highly selective PDE 5 inhibitor to
try to prolong the biological actions of NO did not affect either endothelium-
dependent vasodilatation or endogenous fibrinolysis in CHD patients.
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7.2 ENDOTHELIAL FUNCTION AND RISK OF
ATHEROTHROMBOTIC EVENTS
7.2.1 Regulation of Vascular Tone and Future Cardiovascular Events
Measurement of vascular responses within the coronary circulation is of greatest
relevance to understanding the mechanisms contributing to coronary thrombosis and
MI. Assessing coronary blood flow responses is invasive and can only really be
applied to subjects undergoing coronary angiography with its inherent risks. Despite
these limitations, several studies have demonstrated that impaired endothelium-
dependent vasodilatation within the coronary circulation is an adverse prognostic
marker [Schachinger et al 2000; Suwaidi et al 2000; Halcox et al 2002b]. However,
in only one of these studies [Halcox et al 2002b], was target vessel revascularisation
excluded from the composite endpoint of cardiovascular events. Including
revascularisation procedures as an endpoint is contentious as it may be influenced by
non-biological factors which are not directly due to the pathogenesis of coronary
atherothrombosis and endothelial dysfunction [Widlansky et al 2003].
Although therapeutic interventions may lead to improvements in endothelium-
dependent vasomotor responses, this does not necessarily equate to a reduction in
clinical events. A number of trials of hormone replacement therapy demonstrated
beneficial effects on coronary and peripheral vascular tone, yet primary and
secondary preventative trials have been proven negative [Ganz 2002; Ganz and Vita
2003]. This highlights the difficulty in using only the vasodilator response as a
surrogate marker of endothelial function. The endothelium continuously releases
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paracrine factors, such as NO and prostacyclin, that not only modulate vascular tone
but also influence local platelet activation and aggregation. We [Robinson et al
2006b] have recently shown that those patients with the lowest endothelium-
dependent vasodilatation have the highest levels of circulating platelet-leukocyte
aggregates which are a sensitive and prognostically useful marker of in vivo platelet
activation [Michelson et al 2001; Sarma et al 2002]. These novel findings may be
relevant in understanding the link between impaired endothelium-dependent
vasodilatation and the risk of acute thrombotic-related cardiovascular events.
7.2.2 Acute t-PA Release from the Forearm Circulation Predicts
Future Atherothrombotic Events
The forearm circulation is more accessible than the coronary bed, though as it is
relatively protected from the development of atheroma, its applicability to the study
of CHD has been questioned. Our group had previously shown that cigarette
smokers, a group at particular risk of coronary thrombosis, exhibit impaired acute
t-PA release in response to substance P infusion within both the forearm [Newby et
al 1999] and coronary [Newby et al 2001] circulations. Here we have extended these
observations and shown that acute stimulated t-PA release from the forearm
circulation predicted the future risk of cardiovascular death, MI, CVA, and
emergency hospitalisation for myocardial ischaemia. This association was
demonstrated in a cohort of patients with angiographically proven coronary disease
and confirms the validity of using the forearm model and acute t-PA release as a
novel bio-marker of vascular risk. We specifically excluded events solely related to
revascularisation procedures from our pre-defined endpoint hypothesising that
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impaired t-PA release would be of greatest relevance in predicting thrombotic-related
clinical events. However, impaired t-PA release may increase plaque growth as
incomplete thrombus resolution is known to stimulate smooth muscle migration and
plaque expansion [Davies 2000b]. Future prospective studies examining the
relationship between acute t-PA release and the progression of coronary atheroma in
addition to future atherothrombotic events would be of interest.
7.3 TISSUE PLASMINOGEN ACTIVATOR GENOTYPE AND ACUTE
T-PA RELEASE
Our interest in assessing the importance of t-PA genotype in CHD patients arose
from previous work suggesting several polymorphisms of t-PA gene contributed to
inter-individual differences in basal t-PA release in healthy subjects [Jern et al 1999;
Ladenvall et al 2001]. However, we have found no evidence of a significant effect of
the Alu Ins/Del, -7,351 C/T, 20,099 T/C or 27,445 T/A polymorphisms on either
plasma concentrations, or acute release, of t-PA in a cohort of subjects with stable
CHD. This novel finding is in keeping with a more recent study of 240 Swedish
subjects which found no association between the most common t-PA haplotypes and
plasma levels of fibrinolytic factors [Ladenvall et al 2003], As previous estimates
have suggested heritability for plasma levels of fibrinolytic factors is in the order of
30-60% [Souto et al 2000; de Lange et al 2001], it possible that other genes e.g.
PAI-1 4G/5G polymorphism [Henry et al 1998] may contribute to inter-individual
differences in endogenous fibrinolytic capacity.
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7.3.1 Genotype-Environment Interactions and Cardiovascular Risk
Phenotype
The overall genetic contribution to CHD is presumably due to a combination of
several gene-gene and gene-environment interactions. From this work we cannot
ascertain whether t-PA genotype may contribute to the initiation of endothelial
dysfunction or expression of a pro-atherothrombotic phenotype in healthy subjects,
or in the presence of other vascular risk factors. As in previous studies, cigarette
smoking was associated with significantly impaired acute t-PA release [Newby et al
1999; Newby et al 2001; Pretorius et al 2002] and endothelium-dependent
vasodilatation [Celermajer et al 1993]. This suggests environmental factors such as
smoking, rather than t-PA genotype are the predominant determinant of fibrinolytic
function in patients with established coronary disease. Although we found no
interaction between cigarette smoking and t-PA genotype in a post-hoc analysis, it is
possible that subject numbers may have been insufficient to adequately assess the
relationship between t-PA genotype, cigarette smoking and t-PA release.
7.4 INFLAMMATION DIRECTLY AFFECTS FIBRINOLYTIC
FUNCTION IN PATIENTSWITH CORONARY HEART DISEASE
Acute experimental inflammation, induced by typhoid vaccination in healthy
volunteers, is associated with transient impairments in vascular function [Hingorani
et al 2000b; Chia et al 2003a], This effect is, in part, mediated by the genesis of
cyclooxygeanse activity as it is prevented by systemic, but not local, aspirin therapy
[Kharbanda et al 2002], Systemic inflammation will have biological actions on a
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diverse range of tissues stimulating the release of secondary mediators from organs
such as the liver or activation of neurohormonal reflexes which may alter t-PA
release [Jern et al 1994; Bjorkman et al 2003], Using a model of acute local vascular
inflammation, we have confirmed previous findings in healthy volunteers [Bhagat
and Vallance 1997; Chia et al 2003b], and extended these observations to show that
in subjects with established atherosclerosis, acute local arterial inflammation impairs
NO-dependent vasodilatation whilst increasing t-PA release.
7.4.1 Arterial Inflammation Directly Influences Tissue Plasminogen
Activator Release
These novel results suggest a rationale whereby increased plasma t-PA
concentrations are associated with the risk of future atherothrombotic events
[Hamsten et al 1985; Jansson et al 1993; Meade et al 1993; Ridker et al 1993;
Thompson et al 1995; Thogersen et al 1998], The increase in basal and regulated
t-PA release suggests that inflammation-induced t-PA release is not simply a non¬
specific marker of vascular injury and loss of endothelial integrity. It is possible that
acute arterial inflammation leads to an 'anti-thrombotic' pro-fibrinolytic milieu to
counter a 'pro-thrombotic' reduction in NO-dependent vasodilatation and local blood
flow. As plasminogen activator mRNA expression is greatest in advanced
macrophage and lipid-rich plaques [Lupu et al 1995; Steins et al 1999], increased
levels of pro-inflammatory cytokines might promote rupture of unstable 't-PA rich'
plaques with a risk of platelet-rich thrombus formation and potentially arterial
occlusion. Although unproven, this hypothesis would also be in keeping with the
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observation whereby higher circulating concentrations of inflammatory cytokines
and t-PA predict an increased risk of future cardiovascular events.
7.4.2 Vascular Inflammation andNitric Oxide
We have demonstrated that acute arterial inflammation impairs NO-dependent
vasodilatation in patients with CHD. Previous studies of acute experimental
inflammation in healthy volunteers [Hingorani et al 2000b; Kharbanda et al 2002;
Chia et al 2003a; 2003b] may not be directly comparable to those in patients with
stable CHD who exhibit evidence of impaired endothelium-dependent vasodilation
and increased basal t-PA concentrations reflecting pre-existing vascular injury and
endothelial dysfunction. In patients with rheumatoid arthritis, an inflammatory
condition associated with an increased risk of cardiovascular disease, blunted NO-
dependent vasodilator responses parallel evidence of inflammatory disease activity
[Bergholm et al 2002; Yki-Jarvinen et al 2003]. Furthermore, in patients with auto¬
immune vasculitis, administration of anti-TNF-a therapy is associated with
augmentation of the endothelium-dependent vasomotor responses [Booth et al 2004],
Our current findings in patients with CHD are thus in keeping with those of other
inflammatory conditions and suggest that disruption to the normal physiological NO
signalling pathways and impaired NO bioavailability are a critical factor in
inflammation-induced vascular dysfunction. The relative expression and activity of
inducible and constitutive eNOS, local levels of oxidative stress and free radicals
likely determine the summative effect of an inflammatory stimulus on the
vasculature.
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7.5 PHOSPHODIESTERASE TYPE 5 INHIBITION AND ENDOTHELIAL
FUNCTION
The vascular endothelium appears directly sensitive to each of the known
atherogenic risk factors with loss of endothelially-derived NO appearing to be a
critical factor in the propensity for vasoconstriction, thrombosis, inflammation and
cellular proliferation. We hypothesised that sildenafil, a highly selective PDE 5
inhibitor, might restore normal endothelial function by prolonging the cellular
actions of the downstream signalling molecule of NO. This was, in part, based on
previous work demonstrating that the L-arginine:NO pathway was involved in the
regulation of t-PA release [Newby et al 1998] and that non-selective PDE inhibitors
potentiate the effect of exogenous thrombolytic therapy [Ambrus et al 1994].
Phosphodiesterase isoenzyme type 5 inhibitors have been shown to be highly
efficacious in the treatment of erectile dysfunction [Goldstein et al 1998], eliciting
arterial smooth muscle relaxation in response to increased cGMP concentrations.
Recently, sildenafil was reported to augment forearm vasomotor responses in young
healthy subjects including asymptomatic smokers [Kimura et al 2003] though this is
not a consistent finding [Dishy et al 2004], Despite confirming earlier reports
[Jackson et al 1999; Herrmann et al 2000; Webb et al 2000] of a consistent and
reproducible effect on augmenting basal NO release and reduced vessel tone,
prolonging the biological actions of cGMP did not change acute t-PA release nor
endothelium-dependent vasodilatation in patients with CHD or age-matched healthy
controls.
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Atherogenic risk factors such as free fatty acids and cigarette smoking increase
oxidative stress and the production of free radicals such as superoxide. Superoxide
rapidly deactivates NO [Gryglewski et al 1986] to produce peroxynitrite [Beckman
et al 1990] which is cytotoxic and directly inhibits soluble guanylate cyclase. If
levels of oxidative stress are high, therapeutic intervention with PDE 5 inhibitors
may not be able to circumvent the rapid deactivation of NO before it reaches its
molecular target. Indeed, oral administration of ascorbic acid does not increase t-PA
release in healthy volunteers nor blunt the increased fibrinolytic response to acute
hyperhomocysteinaemia [Labinjoh et al 2001b].
7.5.1 Therapeutic Uses of Phosphodiesterase Type 5 Inhibitors
In the recently published, African-American Heart Failure Trial (A-HeFT), combined
administration of a NO stimulator and an antioxidant (isosorbide dinitrate and
hydralazine) produced significant reductions in cardiac death, MI and risk of
developing symptomatic heart failure [Taylor et al 2004], This dual therapeutic
strategy may better address the altered NO oxidation balance fundamental to the
failing cardiovascular system [Hare 2004], The combination of a PDE 5 inhibitor and
a free radical scavenger might overcome the limitations of our PDE 5 monotherapy
and yield clinically meaningful improvements in vascular function in patients with
CHD. Although we did not observe any change in vasomotor or fibrinolytic function
in CHD patients with sildenafil, PDE 5 inhibitors may have important effects on
platelet function [Halcox et al 2002a] with the combination of sildenafil and aspirin
reducing coronary thrombosis and ex vivo platelet aggregation more than aspirin
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alone in a canine model of coronary obstruction [Lewis et al 2006]. In keeping with
its effects on vascular tone [Webb et al 2000], we have recently demonstrated that
the platelet anti-aggregatory effect of sildenafil appears to be greatest in the presence
ofNO donors [Gudmundsdottir et al 2005],
The high concentration of PDE 5 within the pulmonary circulation suggests that
PDE 5 inhibitors might be a useful adjunctive therapy for the treatment of pulmonary
hypertension (PHT). Early clinical trials of sildenafil have shown encouraging
benefits in patients with primary and secondary PHT [Michelakis et al 2002;
Michelakis et al 2003], conditions usually associated with high morbidity and
mortality. Sildenafil has also been shown to improve brachial reactivity [Katz et al
2000] and exercise capacity in patients with congestive cardiac failure [Bocchi EA
2002], There are large numbers of subjects who might benefit from these areas of
ongoing research on the use of PDE 5 inhibitors in the management of symptomatic
PHT and heart failure.
7.6 FUTURE DIRECTIONS
This body of work has examined factors modifying the acute fibrinolytic capacity
and shown that this is a critical marker of endothelial function which predicts future
vascular risk. Given the central role of inflammation and t-PA release in the
initiation, progression and the final common pathway of atherothrombosis, a series of
further studies are suggested.
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7.6.1 Endogenous Fibrinolytic Function and Future
Atherothrombotic Events
We have shown that, in patients with stable CHD, the acute endogenous fibrinolytic
capacity is a powerful predictor of future atherothrombotic events. This relationship
was demonstrated in subjects receiving secondary preventative medication including
anti-platelet and lipid-lowering therapies. Further work on the relationship between
acute stimulated t-PA release and future cardiovascular events in apparently healthy
subjects, including asymptomatic cigarette smokers, would be of great interest. As
the expected cardiovascular event rate would be lower in such a cohort, increased
subject numbers and duration of follow-up would be necessary. As coronary t-PA
release is inversely related to coronary plaque volume [Newby et al 2001], additional
work examining the association between acute stimulated t-PA release, inflammatory
bio-markers and serial assessment of the progression of coronary atheroma should be
considered. This may yield a better understanding of factors involved in the
progression of atherosclerosis and identify subjects who would benefit from more
intensive risk factor modification or pharmacological intervention before the onset of
symptomatic coronary disease.
7.6.2 Endothelial Nitric Oxide Synthase Polymorphism and Vascular
Function in Patientswith Coronary Heart Disease
Three distinct isoforms of NOS exist. In the vasculature, type III or eNOS is
responsible for the generation ofNO and the regulation of vascular tone [Vallance et
al 1989] and blood pressure [Haynes et al 1993], Several eNOS polymorphisms have
been described but of particular interest is the SNP at position 894 of exon 7
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[Hingorani 2000a]. This coding sequence polymorphism predicts a Glu298Asp amino
acid substitution with a change in codon 298 from glutamic to aspartic acid. This
might alter the mature protein structure and enzyme activity with some [Tesauro et al
2000], but not all [Fairchild et al 2001], authors reporting the eNOS Asp variant is
more susceptible to proteolytic cleavage.
The allelic frequency of this Glu298—>Asp SNP is -30% in control populations but is
significantly higher in patients with coronary artery disease at - 50% [Hingorani et al
1999], The eNOS Asp variant has been associated with functional alterations in
endothelium-dependent regulation of vascular tone which are most marked in
cigarette smokers [Leeson et al 2002], However, no assessment was made of the
acute fibrinolytic function of the endothelium. Given that both NOS inhibition
[Newby et al 1998] and cigarette smoking [Newby et al 1999; Newby et al 2001]
reduce acute t-PA release in vivo in man, there is a potential significant interaction
between the Glu —>Asp polymorphism and cigarette smoking. This hypothesis is
being addressed in a British Heart Foundation Project (FS/2001047) with preliminary
results suggesting that the eNOS Glu298Asp variant does not significantly affect
vasomotor or fibrinolytic function in patients with CHD [Robinson et al 2006d],
7.6.3 Anti-Cytokine Therapy in Patientswith Coronary Heart Disease
The clinical sequelae resulting from arterial inflammation are likely dependent on the
relative balance of its effects on vascular tone, coagulation and fibrinolysis. Clinical
trials of anti-cytokine therapies in patients with advanced heart failure suggest little
prognostic or symptomatic benefit [Mann et al 2004] despite showing improvements
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in endothelium-dependent responses [Fichtlscherer et al 2001]. Although considered
a pro-inflammatory cytokine, the biological effects of TNF-a depend upon the
molecular target, the state of cellular activation, and the local concentrations of the
cytokine [Henriksen and Newby 2003]. Whilst brief local infusion of TNF-a impairs
vasodilator responses [Bhagat and Vallance 1997; Chia et al 2003b, Robinson et al
2006a] more prolonged infusion results in venodilatation [Simper et al 1995], and at
higher doses endotoxin causes hypotension [Suffredini et al 1989]. In keeping with
this, clinical trials suggest greater doses [Chung et al 2003], or more prolonged
duration of anti-cytokine therapy [Mann et al 2004] may be harmful. Non-specific
anti-cytokine therapy may be insufficient to disrupt the network of pro-inflammatory
mediators e.g. interleukin-1 and interleukin-6, and might impair the action of anti¬
inflammatory 'athero-protective' cytokines such as interleukin-10 [Heeschen et al
2003].
Unstable angina is associated with acute inflammation, endothelial dysfunction
[Fichtlscherer et al 2000] and elevated plasma TNF-a concentrations are predictive
of an adverse prognosis and recurrent coronary events [Ridker et al 2000a], These
findings suggest that TNF-a antagonism may provide a novel approach to normalise
the inflammation and endothelial dysfunction associated with acute unstable angina.
We are currently conducting a study to assess the effect of Etanercept (Enbrel), a
recombinant human TNF receptor p75-Fc fusion protein that acts as a competitive
inhibitor of TNF-a, on endothelial and fibrinolytic function in patients with acute
coronary syndromes.
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7.6.4 Particulate Air Pollution and Cardiovascular Disease
Air pollution is now recognised as a significant cause of cardiovascular morbidity
and mortality [Dockery et al 1993; Anderson et al 1996]. Rates of myocardial
ischaemia, heart failure and death are all increased following both short-
[Katsouyanni et al 2001; Pekkanen et al 2002] and long-term [Clancy et al 2002;
Pope et al 2004] exposure to air pollution. The mechanism and components of air
pollution responsible for the adverse cardiovascular effects are unknown but small
combustion-derived particles are suspected to be the major cause.
Within this thesis, and in previous work [Newby et al 1999; Newby et al 2001;
Pretorius et al 2002], reference has been made to the importance of cigarette
smoking in mediating vascular dysfunction and impaired endogenous fibrinolysis.
Combustion products and inhaled particulate matter (PM) are common to
environmental air pollution and cigarette smoking, and both induce an inflammatory
response involving increased oxidative stress [Donaldson et al 2003], Given that
cigarette smoking and air pollution share common toxicological properties, we wish
to investigate the vascular and inflammatory effects of air pollution and its
constituents.
A series of human studies are proposed to determine vascular function, endogenous
fibrinolytic and inflammatory activity following a rigorously controlled PM
exposure. Initially we will study healthy subjects and thereafter patients with stable
CHD. Experimental studies of subjects with established CHD are vital as it has been
suggested that they may be more susceptible to the effects of ambient pollution
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[Brook et al 2004], Two exposure systems will be utilised: (1) Filtered Diesel
Exhaust Exposure in collaboration with Professor Thomas Sandstrom at the
University of Umea, Sweden who has extensive experience of human studies using
this model [Rude11 et 1994; Salvi et al 1999]; (2) Environmental Concentrated
Ambient Air Particles (CAPs) in collaboration with Dr Flemming Cassee from the
National Institute ofPublic Health (RIVM) Netherlands. Using these complementary
systems, the effect of filtered clean air or PM (dilute diesel exhaust or CAPs) on
vascular function will be assessed in a series of double-blind randomised crossover
exposures. We will assess vascular function and inflammatory markers before, and 6
to 8 hours after, the controlled exposure to coincide with the peak response to
airborne pollution [Salvi et al 1999] and s. typhi vaccination [Hingorani et al 2000b;
Kharbanda et al 2002; Chia et al 2003a], The subjects in this study will be exposed to
concentrations of particles that do not exceed what they might encounter in a
polluted urban environment on a smoggy day within an urban environment [UN
Environment Program and WHO Report 1994],
These series of studies should provide important information about the
cardiovascular impact of air pollution relevant to both the general population and
patients with CHD. Moreover, if the detrimental component can be identified, more
effective pollution control strategies could be implemented to reduce the risk for
susceptible individuals. This proposal will also guide future research into the benefits
of anti-inflammatory therapy in susceptible individuals unavoidably exposed to the
currently increasing levels of urban air pollution. The effect of air pollution on
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vasomotor and fibrinolytic function is the subject of an on-going British Heart
Foundation Research Project (03/017/15071; Dr Nicholas Mills).
7.7 CLINICAL PERSPECTIVE
The presence of obstructive coronary atheroma and chronic cigarette smoking are
associated with impaired release of t-PA from the endothelium [Newby et al 2001].
Defective endogenous fibrinolysis may underlie the increased risk of acute coronary
thrombosis and sudden death associated with cigarette smoking [Burke et al 1997;
Doll et al 2004], The invasive nature of measuring coronary t-PA release means it
can only really be undertaken in subjects undergoing coronary angiography limiting
its widespread applicability as a bio-marker of vascular function.
We have shown that a reduction in acute t-PA release from the forearm circulation
predicts the risk of future atherothrombotic events in patients with established CHD.
This was the first longitudinal study to assess the relationship between future
vascular events and endogenous t-PA release. This suggests that the forearm model
may be used to examine the perturbations in vascular function observed in patients
with CHD. A more detailed characterisation of the cellular pathways regulating t-PA
secretion will provide a basis for the investigation of the mechanisms of impaired
secretion. The pleiotropic effects of vascular inflammation on vasomotor and
fibrinolytic function [Hingorani et al 2000b; Kharbanda et al 2002; Chia et al 2003a;
2003b; Robinson et al 2006a] suggests that the term 'endothelial dysfunction' does
not encompass a uniform response to vascular injury.
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Although assessment of t-PA release is unlikely to become part of routine clinical
cardiovascular risk assessment, the findings discussed within this thesis support the
hypothesis that reduced t-PA release is of pathophysiological significance. For
example, angiotensin-converting enzyme inhibitors potently increase stimulated t-PA
release within the forearm [Witherow et al 2002; Cruden et al 2005] and coronary
[Minai et al 2001; Matsumoto et al 2003] circulations. This augmentation of the
endogenous fibrinolytic capacity might underlie the consistent reduction in
thrombotic events including acute MI and CVA observed in several randomised
clinical trials of ACE inhibitors [Rutherford et al 1994; Yusuf S et al 2000; Fox KM
et al 2003],
The future development, and use, of specific therapeutic interventions to increase
endogenous t-PA release in CHD patients might have secondary preventative
benefits such as reducing the risk of future MI and the tragic haemorrhagic
complications which can ensue following the administration of exogenous
fibrinolytic agents. Further work is also needed to establish whether primary
preventative strategies designed to augment endogenous fibrinolytic capacity might
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ORIGINAL ARTICLE H ■III a
Summary. Objectives: To determine if polymorphisms of the
tissue plasminogen activator (t-PA) gene influence acute
endogenous t-PA release in patients with coronary heart disease
(CHD). Methods: Forearm blood flow and plasma t-PA
concentrations were measured in response to intra-brachial
infusion of substance P and sodium nitroprusside in 96 patients
with stable CHD. Genotyping was performed using a Taqman
polymerase chain reaction assay specifically designed to detect
the polymorphisms of interest: (i) ,4/w-repeat insertion/deletion
sequence; (11) C —> T substitution in an upstream enhancer
region (-7351 C/T); (iii) T —> C in exon 6 (20 099 T/C); and (iv)
T -+ A (27 445 T/A) in intron 10. Results: Substance P and
sodium nitroprusside caused dose-dependent increases in
forearm blood flow in all patients (P < 0.001 for all) that were
independent of the four genetic polymorphisms. Similarly, there
were no differences in basal plasma t-PA antigen concentrations
or net t-PA release between genotypes. Compared to non-
smokers, smokers exhibited impaired substance P-induced
vasodilatation (P < 0.001) and t-PA release (P = 0.05).
Conclusions: Despite confirming our previous findings in
cigarette smokers, we have found no effect of polymorphisms
of the t-PA gene on two complementary aspects of endothelial
function. We conclude that genetic variation ofthe t-PA locus is
unlikely to have a major influence on acute t-PA release in
subjects with established CHD.
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olysis, genetic polymorphisms.
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Introduction
Coronary heart disease (CHD) and its risk factors, such as
cigarette smoking, hyperlipidemia and hypertension, are asso
ciated with impaired endothelium dependent vasorelaxation
[1-3] and tissue plasminogen activator (t-PA) release [4-6].
These aspects of endothelial function arc important as plasma
fibrinolytic variables and endothelium dependent vasodilate
tion independently predict future cardiovascular risk [7,8].
Genetic factors influence plasma concentrations of a number
of hemostatic and fibrinolytic factors including t PA, plasmi
nogen activator inhibitor type 1 (PAI-1) and fibrinogen [9]. A
common intronic polymorphism of the t-PA gene is generated
by the insertion of a 311 base pair Alu-repeat sequence [10].
Although not a consistent finding in all populations [11], there
is an independent association between the insertion (II)
genotype and the future risk of myocardial infarction (MI): a
relative risk of 2.24 in comparison with the deletion (DD)
genotype [12]. This Alu intronic sequence is now known to be in
linkage disequilibrium (LD) with three single nucleotide
polymorphisms associated with t-PA release, within the
upstream enhancer region (7351 C —» T), in exon 6 (20 099
T C) and within intron 10 (27 445 T -+ A) [13], The C -> T
substitution within the enhancer region disrupts a binding site
for the Spl transcription factor and appears to be functionally
important [13,14] with TT homozygotes having an increased
risk of both MI [15] and lacunar stroke [16] compared to CC
homozygotes.
Genetic differences in t PA release may alter the fibrinolytic
balance predisposing to local thrombus formation and an
increased likelihood of adverse athero-thrombotic events. Jern
and colleagues previously demonstrated a link between t-PA
release and both the Alu insertion/deletion and -7351 C/T
enhancer polymorphisms in healthy volunteers [13,17], How¬
ever the functional importance of these genetic variants in
patients with established CHD is unknown. We hypothesized
that polymorphisms of the t PA gene may influence endothelial
vasomotor and fibrinolytic function in patients with stable
CHD.
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Methods
Subjects
We recruited patients with CHD confirmed by angiography
(defined as > 70% luminal stenosis of at least one major
epicardial coronary vessel) or a history of Q-wave MI. All
patients had stable anginal symptoms and had not undergone
coronary revascularization within the preceding 3 months.
Exclusion criteria were significant cardiac failure, renal impair¬
ment, systolic blood pressure < 100 or > 190 mmHg,
impaired fasting glucose (> 7 mmol L"1) or prior diagnosis
of diabetes mellitus. Self-reported smoking status was con¬
firmed using plasma cotinine levels [18], All studies were
undertaken with the approval of the local Research Ethics
Committee, the written informed consent of each subject, and
in accordance with the Declaration of Helsinki.
Venous sampling and assays
Venous blood was collected into tubes containing acidified
buffered citrate (for t-PA), trisodium citrate (for PAI 1 and
cotinine), potassium ethylene diamine tctraacctic acid (for DNA
extraction) and serum gel tubes (for C-reactive protein; CRP).
Platelet-free plasma, serum and whole blood (DNA) were
stored at -80 °C before assay. Plasma t PA and PAI 1 antigen
concentrations were determined using enzyme-linked immuno¬
sorbent assays (Coaliza®; Chromogenix, Molnoal, Sweden) [5]
with intra-assay and intcr-assay coefficients ofvariation of7.0%
and 5.5%, and 4.0% and 7.3% for t-PA and PAI-1 antigen,
respectively [19]. All fibrinolytic assays were performed in
duplicate and themean value taken. Serum CRP concentrations
were measured using particle-enhanced immunonephelometry
(Behring BN II nephelometer, Milton Keynes, UK). Plasma
cotinine concentrations were determined using high perform¬
ance liquid chromatography (ABS Laboratories Ltd, London,
UK) [18]. Hematocrit was determined using an automated
Coulter counter (Bcckman-Coulter ACt.8, High Wycombe,
UK). Biochemical assays were undertaken on the fasting venous
serum samples by the hospital clinical laboratory facility.
Genotyping
Genomic DNA was isolated from whole blood. For the -7351
C —» T (upstream enhancer), 20 099 T —> C (exon 6), and
27 445 T —> A (intron 10) polymorphisms genotyping was
performed by allele discrimination analysis using the 5' nuclease
assay. Oligonucleotide primers and fluorescently labeled probes
were obtained from Applied Biosystems (Applied Biosystems,
Foster City, CA, USA) on the basis of previously published
DNA and primer sequences [13,15], In brief, polymorphic
target sequences were amplified by polymerase chain reaction
(PCR) in the presence of two fluorogenic probes specific for
each allele. Probes hybridize to their target during the annealing
step and the reporter dye is cleaved by the 5' nuclease activity of
Taq polymerase. Real time quantitative PCR was performed in
an ABI PRISM® 7900HT Sequence Detector System (Applied
Biosystems). Thermal cycling conditions were two initial holds
(50 °C for 2 min and 95 °C for 10 min) followed by a 40-cycle
two-step program (95 °C for 15 s and 60 °C for 1 min) utilizing
a standardized operating protocol (WTCRF Genetics Core,
Edinburgh UK; http://www.wtcrf.ed.ac.uk; accessed 27 July
2006). The fluorescent contribution ofeach dye was determined
directly after the completion of PCR.
For the Alu-intronic polymorphism, the insertion specific
sequence was submitted to the Applied Biosystems Assay-by-
design service. Gene expression assays consisted of unlabeled
PCR primers and TaqMan® MGB probes (FAM dye labeled).
Forward and reverse primers were 5'-CGTAACAGGACAG-
CTCACAGTT-3 and 5'-CCCTAGGAGAACTTCTCTTTA-
ACTTTGTT-3, respectively. The insertion specific probe was
labeled in its 5' end with FAM and in it 3' end with a NFQ (non
fluorescent quencher): FAM-ACCCTATGAGATTAGAA-
CAC-NFQ. Real time quantitative PCR was performed with
a ABI PRISM® 7900HT Sequence Detector using the stan¬
dardized operating protocol described (WTCRF Genetics
Core; http://www.wtcrf.ed.ac.uk; accessed 27 July 2006). Alu-
inscrtion PCR products were normalized to threshold values
against an endogenous control (single copy RNasc P gene).
Each sample was run in triplicate with both the gene of interest
and the RNase P control. Genotype for the Alu-intronic
polymorphism was calculated from differences in the threshold
cycle between the RNAse P and zl/w-insertion sequence.
A confirmatory assay ofAlu Ins/Del genotypes utilized PCR
amplification ofthe Ins fragment with primers designed to flank
the region of interest (PLAT.l 5' to 3' GTGAAAAGC-
AAGGTCTACCAG and PLAT.2 5' to 3' GACACCGAG-
TTCATCTTGAC). PCR was performed on a DNA engine
tetrad from MJ Research (Bio-Rad Laboratories, Inc, Hercules,
CA, USA). Thermal cycling conditions were 94 °C for 2 min
followed by 35 cycles (30 s at 94 °C for and 30 s at 60 °C and
30 s at 72 °C) with a final extension step of 10 min at 72 °C. A
10-pL sample of this reaction was analyzed on a 2.5% agarose
gel and following electrophoresis DNA was visualized with
ethidium bromide and UV transillumination. Amplification of
the products produces a 570 bp fragment from chromosomes
with the Ins allele and a 260-bp fragment from those without
(Del). All genotyping was performed by an individual without
information on case status or vascular study data.
Drugs
Substance P (2,4 and 8 pmol min-1; Clinalfa AG, Switzerland)
and sodium nitroprusside (2, 4 and 8 pg min-1; David Bull
Laboratories, Warwick, UK) were administered following
dissolution in 0.9% saline. All solutions were freshly prepared
on the day of study.
Forearm study protocol
Subjects were requested to abstain from alcohol for 24 h,
and food, caffeine-containing drinks and tobacco for at least
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4 h before each study. Cardioactive medications were
withheld on the morning of each study visit. All studies
were conducted in a quiet temperature controlled room
maintained at 22-25 °C. Patients rested recumbent, strain
gauges and cuffs were applied. A 17-G venous cannula was
inserted into the antecubital vein of each arm and the
brachial artery of the non-dominant arm was cannulated
with a 27-SWG needle (Cooper's Needle Works Ltd,
Birmingham, UK).
Forearm blood flow was measured in both forearms by
venous occlusion plethysmography as previously described
[5,20]. Following a 30-min saline infusion to allow equilibration
and recording of resting blood flow, intra-arterial substance P
at 2, 4 and 8 pmol min-1 (endothelium-dependent vasodilator
releasing t-PA) and sodium nitroprusside at 2, 4 and
8 |ig min-1 (cndothclium-indcpcndcnt vasodilator which docs
not release t-PA) [20] were each administered for 6 min in a
randomized order with a 15 min saline washout period
between each agent. Forearm blood flow was measured at
baseline and with each dose of vasodilator. Venous blood
sampling for determining plasma t-PA and PAI-1 antigen
concentrations was undertaken at baseline and following the
recording of blood flow response to each dose of substance P.
Blood pressure and heart rate were measured throughout each
study using a semi-automated non-invasive sphygmomanom¬
eter (Omron 705 IT; Omron Healthcare UK, Milton Keynes,
UK).
Statistical analysis
Plethysmographic data were extracted from Chart data files
and forearm blood flow calculated for individual venous-
occlusion cuff inflations by use ofa template spreadsheet (Excel
2002®; Microsoft™, Seattle, WA, USA). The last five flow
recordings in each 3-min measurement period were calculated
and averaged for each arm. Estimated net release of t-PA
antigen was defined [5,20] as the product of the infused forearm
plasma flow (based on the hematocrit and the infused forearm
blood flow), and the concentration difference between the
infused and non-infused forearms. Area under the curves
(AUCs) for the dose-response of t-PA release were calculated
using the trapezoid rule.
Allele frequencies were estimated by gene counting. Chi-
squared test was used to evaluate deviations of genotype
distributions from the Hardy-Weinberg equilibrium. The
LD coefficient D' was calculated as previously described
[21]. Baseline characteristics of the study population are
presented as frequencies or mean values and standard error
of mean. Differences between groups were compared by
Student's /-test, chi-squared test, and, where appropriate, by
analysis of variance (anova) with repeated measures. As
CRP values were not normally distributed they were log
transformed prior to analysis. All statistical calculations were
undertaken using graphpad prism (GraphPad Software,
San Diego, CA, USA). Statistical significance was assigned
at the 5% level.
Table 1 Allele frequencies and pairwise linkage disequilibrium (LD)
coefficient between polymorphisms at the tissue plasminogen activator
(t-PA) locus; (chi-squared, degrees of freedom), P < 0.01 for all
Allelic
frequency Alu -7351 20 099 27 445
Alu Ins -> Del 0.65/0.35 0.63 0.83 0.60
(67.4; 4) (107.8; 4) (76.7; 4)
-7351 C—>T 0.69/0.31 0.85 0.68
(93.7; 4) (82.3; 4)
20 099 T —» C 0.63/0.37 0.66
(98.5; 4)
27 445 T A 0.73/0.27
Results
A total of 96 patients were recruited with a cardiovascular risk
factor profile in keeping with their diagnosis ofCHD and most
were prescribed secondary preventative medications. The
genotype distributions for the Alu insertion/deletion (II 46%,
ID 36% and DD 18%),-7351 C/T enhancer (CC 54%, CT 32%,
and TT 14%), 20 099 T/C exon 6 (TT 42%, CT 43%, and CC
15%) and 27 445 T/A intron 10 (TT 56%, TA 34% and AA
10%) were in keeping with the Hardy-Weinberg equilibrium.
There was significant LD between the four polymorphisms
(Table 1) with allelic frequencies being similar to published
studies of European Caucasian subjects [13,17]. There was
complete agreement between the two PCR methods in the
determinationofAlu insertion/deletion genotype. Three subjects
could be genotyped only for the Alu insertion/deletion variant.
Biometric variables were similar between genotypes
(Tables 2 and 3; data on file, University of Edinburgh,
Edinburgh, UK) although there were significantly fewer smok¬
ers in the -7351 heterozgote group (P = 0.01, chi-squared).
Hemodynamics and forearm blood flow
Resting heart rate, blood pressure and non-infused forearm
blood flow were similar in each group and these did not change
significantly during infusion of either vasodilator (Tables 2-4;
data on file).
Substance P and sodium nitroprusside increased the infused
forearm blood flow in all subjects (P < 0.001, anova). None
of the genetic polymorphisms appeared to influence the
endothelium-dependent or -independent blood flow responses
(Fig. 1; data on file).
Plasma fibrinolytic variables
Baseline plasma t PA and PAI 1 antigen concentrations were
similar for each genotype (Table 4; data on file). Substance P
caused a dose-dependent increase in plasma t-PA antigen
within the infused arm in all three groups (P < 0.01, anova)
whilst plasma PAI-1 antigen concentrations were unchanged
(data on file). There were no differences in substance P-induced
t-PA release between any of the genetic polymorphisms (Fig. 2;
data on file). Similarly, the AUC for net t-PA release over the
© 2006 International Society on Thrombosis and Haemostasis
t-PA polymorphisms and endogenous fibrinolysis 2265
Table 2 Clinical characteristics of subjects according to Alu insertion/
deletion genotype (n = 96)
Genotype
Table 3 Clinical characteristics of subjects according to -7351 C/T geno¬











(n = 30) =3II 13) P%
Age, years 59 ± 1 60 ± 1 59 ± 2 0.88 Age, years 59 ± 1 59 ± 1 61 ± 3 0.82
Gender, male/female 33/11 32/3 14/3 0.16 Gender, male/female 38/12 27/3 11/2 0.28
BMI, kg m"2 29 ± 1 28 ± 1 30 ± 1 0.27 BMI, kg m"2 29 ± 1 28 ± 1 29 ± 1 0.47
Systolic BP, mmHg 136 ± 3 128 ± 4 132 ± 4 0.23 Systolic BP, mmHg 134 ± 3 131 ± 4 123 ± 6 0.27
Diastolic BP, mmHg 79 ± 2 75 ± 2 73 ± 2 0.30 Diastolic BP, mmHg 79 ± 2 75 ± 2 70 ± 3 0.07
Pulse, bpm 57 ± 1 58 ± 2 57 ± 3 0.96 Pulse, bpm 57 ± 1 57 ± 2 54 ± 3 0.57
Current smoker (%) 30 23 47 0.42 Current smoker (%) 46 13 38 0.01
Co-morbidity (%) Co-morbidity (%)
Previous MI 43 46 24 0.28 Previous MI 44 43 38 0.89
Hypertension 50 49 47 0.98 Hypertension 46 40 62 0.43
FHx CHD 52 37 29 0.74 FHx CHD 32 37 31 0.23
Prior hyperlipidemia 93 94 94 1.00 Prior hyperlipidemia 92 93 92 0.98
Extent of coronary disease, (%)* Extent of coronary disease, (%)*
1 vessel 41 51 41 0.33 1 vessel 40 50 38 0.64
2 vessels 27 20 24 0.86 2 vessels 24 23 23 0.99
3 vessels 30 17 35 0.43 3 vessels 30 20 38 0.42
Medical therapy, (%) Medical therapy, (%)
Aspirin 100 100 94 0.10 Aspirin 100 97 100 0.35
Statin therapy 91 97 94 0.52 Statin therapy 88 100 92 0.14
ACE inhibitor, ARB 27 34 29 1.00 ACE inhibitor, ARB 28 23 54 0.98
Urea, mmol L 5.4 ± 0.2 5.6 ± 0.3 5.7 ± 0.4 0.70 Urea, mmol L"1 5.2 ± 0.2 5.7 ± 0.2 6.1 ± 0.5 0.09
Creatinine, pmol L~ 93.1 ± 2.5 94.6 ± 2.1 91.3 ± 2.6 0.72 Creatinine, pmol L_1 93.3 ± 2.2 92.6 ± 2.1 92.3 ± 4.0 0.96
Glucose, mmol L-1 5.6 ± 0.1 5.7 ± 0.2 6.0 ± 0.2 0.24 Glucose, mmol L"1 5.6 ± 0.1 5.6 ± 0.2 6.0 ± 0.3 0.26
Total chol, mmol L_1 4.5 ± 0.2 4.4 ± 0.2 4.4 ± 0.2 0.89 Total chol, mmol L_1 4.6 ± 0.2 4.4 ± 0.2 4.2 ± 0.3 0.37
LDL chol, mmol L~' 2.6 ± 0.1 2.5 ± 0.2 2.2 ± 0.2 0.28 LDL chol, mmol L~ 2.7 ± 0.1 2.6 ± 0.1 2.0 ± 0.3 0.08
Triglycerides, mmol L_l 1.7 ± 0.2 1.7 ± 0.2 2.3 ± 0.3 0.09 Triglycerides, mmol L_1 1.8 ± 0.2 1.6 ± 0.1 2.4 ± 0.3 0.08
CRP, mg L"1 1.87 ± 0.18 1.92 ± 0.35 1.90 ± 0.41 0.97 CRP, mg L"1 2.02 ± 0.29 1.5 ± 0.3 2.3 ± 0.7 0.49
Values are mean ± SEM.
'Angiographic data unavailable on five subjects. — anova or chi-
squared for difference between genotypes. BMI, body mass index;
bpm, beats per minute; CHD, coronary heart disease; MI, myocardial
infarction; FHx, family history; chol, cholesterol; ACE, angiotensin
converting enzyme; ARB, angiotensin receptor blocker; CRP, C-
reactive protein.
Values are mean ± SEM.
'Angiographic data unavailable on five subjects. fP — anova or chi-
squared for difference between genotypes. BMI, body mass index;
bpm, beats per minute: CHD coronary heart disease; MI. myocardial
infarction; FHx, family history; chol, cholesterol; ACE, angiotensin
converting enzyme; ARB, angiotensin receptor blocker; CRP, C-
reactive protein.
30-min period of substance P infusion was similar between
genotypes (data on file).
Smoking status was confirmed by plasma cotinine con¬
centration (median 307.8 vs. 0.6 ng mL_I in smokers and
non-smokers respectively). Subgroup analysis revealed an
interaction between smoking status and vascular function.
Consistent with our previous findings, cigarette smokers had
impaired forearm blood flow (FBF) responses (P < 0.001,
anova) and net t-PA release (P = 0.05, anova; Fig. 3)
compared to non-smokers. In light of the uneven distribution
of smokers across -7351 genotypes and the interaction between
smoking and t-PA release, we performed a post hoc analysis of
t-PA release according to smoking status. However, we found
no difference in the AUC for net t-PA release between CC, CT
and TT -7351 genotypes in either smokers (111 [48-174]; 167
[94—240]; 193 [5-382]; P = 0.41 anova) or non-smokers (187
[114-260]; 160 [100-220]; 188 [50-325]; P = 0.83) respectively
(mean [95% confidence intervals]).
Discussion
This is the first study to assess directly the role of t-PA genetic
polymorphisms in determining acute t-PA release inpatientswith
CHD. Using a validated and reproducible technique [22], we
have found no diffcrcnco in the basal concentration, ornet release
of, plasma t-PA antigen between genotypes. These important
findings suggest that, in patients with established coronary
atherosclerosis, variation at the t-PA gene locus does not
substantially influence acute endogenous fibrinolytic capacity.
Tissue plasminogen activator release from endothelial cells is
the major arbiter of local intravascular fibrinolysis [23] and will
influence vessel patency following acute coronary thrombosis
[24]. Inter-individual differences in t-PA release may contribute
to a pro-thrombotic phenotype and determine the sequelae of
acute MI. Indeed, clustering of individuals with low rates of t-
PA release has been reported in families with a history of
thrombosis [25], Moreover, genetic murine models of t-PA
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Table 4 Effect of Alu insertion/deletion and -7351 C/T genotypes on baseline forearm blood flow, tissue type-plasminogen activator (t-PA) and
plasminogen activator inhibitor type 1 (PAI-1) antigen concentrations; P = ns between genotypes
Alu Insertion/deletion -7351 C/T
ID DD CC CT TT
Forearm blood flow (mL 100 mL tissue 1 min ')
Infused arm 2.7 ± 0.1 2.8 ± 0.2 2.7 ± 0.2 2.6 ± 0.1 2.8 ± 0.2 2.6 ± 0.3
Non-infused arm 2.7 ± 0.2 2.7 ± 0.2 2.5 ± 0.2 2.6 ± 0.1 2.9 ± 0.2 2.4 ± 0.3
t-PA antigen (ng mL""1)
Infused arm 9.1 ± 0.5 10.7 ± 0.8 9.0 ± 0.7 9.4 ± 0.5 9.8 ± 0.8 9.3 ± 1.1
Non-infused arm 9.3 ± 0.5 10.9 ± 0.8 8.8 ± 0.7 9.6 ± 0.5 9.9 ± 0.8 9.3 ± 1.1
PAI-1 antigen (ng mL-1)
Infused arm 43.3 ± 4.2 43.6 ± 3.7 44.1 ± 6.6 44.5 ± 3.5 44.3 ± 4.8 39.8 ± 7.4
Non-infused arm 46.0 ± 4.2 44.0 ± 3.6 43.7 ± 6.5 47.7 ± 3.6 42.4 ± 4.6 40.7 ± 7.2





















Substance P, pmol min"1 Sodium Nitroprusside, pg min"1
Fig. 1. Infused (solid line) and non-infused (dashed line) forearm blood
flow during intra-brachial substance P (left) and sodium nitroprusside
(right) according to (A) Alu insertion/deletion, and (B) -7,351 C/T, geno¬
types. P < 0.001, anova, for infused FBF response to both vasodilators.
deficiency show a reduced thrombolytic potential and an
increased thrombotic tendency [26], We therefore wanted to
explore the potential genetic influences on t-PA release in at
risk patients with CHD.
The t-PA -7351C —» T enhancer site polymorphism has been
associated with an increased risk of first MI [15] and lacunar
stroke [16] although the data on non-lacunar stroke is
conflicting [16,27]. The strong linkage between the -7351 C/T
enhancer and the T//./-repeat polymorphisms may explain the
association between the (non-coding) Alu insertion/deletion
polymorphism and cardiovascular events [12,13]. In healthy
volunteers (n = 51), both the Alu insertion/deletion and -7351
C —» T enhancer polymorphisms were associated with signifi¬
cant differences in basal t-PA release with II and CC homo-
zygotes having around 2-fold greater release rates than the DD
and TT homozygotes respectively [13,17]. Of the genotypes
studied here, the 7351 C -4 T substitution is thought to result in






























Substance P, pmol min 1
Fig. 2. Estimated net release of tissue plasminogen activator (t-PA)
antigen induced by intra-brachial substance P (2, 4 and 8 pmol min"')
according to (A) Alu insertion/deletion, and (B) -7351 C/T, genotypes.
P < 0.001, anova, for dose response.
factor binding site which is negatively regulated by binding of
the thymidine allele [13], However despite this difference in
basal t-PA release rate, acute t-PA release was similar between
all genotypes. Now, in a larger cohort of subjects (n = 96) with
© 2006 International Society on Thrombosis and Haemostasis


























Substance P, pmol min-1
Fig. 3. Infused (solid line) and non-infused (dashed line) forearm blood
flow (A), and net t-PA release (B), in response to intra-brachial substance P
in smokers (filled circle) and non-smokers (hollow circle). *P < 0.001,
2-way anova, infused FBF response in smokers vs. non-smokers; **P =
0.05, 2-way anova, net t-PA release in smokers vs. non-smokers.
established CHD, we have shown that there is no significant
relationship between basal plasma t-PA concentrations or acute
t-PA release, and these genetic polymorphisms. Furthermore,
endothelium-dependent vasodilatation, a complementary
measure of endothelial function, was similarly unaffected by
variation within the t-PA gene locus.
Regulatory control of t-PA release involves distinct path¬
ways from those controlling vessel calibre and indeed t-PA
release can be induced without changes in forearm blood flow
[28], In view of previous work in healthy volunteers [13,17], we
chose to assess whether a number of t-PA genetic polymor¬
phisms were associated with changes in vascular function in
patients with CHD. If t-PA genotype was important in
regulating endogenous t-PA release, certain alleles could favor
the continued presence of thrombus following atheromatous
plaque rupture. Organization of residual thrombus is known to
stimulate further plaque growth and expansion [29], disrupting
endothelial integrity that is critical to the regulation of vascular
tone and coagulation. Impaired endothelium-dependent vaso¬
dilatation is considered a surrogate of endothelial dysfunction
and has been widely studied as a bio-marker of atherosclerosis.
We therefore hypothesized that t-PA genetic polymorphisms
might also be associated with changes in endothelium-depend¬
ent vasodilatation through pathways linking coagulation,
atherogenesis, and endothelial dysfunction. However, we found
no evidence to support the contention that t-PA polymor¬
phisms influence endothelial function in patients with CHD. In
contrast, cigarette smoking and CHD are associated with
endothelial dysfunction as demonstrated by impaired endothe¬
lium-dependent vasodilatation [1] and endogenous t-PA release
[5,30]. Our study confirms these previous findings in cigarette
smokers in a large cohort of patients with established CHD
maintained on secondary preventative medications. These
consistent findings would appear to reaffirm the validity of
our approach and suggest that environmental rather than
genetic factors have a more dominant influence on acute
endogenous t-PA release.
There are a number of differences between the current
study and previous reports demonstrating an interaction
between acute t-PA release and polymorphisms within the t-
PA gene locus. Our population comprised subjects with
established CHD recruited within the UK. In contrast, Jern et
al. [13,17] studied healthy Scandinavian volunteers free of
symptomatic atherosclerosis. A recent meta-analysis of studies
on genetic polymorphisms and CHD risk demonstrated
heterogeneity according to the population studied [31]. The
/(/w-repeat polymorphism was associated with an increased
incidence of acute MI in Dutch subjects [12] but not in studies
from North America [11] or the UK [32]. Our subjects were all
of European Caucasian origin, recruited from within the same
geographical area, and had similar risk factor profiles. It
seems unlikely that biological variability or modulation from
environmental factors obscured true differences in t-PA
release between genotypes. Although our findings may not
be applicable to other racial groups, Rosenbaum and
colleagues [33] failed to demonstrate differences in acute
endogenous t-PA release between healthy black and white
Americans.
Study limitations
Although endothelium-dependent blood flow responses are
similar in the forearm and coronary circulations [34], we
cannot be sure that these polymorphisms of the t-PA gene do
not influence fibrinolytic responses within the coronary
circulation. Indeed, there are limited data to suggest that,
although not apparent in the forearm circulation, angioten-
sin-converting enzyme gene insertion/deletion polymorphism
can influence acute t-PA release in the coronary circulation
[35].
Jern and colleagues previously demonstrated a difference
in basal, though not stimulated, t-PA release according to t-
PA genotype [13,17]. Whilst we cannot determine basal t-PA
release using the venovenous technique described, we have
found no relationship between t-PA genotype and stimulated
t-PA release. Calculation of net t-PA release provides an
accurate assessment of stimulated t-PA release with good
reproducibility [19], and basal release contributes only a
small proportion of the overall venous plasma t-PA
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concentration. In this study we did not find any difference in
acute t-PA release in response to substance P between t-PA
genotypes. However, our study protocol cannot exclude the
possibility that these polymorphisms might alter protein
transcription and endothelial storage, or the very early
(< 6 min) release of, t-PA in response to substance P
infusion [36],
In our cohort, there was an uneven distribution of smokers
between t-PA -7351 CC, CT and TT groups. Although we
found no difference in net t-PA release between thcsp three
groups when analyzed according to smoking status, we accept
that the relationship between cigarette smoking and impaired t-
PA release may have obscured an association between t-PA
genotype and fibrinolytic function with the post hoc analysis
limited by the number of smokers and non-smokers within
each group.
Conclusion
Whilst we have confirmed previous findings showing that
cigarette smokers have impaired endothelial vasomotor and
fibrinolytic function, we have found no major effect of genetic
variation within the t-PA gene locus on either plasma t-PA
concentrations or acute t-PA release in subjects with stable
CHD.
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ABSTRACT
Elevated plasma t-PA (tissue plasminogen activator) and serum CRP (C-reactive protein) concen¬
trations are associated with an adverse cardiovascular risk. In the present study, we investigated
whether acute local inflammation causes vascular dysfunction and influences t-PA release in
patients with stable coronary heart disease. Serum CRP, plasma t-PA and PAI-I (plasminogen
activator inhibitor type I) concentrations were determined in 95 patients with stable coronary
heart disease. A representative subpopulation of 12 male patients received an intra-brachial
infusion of TNF-a (tumour necrosis factor-a) and saline placebo using a randomized double-
blind cross-over study design. Forearm blood flow and plasma fibrinolytic and inflammatory
variables were measured. Serum CRP concentrations correlated with plasma t-PA concentrations
(r=0.37, P<0.00l) and t-PA/PAI-l ratio (r=— 0.21, P<0.05). Intra-arterial TNF-a caused a
rise in t-PA concentrations (P < 0.001) without affecting blood flow or PAI-I concentrations.
TNF-a pretreatment impaired acetylcholine- and sodium nitroprusside-induced vasodilatation
(P < 0.001 for both) whilst doubling bradykinin-induced t-PA release (P = 0.006). In patients with
stable coronary heart disease, plasma fibrinolytic factors correlate with a systemic inflammatory
marker and local vascular inflammation directly impairs vasomotor function whilst enhancing
endothelial t-PA release. We suggest that the adverse prognosis associated with elevated plasma
t-PA concentrations relates to the underlying causative association with vascular inflammation and
injury.
INTRODUCTION
In epidemiologic studies of patientswith CHD (coronary
heart disease) [1] and in prospective studies in healthy
populations [2], higher plasma concentrations of the
pro-fibrinolytic factor t-PA (tissue plasminogen activ¬
ator) positively and independently predict future cardio¬
vascular events. It would be anticipated that high t-PA
concentrations would protect against subsequent cardio¬
vascular events rather than the reverse. This paradoxical
association is, in part, explained by the concomitant
elevation of PAI-1 (plasminogen activator inhibitor
Key words: coronary disease, endothelial function, fibrinolysis, inflammation, tumour necrosis factor-a (TNF-a), vasodilation.
Abbreviations: BP, blood pressure; CHD, coronary heart disease; CRP, C-reactive protein; F1 + 2, fragment 1 and 2; FBF, forearm
blood flow; HR, heart rate; hs-CRP, highly sensitive CRP; IL-6, interleukin-6; IU, international units; NO, nitric oxide; eNOS,
endothelial NO synthase; ns, not significant; PAI-1, plasminogen activator inhibitor type 1; SBP, systolic blood pressure; SNP,
sodium nitroprusside; TNF-a, tumour necrosis factor-a; t-PA, tissue plasminogen activator.
Correspondence: Dr Simon D. Robinson (email simon.robinson@ed.ac.uk).
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type 1) which complexes with, and inactivates, t-PA.
However, the precise stimulus for this increased t-PA re¬
lease remains unclear.
Areas of endothelial denudation and thrombus
deposition are a common finding on the surface of athero¬
matous plaques and are usually subclinical. Through
t-PA release, endogenous fibrinolysis is usually able to pre¬
vent thrombus propagation, although organization of the
residual thrombus may lead to plaque growth and ex¬
pansion [3]. The adverse prognosis conferred by elevated
plasma t-PA antigen concentrations may, therefore,
reflect the extent of occult atheroma and subclinical
plaque rupture stimulating t-PA release.
Markers of systemic inflammation, such as CRP (C-
reactive protein) and TNF-a (tumour necrosis factor¬
ed), are elevated in patients with cardiovascular disease
[4,5]. Indeed, serum CRP concentrations predict the
development of cardiovascular disease independently of
other risk factors. Previous studies have indicated a
direct relationship between serum CRP and plasma t-PA
concentrations [6,7], This raises the question of whether
vascular inflammation is causally related to the elevation
in plasma t-PA concentrations or whether CRP and t-PA
are independently increased by a common factor related
to the atherosclerotic process itself, such as acute plaque
rupture.
Abnormalities of endothelial function have been
demonstrated in patients with atherosclerosis [8] and
vascular inflammation [9,10], In patients with CHD, re¬
storation of endothelium-dependent vasomotor function
occurs when there is normalization of CRP concen¬
trations [11], whereas ongoing chronic inflammation
is associated with an impaired fibrinolytic response
to venous occlusion [12]. As the endothelium is the
major source of plasma t-PA, abnormalities of endo¬
thelial function may therefore mediate the potential
inflammation-induced elevations in plasma t-PA concen¬
trations.
It therefore remains unclear whether elevated t-PA
concentrations are implicated in the mechanisms con¬
tributing to, or arise as a consequence of, atherothrom-
botic events.
The aims of the present study were, in patients with
stable CHD, to confirm the previous association between
plasma CRP and t-PA concentrations and to determine
the effect of acute local vascular inflammation provoked
by direct intra-arterial infusion of TNF-a on vasomotor
function and endothelial t-PA release.
METHODS
Patients
We recruited patients with CHD confirmed by angio¬
graphy (defined as > 70 % luminal stenosis of at least one
major epicardial coronary vessel) or a previous history
of Q-wave myocardial infarction. All patients had stable
anginal symptoms and had not undergone coronary
revascularization within the preceding 3 months. Ex¬
clusion criteria were significant cardiac failure, renal
impairment, SBP [systolic BP (blood pressure)] <100
or >190 mmHg, diabetes mellitus, history or clinical
features of recent infective illness and immuno¬
suppressive or non-steroidal anti-inflammatory medi¬
cation (excluding 75 mg/day aspirin). All studies were
undertakenwith the approval of the local Research Ethics
Committee and in accordance with the Declaration of
Helsinki. Written informed consent was obtained from
each subject.
Venous sampling and assays
Plasma t-PA, PAI-1 (Coaliza®; Chromogenix), pro¬
thrombin Fl+2 (fragment 1 and 2; Enzygnost Fl+2;
Dade Behring), TNF-a (Quantikine; R&D Systems) and
IL-6 (interleukin-6; Dako) concentrations were deter¬
mined using ELISAs, and t-PA activity using a photo¬
metric method (Coatest t-PA; Chomogenix) [13-15],
Assays of hs-CRP (highly sensitive CRP) were under¬
taken using the method of particle-enhanced immuno-
nephelometry (BN II nephelometer; Behring). Venous
blood was collected into tubes containing acidified buf
fered citrate (for t-PA), trisodium citrate (for PAI-1 and
prothrombin F1 +2), potassium EDTA (for cytokines)
and serum gel tubes (for CRP). Platelet-free plasma and
serum were stored at — 80 °C before assay. Haematocrit
and white cell countwere determined using an automated
Coulter counter. Biochemical assays were undertaken
on fasting venous samples by the hospital Clinical
Laboratory facility.
Drugs
TNF-a (Knoll Pharmaceuticals), bradykinin (Clinalfa),
acetylcholine (Novartis) and SNP (sodium nitroprusside;
David Bull Laboratories) were administered following
dissolution in 0.9% saline.
Study design
All subjects abstained from alcohol for 24 h and from
food, tobacco and caffeine-containing drinks for at least
4 h before each study visit. A venous blood sample was
taken from all patients for estimation of serum CRP and
plasma t-PA and PAI-1 antigen concentrations. Twelve
representative male patients were then recruited into a
randomized double-blind placebo-controlled cross-over
study comparing the effect of direct intra-brachial in¬
fusion of TNF-a and saline placebo.
Forearm study protocol
All studies were carried out at 09:00 hours in a quiet
temperature-controlled room maintained at 22-25 °C.
Patients rested recumbent and strain gauges and cuffs
were applied. A 17-gauge venous cannula was inserted
into the antecubital vein of each arm, and the brachial
artery of the non dominant arm was cannulated with a
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27-SWG (standard wire gauge) needle (Cooper's Needle
Works). FBF (forearm blood flow) was measured in both
forearms by venous occlusion plethysmography using
mercury in silastic strain gauges as described previously
[16]. BP and HR (heart rate) were measured using a semi-
automated non-invasive sphygmomanometer (Omron
705 IT).
Subjects (« = 12) attended on two occasions at least
two weeks apart and received an intra-arterial infusion of
either TNF-a (80 ng/min) or saline placebo over 60 min,
followed on each occasion by a further 60 min of saline in¬
fusion. Thereafter intra-arterial bradykinin (100, 300 and
1000 pmol/min), acetylcholine (5, 10 and 20/xg/min)
and SNP (2, 4 and 8 yxg/min) were administered at
1 ml/min with a 15 min saline washout period between
each agent. The dose of TNF-a was chosen to achieve
local cytokine concentrations comparable with healthy
volunteer studies [13] and those seen in cardiovascular
disease [17],
Venous blood samples for t-PA antigen and activity
and PAI-1 antigen were obtained at baseline, after
60 min of TNF-a/placebo infusion, following the 60 min
infusion of saline, before and during each dose of
bradykinin and 15 min after the end of bradykinin
infusion. Plasma cytokines, hs-CRP and prothrombin
F1 +2 were assessed prior to and following the TNF-a/
placebo and saline infusions and at the end of each study.
Statistical analysis
Estimated net release of t-PA was defined previously as
the product of the infused forearm plasma flow and the
concentration difference between the infused and non-
infused forearms [16]. Because basal t-PA concentrations
were altered by pretreatment with TNF-a, net release
of t-PA during bradykinin infusion was calculated by
subtracting the mean t-PA release before and 15 min
after cessation of bradykinin infusion [13]. The area
under the curve was calculated for the estimated net
release of t-PA in response to bradykinin. Data were
examined, where appropriate, by ANOVA with repeated
measures, followed by post-hoc Student's t tests adjusted
with a Bonferroni correction for multiple comparisons.
Spearman's correlation was used to compare CRP and
plasma levels of fibrinolytic factors. As serum CRP
concentrations have a skewed distribution, they were
logarithmically transformed.
All statistical calculations were undertaken using
GraphPad Prism (GraphPad Software). Results are ex¬
pressed as means ± S.E.M., unless otherwise stated, and
statistical significance was assigned at the 5% level.
RESULTS
Patients had a typical cardiovascular risk factor profile
in keeping with their diagnosis of CHD and most were
Table I Baseline characteristics of the 95 subjects with
stable CHD
Values are means+ S.D. or n (%). ACE, angiotensin-converting enzyme; ARB,
angiotensin II receptor blocker; LDL, low-density lipoprotein. "Angiographic data
were unavailable on one subject.
Characteristics
Age (years) 59 + 7
Body mass index (kg/m2) 29 + 5
Male gender (n) 79 (83 %)
Previous myocardial infarction (n) 39 (41%)
Extent of coronary artery disease (n)*
One vessel 42 (44%)
Two vessels 24 (25%)
Three vessels 28 (29%)
Previous coronary revascularization (n) 64 (67%)
Co-morbidity (n)
Hypertension 46 (48%)
Previous hyperlipidaemia 89 (94%)
Family history of premature CHD 32 (34%)




Statin 90 (95 %)
ACE-inhibitor/ARB 30 (32 %)
Serum urea (mmol/l) 5.6+1.3
Serum creatinine (/xmol/l) 93+13
Plasma glucose (mmol/l) 5.7 ± 0.9
Total cholesterol (mmol/l) 4.5 ± 0.9
LDL-cholesterol (mmol/l) 2.5 ± 0.7
Triacylglycerols (mmol/l) 1.8 + 0.9
prescribed secondary preventative medications (Tables 1
and 2). The majority of the subjects were male, two-thirds
had previously undergone coronary revascularization
and approx. one-third were habitual smokers.
Plasma fibrinolytic factors and
correlation with CRP
In the cohort of 95 patients with stable CHD, serum
hs-CRP concentrations correlated with plasma t-PA
antigen concentrations (r= 0.37, P< 0.001) and plasma
PAI-1 antigen concentrations (r=0.28, P= 0.006) and
inversely with the ratio of t-PA/PAI-1 antigen (r =
— 0.21, P< 0.05). As anticipated, plasma t-PA antigen
concentrations correlated with plasma PAI-1 anti¬
gen concentrations (r = 0.49, P < 0.001).
Effect of acute inflammation on vascular
and fibrinolytic function
Those subjects who received TNF-a and saline placebo
had similar baseline characteristics to the main cohort and
all were receiving statin and aspirin therapy. There were
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Table 2 Baseline characteristics of 12 patients receiving
TNF-or and saline placebo in a randomized double-blind
cross-over study design
Values are means+ S.E.M or n (%). ACE, angiotensin-converting enzyme; LDL,
low-density lipoprotein. 'Angiographic data were unavailable on one subject.
Characteristics
Age (years) 60 + 2
Body mass index (kg/m2) 24+1
Male gender (n) 12 (100%)
Previous myocardial infarction (n) 5 (42%)
Extent of coronary disease (n)*
One vessel 5 (42%)
Two vessels 4 (33%)
Three vessels 2 (17%)
Previous coronary revascularization (n) 9 (75%)
Co-morbidity (n)
Hypertension 3 (25%)
Family history of premature CHD 1 (8%)







Serum urea (mmol/l) 5.9 + 0.3
Serum creatinine (/xmol/l) 93 + 2
Plasma glucose (mmol/l) 5.2 + 0.1
Total cholesterol (mmol/l) 3.9 + 0.2
LDL-cholesterol (mmol/l) 2.1+0.2
Triacylglycerols (mmol/l) 1.3 + 0.2
Placebo visit
HR (beats/min) 56 + 2
SBP (mmHg) 145 + 6
Diastolic BP (mmHg) 83 + 4
FBF (ml - 100 ml-1 of tissue - min ')
Infused arm 2.1+0.2
Non-infused arm 2.0 ± 0.2
TNF-a visit
HR (beats/min) 56 + 3
SBP (mmHg) 142 + 4
Diastolic BP (mmHg) 81+2
FBF (ml - 100 ml-1 of tissue - min~')
Infused arm 2.0 ± 0.2
Non-infused arm 2.1+0.2
no differences in resting arterial pressure, HR or FBF
between the two study visits (Table 2).
There was no change in HR or BP during infusion
of either TNF-a or placebo. Haematocrit, temperature,
white cell count and hs-CRP were similar on both study
visits [P = ns (not significant); results not shown]. The











Figure I Plasma TNF-o; concentrations in the infused (solid
line) and non-infused arm (dashed/dotted line) after 60 min
of intra-arterial TNF-o! (•) and saline placebo (O)
P < 0.001 for the TNF-a dose-response in the infused arm, as determined by
ANOVA; P <0.001 when TNF-a compared with saline placebo in the infused
arm, as determined by ANOVA.
Plasma cytokine concentrations
Intra-arterial infusion of TNF-a increased plasma TNF-
a concentrations from 1.4 + 0.2 to 164.5 + 26.8 pg/ml in
the infused arm and from 1.3 + 0.1 to 33.3 ± 5.6 pg/ml
in the non-infused arm (P < 0.001; Figure 1). At 1 h after
TNF-a infusion, plasma IL-6 concentrations increased
from 4.1 + 1.9 to 6.4 + 2.3 pg/ml in the infused arm
(P< 0.001, as determined by ANOVA), but were un¬
changed in the non-infused arm (4.0 + 1.9 to 3.7 +1.3 pg/
ml). Placebo infusion had no effect on plasma IL-6
concentrations in the infused arm (3.9 + 1.7 to 4.3 +
1.3 pg/ml; P— ns). Serum CRP concentrations were
unchanged following the 60 min infusion of TNF-a and
saline placebo.
Vasomotor and fibrinolytic responses
There was no significant change in resting FBF in the 2 h
after the start of either TNF-a or placebo infusion. After
60 min of TNF-a, plasma t-PA antigen and activity con¬
centrations in the infused arm had increased from 9.4 +
1.1 to 11.3 + 1.2 ng/ml and 0.3 + 0.1 to 2.1 + 0.6 IU (in¬
ternational units)/ml respectively (P< 0.001), and these
remained elevated in the 2 h following discontinuation
of the TNF-a infusion (Figure 2). There was no change
in plasma PAI-1 antigen concentrations in the infused
arm and no change in either plasma t-PA or PAI-1
concentrations in the non-infused arm during the study
(results not shown). Prothrombin F1 +2 concentrations
in the infused arm were unaltered following either saline
placebo (0.9 + 0.1 to 0.9 + 0.1 ng/ml; P = ns) or TNF-a
infusion (0.9 + 0.1 to 1.0 + 0.1 ng/ml; P= ns).
There was a dose-dependent increase in FBF during
bradykinin, acetylcholine and SNP infusion (P^O.01,
© 2006 The Biochemical Society




Figure 2 Plasma t-PA activity (upper panel) and antigen
(lower panel) concentrations in the infused (•) and
non-infused (O) arms after 60 min infusion of intra-arterial
TNF-a
fP<0.00l when infused compared with non-infused arms, as determined by
ANOVA. *P<0.05 and ***P < 0.001, as determined by post-hoc Student's t
test for treatment effect.
as determined by ANOVA). Compared with the saline
placebo, TNF-a pretreatment impaired acetylcholine-
and SNP-induced vasodilatation (P < 0.001 for both), but
did not alter the response to bradykinin (Figure 3).
Plasma t-PA concentrations increased in a dose-depen¬
dent manner during bradykinin infusion on both study
visits (P < 0.001). Pretreatment with TNF-a augmented
the bradykinin-induced rise in plasma t-PA antigen and
activity concentrations (P < 0.001 for both; Figure 4)
and significantly increased estimated net release of t-PA
antigen (63.7+14.8 compared with 120.6 + 26.1 ng •
100 ml"1 of tissue-min-1 at peak dose; P< 0.05) and
activity (54.8+14.8 compared with 98.8 + 21.0 IU-
100 ml"1 of tissue • min"1 at peak dose; P < 0.05). Over the
30 min period of bradykinin infusion, TNF-a increased
the area under the curve for net t-PA antigen and activity
release by 120% and 188% respectively (P= 0.006).
Subgroup analysis showed a significant impairment
of endothelium-dependent vasodilatation as well as
bradykinin-induced t-PA response in cigarette smokers.
Qualitatively the effect of intra-arterial TNF-a on the
blood flow and fibrinolytic responses was similar in both
smokers and non-smokers.
DISCUSSION
In the present study, we have confirmed the direct asso¬
ciation between plasma t-PA and serum CRP concen¬
trations in patients with stable CHD. For the first time,
we have extended this observation using an acute local
vascular inflammatory model and demonstrated that
direct intra-arterial infusion of TNF-a causes a slow
onset and sustained increase in basal t-PA release. This
arterial inflammation was also associated with increased
stimulated t-PA release in the presence of impaired
vasomotor function. Our findings are consistent with
the suggestion that t-PA is released during vascular
inflammation and endothelial injury and this may, in part,
explain the adverse prognosis associated with increased
plasma t-PA concentrations.
The link between markers of inflammation and plasma
t-PA concentrations suggests that vascular inflammation
and injury may be responsible for endothelial t-PA
Figure 3 Infused (solid line) and non-infused (dashed/dotted line) FBF during incremental doses of acetylcholine (left-hand
panel), SNP (middle panel) and bradykinin (right-hand panel) following pretreatment with TNF-a (•) or saline placebo (O)
P 5(0.01 for all infused arm responses, as determined by ANOVA. |P < 0.001 when TNF-a compared with saline placebo treatments, as determined by ANOVA.
*P < 0.05, as determined by post-hoc Student's t test for treatment effect.
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Figure 4 Plasma concentrations of t-PA antigen (left-hand panel) and t-PA activity (right-hand panel) during bradykinin
infusion following pretreatment with TNF-ar (•) or saline placebo (O)
fP < 0.001 when TNF-a compared with saline placebo treatments, as determined by ANOVA. *P<0.05 and **P<O.OI, as determined by post-hoc Student's t
test for treatment effect.
release. However, this association may arise from com¬
mon aetiological factors and does not establish a causal
relationship. A recent meta-analysis has suggested that
increases in piasma t-PA concentrations largely reflect the
presence of concomitant cardiovascular risk factors [7],
We therefore sought to induce vascular inflammation in a
representative sample of our study population. Inducing
systemic inflammation will have many biological actions
and could be confounded by indirect or extra-vascular
effects. This may explain some of the differences between
our present results and those of previous work in healthy
volunteers using Salmonella typhi vaccination [9,10]. We
chose to employ an acute local inflammatory model
[13] to assess the direct effects of intra-arterial TNF-a
administration on t-PA release. We were able to induce
local vascular inflammation with a rise in local plasma
IL-6 concentrations to levels comparable with those seen
in patients with unstable angina [17], without evidence
of a systemic inflammatory response or change in plasma
t-PA or PAI-1 concentrations in the non-infused arm.
This local vascular inflammation caused a slow onset and
sustained increase in plasma t-PA concentrations that
continued for at least 2 h after cessation of the TNF-a
infusion. This establishes that vascular inflammation
directly causes endothelial t-PA release in humans.
The mechanism of TNF-a-induced t-PA release has
not been established. Inflammatory cytokines, such as
TNF-a, may cause t-PA release via induction of local
thrombus formation, activation of specific cellular recept¬
ors or through generation of secondary mediators within
the local vasculature. The former seems unlikely given
that we observed no increase in prothrombin F1 + 2,
a sensitive marker of in vivo thrombin generation [15].
Although it is likely that plasma t-PA concentrations
are increased by inducing endothelial injury, smooth
muscle cells, macrophages and monocytes also express
t-PA mRNA following stimulation by inflammatory
cytokines within atherosclerotic plaques [18] and could
theoretically contribute to this fibrinolytic response.
Effects of TNF-a on vasomotor function
Impaired vasodilator responses to acetylcholine [19,20]
and SNP [20] in patients with cardiovascular risk fac¬
tors predict an increased risk of adverse cardiovascular
events. Previous studies in healthy volunteers have
shown acute systemic inflammation is associated with
a transient impairment in vasomotor function [9]. In the
present study, we have now shown that, in patients with
CHD, acute local vascular inflammation decreases the
vasomotor response to both acetylcholine and SNP.
Acetylcholine is known to stimulate NO (nitric oxide)
production via activation of eNOS (endothelial NO
synthase) and, together with the impaired SNP response,
these findings suggest that local arterial inflammation
can decrease NO bioavailability. Interestingly, impaired
vasodilator responses to both acetylcholine and SNP
have been correlated with plasma TNF-a concentrations
in patients with rheumatoid arthritis, a chronic inflam
matory condition which is itself associated with an excess
cardiovascular risk [21]. Furthermore, intra-arterial in¬
fusion of the free radical scavenger vitamin C restores
forearm blood flow responses in patients with CHD and
elevated serum levels of CRP [22].
Our results suggest that acute inflammation is
associated with impaired NO dependent smooth muscle
relaxation in response to direct NO donors such as SNP
or endogenously derived NO following stimulation of
eNOS. Several lines of evidence support the contention
that cytokines, such as TNF-a, may impair NO-
dependent signalling. TNF-a decreases eNOS expression
[23] as well as increasing reactive oxygen species, such as
superoxide anion, that rapidly inactivate NO and are dir¬
ectly cytotoxic to vascular tissues. TNF-a also increases
plasma ADMA (asymmetric dimethylarginine), an endo¬
genous inhibitor of eNOS that inhibits endothelium-
dependent vasodilatation [24]. Finally, inflammatory
states may increase iNOS (inducible NO synthase) ex¬
pression which is associated with receptor uncoupling
and endothelial dysfunction [25].
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Bradykinin-induced vasodilatation was unaltered by
pretreatment with TNF-a. Previous work has suggested
that NO contributes only a small proportion (approx.
15%) to bradykinin-induced vasodilatation [26,27] and
does not contribute to the mechanism of bradykinin-
induced t-PA release [28]. Moreover, in patients with vas¬
cular dysfunction, there may be an increased contribution
of EDHF (endothelium-derived hyperpolarizing factor)
to smooth muscle vasorelaxation [29], particularly ifNO
is consumed by free radicals generated by locally active
inflammatory cells. These observations are consistent
with our present findings of impaired acetylcholine- and
SNP-induced vasodilatation, but preserved bradykinin
responses.
Effects of TNF-a on acute endogenous
fibrinolysis
Despite the presence of higher baseline plasma t-PA
concentrations in patients with atherosclerosis [7], we
have shown in the present study that direct intra¬
arterial TNF-a: infusion increases bradykinin-induced
t-PA release in patients with stable CF1D. Thus, although
vasorelaxation was impaired, acute inflammation initiates
a sustained increase in both basal and stimulated t-PA
release. The mechanism of this effect is unknown, but
may involve direct endothelial injury, up-regulation of
t-PA synthesis or alterations in bradykinin receptor
expression.
Under some circumstances, increases in t-PA may
protect against the propagation of intravascular throm¬
bosis and thereby avoid the development of an acute
coronary syndrome. However, elevations in plasma t-PA
concentrations may reflect more widespread endothelial
dysfunction and a dominant pro-inflammatory vascular
response that may overwhelm any locally protective pro-
fibrinolytic effect. Indeed, the pro-fibrinolytic actions
of vascular inflammation may potentiate degradation of
extracellular matrix and aggravate plaque instability [30].
The clinical outcome of acute vascular inflammation may,
therefore, depend upon the relative balance between the
protective antithrombotic actions and potential plaque
destabilization associated with increased vascular t-PA
release.
In the present study, all patients who received TNF-
a and placebo infusion were already receiving secondary
preventative therapy, including aspirin and lipid-lowering
medications. Although these may have influenced the
vascular response to TNF-a, it was considered unethical
to withhold these and, in clinical practice, a large
proportion of patients presenting with acute coronary
syndromes and raised inflammatory markers are already
established on such therapies. As our study design was
focused on the question of the link between vascular
inflammation and t-PA release in patients with CHD, we
did not include a control population of healthy subjects.
However, we have shown previously [13] that intra¬
arterial TNF-a enhances endothelium-dependent t-PA
release by a similar degree in younger healthy volunteers.
Although we have again demonstrated that smokers
have impaired endothelial responses, including t-PA re¬
lease [14], intra-arterial TNF-a increased plasma t-PA
concentrations to a similar degree in both smokers and
non-smokers with established CHD.
We have found that, although TNF-a adversely affects
NO-dependent vasodilatation, it enhances other pro¬
tective mechanisms, such as the endogenous fibrinolytic
capacity. This reflects the complex and pleiotropic nature
of TNF-a which functions as part of the normal host sur¬
veillance mechanisms and response to tissue injury.
Although we only determined the effect of acute vas¬
cular inflammation in 12 patients, our results may explain
some of the contradictory findings of previous clinical
studies. For example, in patients with heart failure,
TNF-a antagonism causes marked improvements in
endothelium-dependent vasodilatation [31], but has
failed to demonstrate clinical benefit in randomized con¬
trolled trials [32]. Thus the benefits of restoring endo¬
thelium-dependent vasomotor function by TNF-a ant¬
agonism may be counterbalanced by inhibiting other
potentially beneficial acute effects, such as enhancing
endogenous t-PA release.
Conclusions
In the present study, we have shown that, in patients with
stable CHD, plasma fibrinolytic factors are correlated
with CRP, a sensitive and prognostically relevant marker
of vascular inflammation. We have also demonstrated that
acute vascular inflammation directly impairs vasomotor
function whilst enhancing endothelial t-PA release.
We suggest that the adverse prognosis associated with
elevated plasma t-PA concentrations reflects a causative
association with vascular inflammation and injury, rather
than representing a marker of occult plaque rupture.
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Phosphodiesterase type 5 inhibition does not reverse
endothelial dysfunction in patients with coronary
heart disease
S D Robinson, C A Ludlam, N A Boon, D E Newby
Heart 2006;92:170-176. doi: 10.1136/hrt.2004.059683
Objectives: To investigate whether sildenafil citrate, a selective phosphodiesterase type 5 inhibitor, may
improve endothelial vasomotor and fibrinolytic function in patients with coronary heart disease.
Design: Randomised double blind placebo controlled crossover study.
Patients and methods: 16 male patients with coronary heart disease and eight matched healthy men
received intravenous sildenafil or placebo. Bilateral forearm blood flow and fibrinolytic parameters were
measured by venous occlusion plethysmography and blood sampling in response to intrabrachial infusions
of acetylcholine, substance P, sodium nitroprusside, and verapamil.
Main outcome measures: Forearm blood flow and acute release of tissue plasminogen activator.
Results: Mean arterial blood pressure fell during sildenafil infusion from a mean (SEM) of 92 (1) to 82
(1) mm Hg in patients and from 94 (1) to 82 (1) mm Hg in controls (p < 0.001 for both). Sildenafil
increased endothelium independent vasodilatation with sodium nitroprusside (p < 0.05) but did not alter
the blood flow response to acetylcholine or verapamil in patients or controls. Substance P caused a dose
dependent increase in plasma tissue plasminogen activator antigen concentrations (p < 0.01) that was
unaffected by sildenafil in either group.
Conclusions: Sildenafil does not improve peripheral endothelium dependent vasomotor or fibrinolytic
function in patients with coronary heart disease. Phosphodiesterase type 5 inhibitors are unlikely to reverse
the generalised vascular dysfunction seen in patients with coronary heart disease.
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The endothelium is important in the regulation of vascularfunction including local blood flow and endogenousfibrinolysis. Coronary heart disease (CHD) and its risk
factors, such as cigarette smoking, hyperlipidaemia, and
hypertension,1-3 are associated with impaired endothelium
dependent vasorelaxation and reduced endothelial release of
the endogenous fibrinolytic factor tissue plasminogen acti¬
vator (t-PA).45 These aspects of endothelial function are
important, since plasma fibrinolytic variables and endothe¬
lium dependent vasodilatation independently predict future
cardiovascular risk.6 7
Nitric oxide is a key factor linked to the beneficial
protective effects of the endothelium and a decrease in nitric
oxide bioavailability favours atherogenesis.8 Nitric oxide
exerts many of its biological effects through generation of
cyclic guanosine monophosphate (cGMP) after activation of
soluble guanylate cyclase. Phosphodiesterase type 5 (PDE5)
inactivates cGMP within vascular smooth muscle and thus
negatively regulates nitric oxide mediated cellular actions.9
Recently, highly selective PDE5 inhibitors that prolong the
action of cGMP and thereby enhance nitric oxide mediated
effects have become available for clinical use.
It has been suggested that the PDE5 inhibitor sildenafil
citrate (Viagra; Pfizer) can improve endothelial vasomotor
function in the peripheral circulation of healthy cigarette
smokers10 and the coronary circulation of patients with
CHD.11 Although we have previously reported a link between
nitric oxide and acute t-PA release,12 the potential beneficial
effects of sildenafil on t-PA and its inhibitor, plasminogen
activator inhibitor type 1 (PAI-1), are unknown.
We therefore hypothesised that sildenafil would favour¬
ably alter endothelium dependent vasomotor function
and acute t-PA release in patients with stable CHD. If so,
PDE5 inhibitors may become a useful adjunctive treatment




Sixteen male patients with stable CHD and eight age
matched healthy control men participated in the study. The
investigation was undertaken with the approval of the local
research ethics committee, with the written informed
consent of each patient, and in accordance with the principles
outlined in the Declaration of Helsinki.
A history of CHD was confirmed by angiographic evidence
of > 50% luminal stenosis of at least one major epicardial
coronary vessel or a history of myocardial infarction (con¬
firmed by a serial rise in creatine kinase of twice the upper
limit of the normal reference range and the development of
pathological Q waves in at least two contiguous leads of the
ECG). Nitrate medications were withdrawn for 48 hours
before each visit and other medications were withheld on the
morning of study. Patient exclusion criteria were significant
cardiac failure, renal impairment, systolic blood pressure
< 100 or > 190 mm Hg, and diabetes mellitus. Control
subjects were healthy normotensive euglycaemic non-smo¬
kers without any history of cardiorespiratory or vascular
disease and were not taking any regular medications. No
participant had received sildenafil or other phosphodiesterase
inhibitors before or during participation in this study.
Abbreviations: cGMP, cyclic guanosine monophosphate; CHD,
coronary heart disease; FBF, forearm blood flow; PAI-1, plasminogen
activator inhibitor type 1; PDE5, phosphodiesterase type 5; t-PA, tissue
plasminogen activator
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Measurements
Forearm blood flow (FBF) was measured in both forearms by
venous occlusion plethysmography with mercury in silastic
strain gauges applied to the widest part of the forearm as
previously described.12"14 During measurement periods the
hands were excluded from the circulation by rapid inflation
of the wrist cuffs to a pressure of 220 mm Hg with E20 rapid
cuff inflators (DE Hokanson Inc, Bellevue, Washington,
USA). Upper arm cuffs were inflated intermittently to
40 mm Hg for 10 seconds in every IS seconds to achievp
venous occlusion and obtain plethysmographic recordings.
Analogue voltage output from an EC-4 strain gauge
plethysmograph (DE Hokanson) was processed by an
analogue to digital converter and Chart version 5 software
(AD Instruments Ltd, Chalgrove, UK). Instruments were
calibrated with the internal standard of the plethysmograph.
Blood pressure and heart rate were monitored in the non-
infused arm by a semiautomated non-invasive sphygmo¬
manometer (Agilent V24; Phillips Medical Systems). Mean
arterial pressure was defined as the diastolic pressure plus a
third of the pulse pressure.
Plasma t-PA and PAI-1 antigen concentrations were
measured as previously described with enzyme linked
immunosorbent assays (Coaliza t-PA and PAI-1;
Chromogenix AB, Molndal, Sweden) at baseline, after
sildenafil or placebo, and during intra-arterial substance
P.41214 Haematocrit was determined by an automated Coulter
counter (ACt.8; Beckman-Coulter, High Wycombe, UK).
Biochemical assays were undertaken on the fasting venous
samples by the hospital clinical laboratory facility.
Study design
Participants were requested to abstain from alcohol for 24
hours and from food, caffeine-containing drinks, and tobacco
for at least four hours before each study. Ail studies were
carried out in a quiet temperature controlled room main¬
tained at 22-25°C. Each participant attended at 9 am on two
separate occasions at least two weeks apart and received
matched placebo and sildenafil in a randomised double blind
crossover design.
While participants rested recumbent, strain gauges and
cuffs were applied. A 17 gauge venous cannula was inserted
into the antecubital vein of each arm and a 23 gauge cannula
into the dorsal foot vein for the administration of either
intravenous sildenafil or matched placebo. The brachial
artery of the non-dominant arm was cannulated with a 27-
SWG needle (Cooper's Needle Works Ltd, Birmingham, UK)
under local anaesthesia. The intra-arterial infusion rate was
maintained constant at 1 ml/min throughout the study with
an IVAC syringe pump (Alaris Medical Ltd, Basingstoke, UK).
Saline was infused inlra-arterially for the first 20 minutes
to allow recording of resting FBF, blood pressure, and heart
rate. After this period, sildenafil or matched placebo (Pfizer
UK Ltd, Sandwich, Kent, UK) was administered intrave¬
nously as a single 26.25 mg bolus over five minutes, then as a
continuous infusion of 10 mg/hour to achieve stable plasma
concentrations equivalent to the peak concentration of a
single 100 mg oral dose (pharmacokinetic data, Pfizer UK
Ltd). Twenty minutes after the sildenafil or placebo infusion
was started, basal FBF was determined and thereafter
acetylcholine (5, 10, and 20 pg/min; Novartis UK Ltd,
Farnborough, UK), substance P (2, 4, and 8 pmol/min;
Clinalfa AG, Laufelfingen, Switzerland), sodium nitroprus-
side (2, 4, and 8 pg/min; David Bull Laboratories, Warwick,
UK), and verapamil (10, 30, and 100 pg/min; Abbott UK Ltd)
were infused intra-arterially for six minutes at each dose.
Acetylcholine, substance P, and sodium nitroprusside were
given in a random order and separated by 20 minute saline
washout periods but, because of its prolonged vasodilator
Table 1 Baseline characteristics
Patients Controls
Age (years) 57 (2) 54 (2)
Body mass index (kg/m2) 27 {1) 27 (1)
Co-morbidity
Myocardial infarction 10 0
Hypertension 12 0
Diabetes mcllitus 0




ft Adrenergic blocker 13 0
Calcium antagonist 3 0
Long acting nitrate/nicorandil 2 0
ACE inhibitor, AT II antagonist 5 0
16 0
5.5(0.3) 5.1(0.4)
92 (3) 95 (4)
5.6 (0.2) 5.5 (0.3)




95 (2) 95 (4)
2.5 (0.2) 2.2 (0.2)
2.3 (0.2) 2.1 (0.4)
55(1) 65(3)-
95 (2) 91 (3)
2.5 (0.2) 2.6 (0.3)
2.5 (0.2) 2.4 (0.3)
Data are mean (5EM) or number.
*p<0.001 unpaired / test, patients v controls.
ACE, angiotensin converting enzyme; AT li, angiotensin II type I receptor;
FBF, forearm blood flow; HDL, high density lipoprotein; MAP, moan
arterial pressure.
action, verapamil was infused last. The order of the infusions
was maintained constant for each participant across both
visits.
Statistical analysis
Plethysmographic data were extracted from Chart data files
from which the last five linear recording in each measure¬
ment period were averaged and FBF was calculated.
Estimated net t-PA antigen was defined as the product of
the infused forearm plasma flow (based on the haematocrit
and the infused FBF) and the concentration dif¬
ference between the infused ([t-PA]inf) and non-infused
([t-PA]Non.inf) forearms,12 14 where estimated net t-PA release
= FBF x (1 —haematocrit) x ([ t-PA] inf) — ([ t-PA] Non-inf) -
Data were examined, where appropriate, by analysis of
variance with repeated measures and two tailed Student's t
test by GraphPad Prism (GraphPad Software, San Diego,
California, USA). All results are expressed as mean (SEM).
Significance was assigned at the 5% level. On the basis of a
previous study,15 this study had an 80% power to detect a 23%
change in plasma t-PA concentrations and a 22% difference
in FBF in patients with CHD between sildenafil and placebo
at the 5% level.
RESULTS
Most patients with CHD had a history of myocardial
infarction, hypertension, and hyperlipidaemia (table 1).
Reflecting concomitant treatment, mean resting heart rate
(55 (1) v 63 (2) beats/min, respectively, p < 0.001, unpaired t
test) and serum total cholesterol concentration (4.2 (0.2) v
5.5 (0.2) mmol/1, p < 0.001) were lower in patients with






















Downloaded from heart.bmjjournals.com on 28 August 2006























Figure 1 (A) Heart rate and (B) mean arterial pressure (MAP) during
sildenafil (closed circles, solid line) or placebo (open circles, dashed line)
infusion (shaded box) in patients with coronary heart disease (CHD).
*p < 0.001 analysis of variance, sildenafil versus matched placebo.
Control subject data on file (p < 0.001, analysis of variance, MAP
sildenafil versus matched placebo).
resting heart rate, baseline FBF, or haematocrit did not differ
between the two study visits. Infusions were well tolerated
and there were no serious adverse events. For technical
reasons, one control subject was unable to complete both
visits.
Haemodynamic effects
Over the course of the study, the average mean arterial
pressure was lower during sildenafil than placebo infusion in
patients with CHD (82 (1) v 92 (1) mm Hg, p < 0.001 paired
t test sildenafil versus placebo) (fig 1) and control subjects
(82 (1) v 94 (1) mm Hg, p < 0.001 paired t test). It returned
to baseline after discontinuation of infusion (data not
shown). Heart rate rose transiently after the sildenafil bolus








































Figure 2 Infused (solid line) and non-infused (dashed line) forearm
blood flow in patients with CHD (•) and controls (O) during
intrabrachial acetylcholine (panel A), sodium nitroprusside (panel B),
and verapamil (panel C) with placebo infusion, p < 0.001 analysis of
variance, dose response in infused arm; *p = 0.005 analysis of
variance patients with CHD versus controls.
Placebo visit
Acetylcholine caused a dose dependent increase in FBF in
both groups, although this rise was significantly less in
patients with CHD than in controls (p = 0.005, analysis of
variance) (fig 2). FBF responses did not differ between the
two groups during sodium nitroprusside and verapamil
infusions (fig 2). There were no significant changes in the
non-infused FBF.
Sildenafil and vascular function
Compared with placebo, administration of sildenafil caused
no significant difference in the infused FBF during intra¬
arterial infusion of acetylcholine (at 20 pg/min, mean
difference 0.1 ml/100 ml/min, 95% confidence interval (CI)
—0.2 to 0.4), substance P (at 8 pmol/min, mean difference
0.5 ml/100 ml/min, 95% CI 0.00 to 0.9), or verapamil (at
8 pmol/min, mean difference 0.3 ml/100 ml/min, 95% CI
-0.1 to 0.7). However, sildenafil augmented the vasodilata¬
tion to sodium nitroprusside in both patients with CHD
(p < 0.05, analysis of variance) (fig 3) and control subjects
(p < 0.001, analysis of variance) (fig 4).
Plasma fibrinolytic variables
Baseline plasma t-PA antigen concentrations were
unchanged by sildenafil in either group (table 2, fig 5).
Substance P caused a dose dependent increase in plasma t-PA
concentrations in both patients and controls (p < 0.01 for
both, analysis of variance) (table 2). The substance P induced
increase in plasma t-PA concentrations did not differ during
the sildenafil or placebo infusion (at 8 pmol/min, mean
difference 0.02 ng/ml, 95% CI —1.15 to 1.18) (table 2) and
www.heartjnl.com
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Figure 3 Infused (solid line) and non-infused (dashed line) forearm
blood flow in patients with CHD during intrabrachial sodium
nitroprusside (panel A), acetylcholine (panel B), and verapamil (panel C)
with sildenafil (•) and matched placebo (O) infusion, p < 0.001
analysis of variance, dose response in infused arm; *p < 0.05 analysis




































Figure 4 Infused (solid line) and non-infused (dashed line) forearm
blood flow in healthy controls during intrabrachial sodium nitroprusside
(panel A), acetylcholine (panel B), and verapamil (panel C) with
sildenafil (•) and matched placebo (O) infusion, p < 0.01 analysis of
variance, dose response in infused arm; *p < 0.001 analysis of
variance, sildenafil versus matched placebo.
plasma PAI-1 concentrations did not change significantly
throughout either study.
DISCUSSION
We have shown that sildenafil, a selective PDE5 inhibitor,
does not modify endothelium dependent vasodilatation or
acute t-PA release in men with stable CHD. However,
sildenafil did augment the vasodilator effect of the exogenous
nitric oxide donor sodium nitroprusside. Thus, while our
study confirms the well described interaction of sildenafil
with nitric oxide donors,1016 we have found no evidence to
support the contention that PDE5 inhibitors improve
endothelium dependent vasomotor or fibrinolytic function
in patients with CHD.
Compared with matched controls, patients with CHD
exhibited impaired endothelium dependent responses to
acetylcholine while having preserved vasodilator responses to
the endothelium independent agonists sodium nitroprusside
and verapamil. This prognostically significant impairment717
was evident in patients who were already receiving standard
antianginal, antiplatelet, and lipid lowering treatments.
Sildenafil had no effect on peak flow mediated dilatation
of the brachial artery in patients with CHD" and reports on
the vasomotor responses of the coronary vessels to sildenafil
are conflicting. Herrmann et al'a found no change in coronary
artery diameter, blood flow, or coronary vascular resistance,
whereas Halcox et al" reported enhanced coronary artery
vasodilatation to acetylcholine. Unlike previous studies, we
used a more robust double blind randomised placebo
controlled crossover study design and have shown that
PDE5 inhibition does not alter either endothelium depend¬
ent vasomotor or fibrinolytic function in patients with
www.heartjnl.com
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Table 2 Plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor
type 1 (PAI-1) concentrations at baseline and during sildenafil and matched placebo
infusion in patients with coronary heart disease
Sildenafil/placebo
0 Bolus Continuous infusion (10 ma/hl
Substance P dose (pmol/min) 2 4 8
Placebo
Plasma t-PA antigen (ng/ml)
Infused arm 9.0 (0.7) 8.7 (0.6) 9.3 (0.6) 9.8 (0.7) 10.5 (0.8)*
Non-infused arm 9.0 (0.6) 9.1 (0.6) 9.1 (0.6) 8.9 (0.6) 9.1 (0.6)
Plasma PAI-1 antigen (ng/m!)
Infused arm 46.8 (6.9) 43.1 (6.0) 0 0 34.4 (5.4)
Non-infused arm 45.2(7.1) 45.5 (7.6) 0 0 36.4 (6.3)
Sildenafil
Plasma t-PA antigen {ng/ml}
Infused arm 9.0 (0.6) 8.7 (0.6) 9.1 (0.6) 9.4 (0.6) 10.5(0.7)*
Non-infused arm 9.1 (0.6) 8.8 (0.6) 9.0 (0.6) 8.9(0.6) 9.0 (0.6)
Plasma PAI-1 antigen (ng/m!)
Infused arm 44.0 (5.6) 39.6 (4.6) 0 0 36.0 (3.8)
Non-infused arm 47.9 (5.6) 43.2 (4.9) 0 0 38.6 (4.2)
*p<0.001, analysis of variance for t-PA response.
Control subject data on file (p = 0.003, analysis of variance for t-PA response).
CHD or in age matched controls. Moreover, we used a
bolus and continuous intravenous sildenafil infusion to
minimise variations in plasma concentrations during the


















Figure 5 Infused (solid line) and non-infused (dashed line) forearm
blood flow (panel A) and estimated net release of tissue plasminogen
activator (t-PA) antigen (panel B) at baseline, during sildenafil (•) and
matched placebo (O) infusion (shaded box), and subsequently with
inrrabracnial substance P (2, 4, 8 pmol/min) in patients with CHD.
p < 0.01 analysis of variance for all, dose response for infused arm FBF
and net t-PA release.
is an important study consideration given the short half life
of sildenafil in humans.
We observed a decrease in mean arterial pressure in both
patients and controls during administration of sildenafil that
presumably reflected an augmentation of the vascular effects
of basal vascular nitric oxide release and is mediated through
an increase in cGMP. Our findings are consistent with the
published haemodynamic data from both healthy volun¬
teers" and patients with CHD18"20 and confirm that we
achieved a physiological effect with sildenafil infusion. The
consistent vasodilatory response to the nitric oxide indepen
dent agonist verapamil makes it unlikely that administration
of the PDE5 inhibitor impaired vascular smooth muscle
function or obscured potentially beneficial effects on
endothelial function. Moreover, both acetylcholine and
substance P produced similar, consistent, and reproducible
responses on both study days. This suggests that prolonging
cGMP actions in patients with established atherosclerosis
would not reverse endothelial dysfunction. As would be
predicted from its mechanism of action, sildenafil augmented
the responses to sodium nitroprusside, an exogenous nitric
oxide donor, in both controls and patients with CHD.
There are several potential reasons for the differences
observed in the effect of sildenafil on the acetylcholine and
sodium nitroprusside responses. The modest decrease in
acetylcholine induced vasodilatation2122 seen after nitric
oxide synthase inhibition suggests that non-nitric oxide
dependent pathways such as endothelium derived hyper-
polarising factor (EDHF) may predominate particularly in the
presence of endothelial dysfunction.2'24 Furthermore, differ¬
ences in the relative contribution of endothelium derived
nitric oxide across vascular beds may explain some of the
previously conflicting data on the vascular responses to
sildenafil." 25 26 As well as endothelial dysfunction, athero¬
sclerosis is associated with high concentrations of free
radicals such as superoxide anion that rapidly react with
nitric oxide to generate peroxynitrite, a powerful oxidant
species that induces significant cellular damage and directly
inhibits soluble guanylate cyclase.27 Elegant studies in
animals with specific knockouts of nitric oxide dependent
pathways also suggest that tissue specific downregulation of
nitric oxide/cGMP, including cGMP dependent protein
kinase, may be an early feature of endothelial dysfunction
in atherosclerotic conditions.28 29 PDE5 inhibition would not
be anticipated to influence changes in oxidative stress or
directly affect cGMP independent nitric oxide molecular
targets that contribute to endothelial dysfunction and
www.heartjnl.com
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atherogenesis. Therefore, the contrasting effects of silde¬
nafil on acetylcholine and sodium nitroprusside induced
vasodilatation are likely to reflect a major dependence on
non-nitric oxide mediated pathways, increased oxidative
stress, and decreased nitric oxide bioavailability associated
with CHD.
Although the precise mechanism underlying acute t-PA
release remains uncertain, several reports have previously
suggested involvement of nitric oxide and cyclic nucleotides
regulated by phosphodiesterases. In animals, pentoxifylline
and its analogues, non-selective phosphodiesterase inhibi¬
tors, increased acute t-PA release30 and potentiated the effects
of thrombolytic treatment." We and others have reported
acute endothelial t-PA release during intra-arterial substance
P,414 bradykinin,32 and methacholine33 infusions, as well as
an inverse relation between acute t-PA release and athero¬
sclerotic plaque burden within the coronary circulation.34 In
the present study, we have again shown a rise in both plasma
t-PA antigen concentrations and net t-PA release with local
intra-arterial substance P infusion. However, infusion of
sildenafil did not change basal plasma t-PA concentrations or
substance P induced t-PA release. Therefore, enhancement of
cGMP apparently does not directly augment endothelial t-PA
release in humans.
Although we found no such change in acute t-PA release
with substance P, sildenafil may improve the response
to other agonists such as bradykinin, which causes B2
receptor mediated prostacyclin and nitric oxide generation.35
However, the dominant mechanism of t-PA release with
bradykinin appears to be nitric oxide and prostacyclin
independent with coupling of the B2 receptor to the calcium
dependent Gq/phospholipase C-beta pathway.36 Some of the
conflicting results on the effect of nitric oxide synthase
inhibitors on t-PA release may suggest that there is
physiological redundancy within the nitric oxide dependent
pathways which contribute to the regulation of acute t-PA
release in humans.
Study limitations
In light of the haemodynamic changes seen in our study,
intrabrachial infusion of sildenafil in subsystemic locally
active doses would be one approach to assess the direct
vascular actions of PDE5 inhibition. However, sildenafil is
metabolised by the liver to an active metabolite that accounts
for nearly half of its phosphodiesterase inhibitory activity.
Local intra-arterial infusion would not assess the action of
this important metabolite. The effect of long term PDE5
inhibitor therapy remains unclear, and further studies with
women and patients with diabetes mellitus would be of
interest, as these groups may show differences within nitric
oxide dependent pathways.37 38
Conclusion
Despite being highly effective in the management of erectile
dysfunction, sildenafil does not modify endothelium depen¬
dent vasomotor or fibrinolytic function in patients with CHD.
Phosphodiesterase inhibitors have already shown promise as
novel treatments for conditions such as chronic heart failure25
and pulmonary hypertension,39 and these areas clearly
warrant further research. However, on the basis of our
results, we believe that PDE5 inhibitors are unlikely to
reverse the generalised vascular dysfunction seen in patients
with CHD.
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IMAGES IN CARDIOLOGY
Pseudo-supraventricular tachycardia
A79 year old man with dilated phase of Ahypertrophic cardiomyopathy and ahistory of anteroseptal myocardial
infarction was admitted because of frequent
episodes of tachyarrhythmia requiring cardio¬
version. A 12 lead ECG demonstrated small
positive waves (closed circles) followed by
larger positive waves (open circles) in limb
leads and leads V4—6, which, at first glance,
seemed to represent P waves followed by QRS
complexes (panel A). A closer look indicated
that the presumed P waves (closed circle) in
leads V4-6 corresponded to R waves (arrow¬
head) in leads VI and V2 as well as
dissociation of true P waves (arrows) from
QRS complexes. The diagnosis of ventricular
tachycardia was confirmed by electrophysio¬
logic study, which revealed that the first and
second positive wave corresponded to the
local ventricular potential recorded from the
apex of right and left ventricle, respectively
(panel B). Catheter ablation of the ventricular
tachycardia was not possible because the
tachycardia was not stable. The patient was
treated with mexiletine and followed
uneventfully.
This case re-emphasises the importance of
recording a 12 lead ECG for the diagnosis of
arrhythmia, even when the diagnosis from
an ECG with fewer leads such as telemetry
seems to be straightforward (sinus tachy¬
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